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Abstract 
Age-related macular degeneration (AMD) is the most prevalent form of 
irreversible blindness in those over 50 years old in Western countries. It is a late-
onset, neurodegenerative retinal disease, which is characterised by extracellular 
deposits containing amyloid beta peptides (Aβ) on the Bruch’s membrane. In half 
of AMD cases, polymorphisms in the gene encoding complement factor H (CFH) are 
associated with susceptibility to the disease. 
 
The aims of this thesis were; (1) to identify sites of Aβ accumulation in mouse 
ageing eye and macrophage up-regulation, (2) to investigate the effects of 
immunotherapy targeting Aβ as a potential treatment for AMD, (3) to examine how 
pathogens trigger retinal disease in CFH mice, (4) to determine whether the 
strategy of inhibiting complement component C3 (C3) and complement activation 
is beneficial or detrimental in CFH mice. 
 
I show that Aβ deposition increases with age and is accumulated on photoreceptor 
outer segment and on Bruch’s membrane. Systemic administration of an antibody 
targeting Aβ improved retinal pathology, by decreasing deposits and reducing the 
activation of C3. I also show that genetic mutation or polymorphism is not the only 
factor triggering the onset of AMD but also environmental factors such as pathogen 
load are also critical. C3 deficiency resulted in Aβ deposition and photoreceptor 
cell loss along with failure to activate macrophages, supporting a beneficial, 
neuroprotective role of C3 in the retina. 
 
Collectively these data show that inflammation is one factor that forms an 
umbrella for the onset and progression of AMD. However, inflammation is not 
always a negative phenomenon. Aβ deposition and pathogen load are factors that 
will trigger an inflammatory response in tissue and therefore ways to regulate 
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inflammatory responses to physiological levels and subsequently removing the 
factor causing the inflammation without affecting the homeostasis of the tissue will 
be a step forward in treating AMD. 
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1. Introduction to the Mammalian Eye 
 
The eye is a highly specialised extension of the brain, which consists of three 
distinct coats. The outermost coat consists of a fibrous layer that is the sclera and 
the cornea, a transparent window of the eye through which light passes. The 
middle coat contains the main blood supply to the eye and consists of the choroid, 
the ciliary body and the iris. The innermost layer is a nerve membrane containing 
the retina (1). 
 
Figure 1.1 - A schematic picture of a sagittal section through the human eye with an enlargement of the retina. 
(url: webvision.med.utah.edu) 
 
During the earliest stage in eye development, the diencephalon evaginates 
bilaterally to form a pair of optical vesicles outpouching on either sides of the 
forebrain from the neural tube (Figure 1.2). These optic vesicles expand laterally 
into the mesoderm of the head and form a stalk-like connection to the central 
nervous system. As the vesicles continue to grow, the surface of the ectoderm 
thickens to form the lens placode. Coordinated invagination of the lens placode and 
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the optic vesicle results in the formation of lens vesicle and a double layered optic 
cup (1-3).  
 
After invagination of the optic cup, the cells from the inside of the cup differentiate 
into the neural retina and the outside remaining monolayer of cells differentiates 
into the retinal pigment epithelium (RPE). These two layers are separated by a thin 
remnant of lumen, itself filled with the interphotoreceptor matrix. At first, both 
layers are single cell thick, but then the inner layer divides to form a 
neuroepithelial layer of several cells thick (1). The presence of the transcription 
factors OTX2 (homeodomain-containing transcription factor) and MITF 
(microphthalmia-associated transcription factor) will determine if the cells of 
neuroepithelium will differentiate into RPE (3, 4).  
 
RPE progenitors arise from the dorsal portion of the vesicle and with the folding of 
the optic vesicle, these progenitors adopt a cuboidal appearance and reside in the 
dorsal aspect of the outer layer of the cup (5). RPE then eventually spreads and 
completely surround the neural retina, occupying the original position of the 
ventral optic stalk precursors, which have now invaginated, allowing the closure of 
the ventral fissure (1, 2, 5).  
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Figure 1.2 - Development of the eye from the neural tube through the optic vesicles and the inverted optic cup 
forming the retina. 
(url: webvision.med.utah.edu) 
 
1.1. The Retina 
 
The retina contains three layers of the nerve cell bodies; the outer nuclear layer 
contains cell bodies of the rods and cones of the photoreceptors while the inner 
nuclear layer contains cell bodies of bipolar, horizontal and amacrine cells. The 
ganglion cell layer contains cell bodies of ganglion cells and displaced amacrine 
cells. Between these nerve cell layers, there are two plexiform layers in which 
synaptic contacts occur and neuronal processes are present (1). 
 
Figure 1.3 - Schematic diagram of the human retina. 
(url: thebrain.mcgill.ca) 
 
There are two basic types of photoreceptors: rods and cones (figure 1.4.). The rods 
are slim-shaped structures that contain the visual pigment-rhodopsin and are 
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sensitive to blue-green light. They are highly sensitive and are used for vision 
under dark-dim conditions. Cones are structures that contain visual pigments 
called cone opsins. They are sensitive to either long wavelengths of light (red 
light), medium wavelengths of light (green light) or short wavelength of light (blue 
light). They are therefore the basis of colour perception in our visual image. In 
mammals there is only one type of rod, and usually two types of cones (Medium 
and short wavelength); however primates have all three classes of cones (Long, 
medium and short wavelength) (1, 6).  
 
 
Figure 1.4 - Schematic diagrams of a rod and cone. 
 (url: thebrain.mcgill.ca) 
 
Photoreceptor cells are highly specialised and polarised. They consist of an outer 
segment filled with membranous stacks of discs packed with visual pigment 
molecules such as rhodopsins, an inner segment consisting of mitochondria, 
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ribosomes and membranes, a cell body containing the nucleus of the 
photoreceptor cell and a synaptic terminal where visual information is passed to 
second-order neurons (1, 6). 
 
The outer segments of the rods and cones transduce the light and signal through 
the cell bodies of the outer nuclear layer and out to their axons. In the outer 
plexiform layer, photoreceptor axons contact the dendrites of bipolar cells and 
horizontal cells. The bipolar cells in the inner nuclear layer process the input and 
transmit the signal to their axons in the inner plexiform layer whereby they 
contact the ganglion cell dendrites and amacrine cells. The ganglion cells then send 
their axons through the outer fibre layer to the optic disc via the optic nerve and 
send the visual information to the brain. Connections between the rods and cones 
and vertically-running bipolar cells and horizontal cells occur in the outer 
plexiform layer while the inner plexiform layer acts as a relay station for the 
vertical nerve cells, for the bipolar cells to connect to ganglion cells. 
Photoreceptors are not distributed evenly throughout the retina. The fovea of 
primates, an area associated with the ability to visualise fine details, is made up 
mainly of cones and does not contain any rods. From the fovea to the peripheral 
retina, the density of cones decreases rapidly while the density of rods increases. 
Therefore rods are the major component of the peripheral retina (7, 8). 
Photoreceptors are subject to functional and structural polarisation, and about 
10% of rod outer segment discs are shed everyday (9). 
 
The retina also contains three types of glial cells; Müller cells, astrocytes and 
microglia. Müller cells are the main glial cells of the retina. Müller cells contain 
glycogen, mitochondria and intermediate filaments. They are important for the 
health of the retinal neurons as they function in a symbiotic relationship with the 
neurons by supplying nourishment to the nerve cells. They help in the removal of 
neural waste products and also involved in both phagocytosis of neuronal debris 
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and release of neuroactive substances. Müller cells control homeostasis and 
protect the neurons from changing environment (1, 6). 
 
Astrocytes are generated outside the retina and invade the retina from the brain 
via the optic nerve. They have flat cell bodies with a series of radiating processes 
that are filled with intermediate filaments. The processes of the astrocytes are 
confined to the ganglion cell layer and the nerve fibre layer of the retina where 
they tangle along the ganglion cell axons. They form part of the blood brain barrier 
as their processes cover the blood vessels of the nerve fibre layer, suggesting that 
they are axonal and vascular glial sheaths. Astrocytes may help in homeostasis, 
regulating the potassium levels and neurotransmitters uptake (1, 6). 
 
There are two types of microglia; resident microglia, which enter the retina during 
early development from the optic nerve and remain dormant in the retinal layers 
while the other type enters the retina from the blood vessels when they are 
stimulated. Microglia are mesodermal in origin and can be activated into 
macrophagic function when there is injury to the retina and they phagocytose 
degenerating neurons. Microglia within the retina are continually replaced from 
the bone-marrow and are the resident myeloid-derived cells within the retina.  
Microglia control inflammation as well as enable normal development and 
maintain normal retinal function. 
 
1.1.1. Blood supply to the retina 
The human retina is supplied by a dual vasculature. There is an intraretinal 
vasculature in the inner retina and a vasculature external to the pigment 
epithelium, the choroidal circulation. The choroid receives the greatest blood flow 
(65%-85%) and its main function is to nourish the outer retina, containing 
photoreceptors. The intraretinal vasculature flows to the retina from the optic 
nerve head to nourish the inner retinal layers. The human intraretinal vasculature 
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has four main branches. The choroidal circulation is a thin, highly vascularised and 
pigmented tissue positioned under the sensory retina that form the posterior 
portion of the uveal tract and arise from long and short posterior ciliary arteries 
and branches of Zinn’s circle (around the optic disc). Each posterior ciliary artery 
breaks up into a fan-shaped lobules of capillaries that supply localised regions of 
the choroid (10). The macular area of the choroidal vessels is not as specialised as 
the retinal blood supply is (11). The arteries pierce the sclera around the optic 
nerve and fan out to form the three vascular layers in the choroid: outer (most 
sclera), medial and inner (nearest Bruch’s membrane of the pigment epithelium) 
layers of blood vessels. The corresponding venous lobules drain into the venules 
and veins that run anterior towards the equator of the eyeball to enter the vortex 
veins. One or two vortex veins drain each of the 4 quadrants of the eyeball. The 
vortex veins penetrate the sclera and merge into the ophthalmic vein (11). The 
choriocapillaris of the choroid is a highly anastomosed network of capillaries, 
forming thin sheet juxtaposed to Bruch’s membrane. It is about 10μm thick at the 
fovea, where there is the greatest density of capillaries, thinning to about 7μm in 
the periphery. The capillaries are fenestrated but highly permeable to proteins. 
The choroid has at least three other functions: thermoregulation, adjustment of the 
position of the retina by changes in choroidal thickness, and secretion of growth 
factors (12).  
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1.2. Retinal Pigment Epithelium 
 
The retinal pigment epithelium (RPE) is a highly polarised and specialised 
monolayer of hexagonal cells located between vessels of the choriocapillaris and 
the light-sensitive outer segment of the photoreceptors. The apical membrane of 
the RPE faces the photoreceptor outer segments. The RPE cells have apical 
microvilli that surround the light-sensitive outer segments establishing a complex 
of close structural interaction. The RPE faces the Bruch’s membrane with its 
basolateral membrane, which separates the RPE from fenestrated endothelium of 
the choriocapillaris. RPE cells contain melanosomes, a lysosome-related organelle 
responsible for the production and storage of the melanin pigments (5, 13-15). 
 
The RPE is a multifunctional and indispensible component of the vertebrate eye. It 
absorbs the light energy focused by the lens on the retina. It acts as the outer blood 
retinal barrier and operates as a transporting epithelium that carries nutrients, 
ions, gases and metabolic end products between the photoreceptors and the 
choroidal blood vessels. RPE is important for photoreceptor renewal as it 
phagocytoses and digests the outer segment membrane disc and essential 
substances such as retinal are recycled and returned to photoreceptors to rebuild 
light-sensitive outer segments from the base of the photoreceptors. The RPE 
participates in the visual cycle in which retinal used by the photoreceptors to 
manufacture visual pigments are constantly exchanged between the RPE and the 
neural retina (13). RPE cells also produce growth and trophic factors essential to 
maintain the structural integrity of choriocapillaris endothelium and 
photoreceptors. They also secrete immunosuppressive factors and thus 
establishing the immune privilege of the eye (4). 
 
Chapter One – Introduction to the Mammalian Eye 
28 
 
1.2.1. Visual Cycle 
The visual cycle is a chain of biochemical reactions that regenerate visual pigment 
following exposure to light. During visual cycle, the visual pigment present in rods 
and cones absorbs photons and produces a cis-to-trans isomerisation of its retinal 
chromophore by a series of enzymatic reactions, resulting in an activation of the 
visual pigment (4, 16). This first step in photochemical event triggers the 
activation of the visual transduction cascade that leads to the transmission of 
visual signal from the photoreceptor to other cells within the retina and then the 
brain. Once the chromophore has undergone photoisomerisation, the visual 
pigment is then unable to absorb any photons and therefore it is said to be 
bleached. The regeneration of the visual pigment to its original state occurs by a 
series of biochemical reactions referred to as the visual cycle. During the first step 
in the visual cycle all the trans-retinal chromophore from opsin, the apoprotein 
portion of the visual pigment, separates followed by its reduction to all trans-
retinol. Beyond this stage, the visual cycle for rod and cone photoreceptors has 
different pathways. Rods are more sensitive to light and a wider range of 
wavelengths compared to cones. They are not colour-sensitive and therefore are 
used in dim light. In rods, retinol moves from the outer segment to the RPE, where 
it is converted to 11-cis-retinal. After this regenerative isomerisation, the 11-cis-
retinal chromophore is returned back to the rod outer segments, where it is 
condensed with the apoprotein to regenerate the trans-retinal. In cones, all trans-
retinol is transported from the outer segments to Müller cells of the inner retina, 
where isomerisation to 11-cis-retinol by enzymes occur (17, 18). 11-cis-retinol 
from Müller cells then enters the inner segments of the cone photoreceptors and is 
oxidised to 11-cis-retinal. After that, the retinal is moved back to the outer 
segments where it is conjugated with opsin to form the visual pigment (19).  
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1.3. Bruch’s Membrane 
 
The RPE basement membrane and the basement membrane of the endothelium 
form the Bruch’s membrane (BM). The BM develops into a five-layered structure: 
the basement membrane of the RPE, the inner collagenous layer, the elastin layer, 
the outer collagenous layer, and the basement membrane of the choriocapillaris. 
The basement membrane of the RPE is 0.14-0.15μm in thickness and contains 
many components similar to the basement of the choriocapillaris; collagens type IV 
(20), laminin (21), fibronectin (22), and heparin sulphate and chondroitin/ 
dermatan sulphate (23). The inner collagenous layer is about 1.4 μm thick. It 
contains striated fibres of collagen type I, III and V, organised in a multilayered 
grid-like structure (24), which are embedded in glycosaminoglycans and 
components of coagulation and of complement system. It is thought that type I 
confer tensile strength to the tissue while type III provides elastic properties and 
type V acts to anchor the basement membrane to stromal matrix (25).  
 
The elastin layer is made up of layers of elastin fibres, forming perforated sheets 
and contains collagen type VI, fibronectin and other protein-associated substances. 
The outer collagenous layer is thinner than the inner collagenous layer but they 
have the same composition. The basement membrane of the choriocapillaris is 
0.14mm in thickness in a young mammalian eye and is a discontinued layer of the 
BM because of the presence of intercapillary columns of the choroid. It consists of 
laminin, heparin sulphate and collagen type IV, V and VI. Bruch’s membrane acts as 
a semi permeable filtration barrier as it controls the exchange of biomolecular 
nutrients, oxygen, fluids and metabolic waste products between the retina and the 
choriocapillaris. It provides physical support for RPE cell adhesion, migration and 
perhaps differentiation. It acts as an inhibitor of endothelial cell migration into the 
BM (26). The nature of the BM is highly dynamic, and depends on genetic factors, 
environmental burden, and the topographic position in the retina, age and disease. 
A large number of biomolecules and waste products from the RPE and choroid 
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pass through the BM and can get trapped there influencing both the structure and 
function of BM (26). 
 
Diffusion through the BM is passive and depends on its molecular composition and 
hydrostatic pressure on both sides of the BM and the concentration of 
biomolecules and organic ions (26). BM’s permeability to water is influenced by 
age-related collagen cross-linking, and the build-up of hydrophobic lipids and 
membranous debris in the ageing BM (27). It was found that BM thickens and 
calcifies with age, which may also prevent RPE attachment to the BM (26). 
 
 
Figure 1.5 - Light micrographs of transverse section through the human retina (85 y/o) (A) and mouse retina (12 
m/o) (B). 
They show the outer segment of the retina (OS/PR), the RPE and the BM. 
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1.4. Effects of Ageing on the Retina 
 
One of the characteristics of ageing in the human retina is neuronal cell loss. Rods 
appear to be more affected by ageing than are cones (28, 29). Between the second 
and fourth decades, approximately half of all rods are lost with an annual 
disappearance of 970 cells/mm2 from the peripheral retina (29). The density of 
rods in the central retina decreases by 30% between the ages of 34 and 90 years, 
while the number of cones in the macular area remains stable (28).  
 
The number of ganglion cells in the fovea and peripheral retina also decreases with 
age by approximately 16% from the second to sixth decade (28, 29). Astrocytes 
display higher levels of glial fibrillary acidic protein, have more cytoplasmic 
organelles and abundant lysosomes and dense bodies during ageing (30). This 
reactive astrocyte population may protect neurons from free radicals by up-
regulating enzymatic and non-enzymatic antioxidant defences (30). The capillaries 
present thickening of the basal membrane and these membranes contain 
numerous clumps of lipids (30).  
 
The retinal cells encounter a cumulative amount of oxidative and metabolic stress 
that is a common feature of the ageing process. Increased oxidative stress and the 
accumulation of oxidatively damaged molecules lead to the dysfunction of various 
metabolic and signalling pathways (7). The outer retina is exposed to sunlight and 
to a relatively high oxygen tension from the arterial blood. The photoreceptor 
membranes are rich in polyunsaturated fatty acids, and together with sunlight and 
oxygen results in a tissue that is prone to oxidative damage (31). The degradation 
of oxidised and misfolded proteins is partly dependent on the proteasomal 
pathway. 
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1.5. Effects of Ageing in the BM 
 
The thickness, ultrastructure and histochemistry of Bruch’s membrane change 
with age. Changes in its extracellular matrix and biophysical properties will lead to 
altered nutrition and consequent dysfunction of the RPE and photoreceptors (32). 
The structure of the BM depends on the integrity of the collagen fibres. The 
number of striated collagen fibres both in the inner and outer collagenous layer 
increase with age. There is an increase in cross-linking of the collagen fibres, which 
has a negative effect on the permeability of BM and changes the nature of the 
extracellular matrix. The collagen network becomes stronger and denser with 
cross-linking and thus decreases its elasticity, flexibility and its filtration 
capabilities. This cross-linking also decreases the effective turnover of collagen as 
it prevents enzymatic action of RPE collagenases to access BM components (33). 
Another change that happens to an ageing BM is calcification of the elastic fibres 
which renders BM more brittle and easy to break, allowing neovascularisation to 
take place (34). 
 
Proteoglycans are important structural components of the BM. They act as glue for 
extracellular matrices in the BM. They may play a role in anti-inflammatory 
response and help in the BM filtration process (26). The negatively-charged side 
chain of the proteoglycans binds to water and positively-charged molecules such 
as potassium, sodium and calcium, thus regulating the movement of molecules 
through the BM matrix (23, 35). Proteoglycans also interact with complement 
factor H which is an essential regulator of the complement cascade and a regulator 
of the local immune response by inhibiting the cleavage of complement component 
3 and complement factor B, hence they have anti-inflammatory properties (36). 
 
The thickness of the BM increases with age due to the accumulation of waste 
material and cross-linking of collagen fibres (26). This thickening reduces the 
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filtration capacity of BM. Progressive accumulation of biochemical waste material, 
called drusen, on BM increases with age (26). Drusen are formed in between the 
RPE basement membrane and the inner collagenous zone of BM. They have a high 
lipid content but this varies between individuals (37, 38). Drusen are waste 
products from photoreceptor outer segments and RPE metabolism. They are also 
the result of lipoidal degeneration of the RPE or as an autolytic defect of the RPE 
attributable to abnormal lysosomal enzyme activity (39, 40). Drusen form when 
the RPE expels or sheds cellular waste material basally toward BM, possibly as a 
mechanism for removing damaged cellular components or as a by-product of 
phagocytic degradation (41, 42). Drusen development occurs in at least two 
distinct stages: a nucleation stage, in which RPE debris and dentritic cell-derived 
material accumulates in the sub-RPE space, and a maturation stage, in which 
drusen-associated constituents are deposited around the core (43). This 
accumulation of cellular debris in the extracellular space between the RPE and the 
Bruch’s membrane is a proinflammatory event and therefore constitutes a 
potential ‘nucleation’ site for drusen formation (44). 
 
 
Figure 1.6 - Immunofluorescence image of drusen from an 87 y/o human retina. 
Drusen forms between the RPE and BM, shown by the arrows. Scale bar= 50µm.  
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There are two types of drusen; one with defined (hard) and another one which has 
less-defined borders (soft and confluent drusen) (45). The main component of 
drusen is lipids but they also contain numerous proteins related to the process of 
inflammation or its aftermath such as C-reactive protein, complement components, 
complement inhibitors, apolipoproteins, amyloid beta and many more proteins 
(44, 46, 47). Drusen are the hallmark of age-related macular degeneration (AMD), 
the leading cause of blindness in developed countries (37, 48-50). The hard drusen 
appear funduscopically as small, punctuate, and yellow nodules with well-defined 
edges while soft drusen tend to be larger in diameter than the hard drusen and 
more irregular in shape (51-53). In fundus photographs, they appear as large pale 
yellow or grayish-white, dome-shaped elevations. They are often associated with 
clinical evident RPE detachments and choroidal neovascularisation (54). An 
accumulation of drusen could cause local interference with the exchange of 
metabolites and waste products between the choriocapillaris and an otherwise 
normal RPE, leading to RPE dysfunction and death. On the other hand, drusen may 
develop as a consequence of RPE cell dysfunction caused by a variety of 
microenvironmental and/or genetic influences.  
 
1.6. Effect of ageing in RPE 
 
RPE changes with age are characterised by accumulation of residual bodies 
containing lipofuscin. RPE is metabolically very active with specialised functions to 
sustain the photoreceptors and in the renewal of the outer segments (55). It 
releases cytoplasmic material into the choroid via the BM. RPE cells phagocytose 
and degrade the shed tips of the rod outer segments (9). The engulfed rod outer 
segments are enclosed in a phagocytic vacuole (phagosome), and a primary 
lysosome containing degradative enzymes will fuse with the vacuole forming a 
secondary lysosome or phagolysosome. The undigested end products within the 
phagolysosome, called residual bodies, contain the fluorescent granules of the 
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lipofuscin. With age, the quantity of fluorescent granules increases and loss of RPE 
cells results in an increase in metabolic demand on each cell (32).  
 
Lipofuscin, also known as age-pigments, are photoinducible generators of reactive 
oxygen species (57). They have three distinct characteristics; they consist of 
intracellular secondary lysosomes, they have yellow autofluorescent when excited 
with ultraviolet light and thirdly, they accumulate with age. RPE lipofuscin is 
mainly the by-product of the photoreceptor outer segments, which are 
phagocytosed by the RPE and are also rich in polyunsaturated fatty acids and 
vitamin A (57). This observation was due to the fact that RPE contains inclusions 
that have ultrastructural features of both lipofuscin and phagosomes derived from 
the outer segments. In pigmented eye, melanin is incorporated into the lipofuscin 
granules (56, 57). Excessive production and accumulation of lipofuscin leads to 
local loss of RPE function. 
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1.7. Aged-related Macular Degeneration 
 
Aged-related Macular Degeneration (AMD) is one of the leading causes of 
blindness in the elderly in the western countries (37, 48-50). It is a blinding 
disorder that affects the central vision and is characterised by the degeneration of 
the macular retina and choroid by atrophy or detachment and scarring caused by 
the formation of new blood vessels from the choroid a phenomenon called 
choroidal neovascularisation (45). An early clinical manifestation and pathological 
feature of AMD is the development of drusen, extracellular deposits of 
glycoproteins, lipids, and cellular debris located inside Bruch’s membrane and 
beneath the retinal pigment epithelium (49, 51). Drusen size, number, and degree 
of confluence are significant risk factors for the development of AMD. It has been 
suggested that drusen as well as other aged-related changes that occur near BM, 
may lead to the dysfunction and /or degeneration of the RPE and retina by 
inducing ischemia and/or restricting the exchange of nutrients and waste products 
between the neural retina and choroid (58).  
 
AMD has been classified into two subtypes: dry AMD and wet AMD. Dry AMD 
progresses more slowly and manifests with drusen, geographic atrophy of RPE, 
and photoreceptors dysfunction and degeneration (45).  Wet AMD is more 
debilitating and often presents after dry AMD. The key feature of wet AMD is 
choroidal neovascularisation, the growth of new blood vessels from the choroid 
into the region underlying the RPE or extending past the RPE into the subretinal 
space and retina. This choroidal neovascularisation can lead to leakage of blood 
into the subretinal space which, along the RPE atrophy and photoreceptor 
degeneration, leads to vision loss (54). 
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1.8. The Complement System 
 
Studies on the molecular composition of drusen have implicated inflammation, and 
particularly local activation of the alternative pathway (AP) of the complement 
system in the retina, in the pathogenesis of AMD (59). The complement system is 
made up of three pathways; the classical pathway, the lecithin pathway and the 
alternative pathway. It consists of about 30 soluble and membrane bound proteins 
(60).  The classical pathway is activated mainly by immune complexes i.e. antibody 
bound to antigen, the lecithin pathway is activated by mannose and N-acetyl 
glucosamine residues that are present on bacterial cell surfaces and the alternative 
pathway is activated by pathogens. These pathways will result in a 
proinflammatory response which will lead to the cleavage of complement 
component C4 and C3 and to the formation of a covalent linkage between C4b and 
C3b and the activating structures. The three pathways all lead to C3 activation 
followed by the formation of membrane attack complexes which will mediate cell 
lysis. These proinflammatory responses include the production of C3 convertase 
which is an enzyme that cleaves C3 into its active forms C3a and C3b. This enzyme 
has an internal thioester bond and the cleavage of C3 to C3b by C3 convertase 
activates this bond and temporarily allows the stable covalent binding of C3b to 
hydroxyl groups on carbohydrates and proteins in the immediate vicinity. C3a acts 
as an anaphylatoxin and antimicrobial substance. The hydroxyl group of the C3b 
binds covalently to surfaces of the pathogens and will trigger the complement 
activation. Regulation of the cleavage of C3 is critical. Once C3 is deposited 
covalently as C3b on a membrane, it either goes into an amplification step whereby 
more C3 is being cleaved and bound to the membrane and this process requires 
the help of factor B and D to form C3 convertase or the bound C3b is rendered 
inactive by factor I and H which are regulatory proteins of the complement system 
(60).  
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Figure 1.7 - Schematic diagram of the complement system. 
Source: Walport MJ (2001) Complement. First of two parts. (Translated from eng) N Engl J Med 344(14):1058-
1066 (in eng). 
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The alternative pathway does not depend on a pathogen-binding protein for its 
initiation; instead it is initiated through the spontaneous hydrolysis (also known as 
‘tickover’) of C3 to form C3b. C3 is abundant in the plasma and is mainly produced 
by the liver. This occurs through the spontaneous hydrolysis of the thioester bond 
in C3 to form C3 (H2O) which has an altered conformation, allowing binding of the 
plasma protein factor B (Figure 1.7). The binding of factor B by C3 (H2O) then 
allows a plasma protease called factor D to cleave factor B to Ba and Bb. The Bb 
remains attached to C3 (H2O) to form C3 (H2O) Bb complex, which is a fluid-phase 
C3 convertase which cleaves C3 into C3a and C3b. The C3 convertase has two 
possible fates, it either goes into the amplification step whereby more and more C3 
molecules are being broken down to form more C3 convertases or it acts as an 
opsonin or as a C5 convertase by binding to more C3b molecules forming the 
complex C3 (H2O) BbC3b which then cleaves C5 to produce the anaphylatoxin C5a 
and the C5 activation product, C5b. The latter binds to membrane beginning the 
formation of the membrane attack complex (MAC) (C5bC6C7C8C9). MACs (C5b-9) 
damage cells by assembling a lytic pore, composed mainly of multiple C9 proteins, 
on cell surfaces. The production of the proinflammatory anaphylotoxins, 
opsonisation and MAC–mediated cellular injury all ultimately lead to cytokine-
mediated recruitment and activation of immune cells to the site of complement 
activation (61). 
 
The extent of complement activation is critically dependent on the stability of the 
C3bBb convertase. This stability is controlled by positive and negative regulatory 
proteins. Negative regulatory proteins protect the normal host cells from 
complement activation. These proteins interact with C3b and either prevent the 
enzyme convertase from forming or promote its rapid dissociation. This is done 
when a membrane-attached protein known as decay-accelerating factor competes 
with factor B for binding to C3b on the cell surface, and can displace Bb from the 
convertase that has already been formed. C3b can also be cleaved to its inactive 
form iC3b by binding to the plasma protease, factor I, thus preventing the 
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formation of C3 convertase. Factor H, the major inhibitor of the alternative 
pathway in plasma, binds to C3b on the host cells and competes with factor B to 
displace Bb from the convertase hence inhibits complement activation (61). Factor 
H accelerates the decay of this convertase and acts as a cofactor for the factor I-
mediated proteolytic inactivation of C3b into iC3b and C3dg (62). In contrast, when 
complement is activated on foreign surfaces, C3 convertase enzymes are stabilised 
by binding to a positive regulatory plasma protein, known as properdin or factor P, 
causing amplification of the complement activation (61).  
 
Factor H is among the most abundant complement proteins in serum, synthesised 
mainly in the liver, but to a lesser extend it is also locally synthesised in the eye by 
RPE cells. Strong evidence for a role of complement in AMD showed that variants 
in the complement factor H (CFH) gene are significantly associated with an 
increased risk of the disease in Caucasian populations. The mutational screening of 
CFH gene resulted in the identification of a polymorphism in the CFH gene. The 
latter is located on human chromosome 1q32 (62). CFH gene transcription can 
produce both the full-length 155kDa CFH protein and the truncated form, termed 
the 43kDa complement factor H like protein-1 (CFHL-1) (62). Both CFH and CFHL-
1 regulated the complement system by acting as cofactor for Factor I mediated 
inactivation of C3b and have decay accelerating activities. Both CFH and CFHL1 are 
present in vitreous fluid of the eye and expressed by RPE cells (63). A tyrosine to 
histidine mutation at codon 402 (Y402H) within the CFH is strongly associated 
with AMD pathology (64-67). The tyrosine residue at position (CFHyy402) is 
considered as a protective variant whereas the histidine residue at this position 
(CFHYH402 and CFHHH402) as a risk variant for AMD. Due to the coding 
polymorphism at position 402, risk variants of both CFH and CFHL-1 have reduced 
cell-binding activity that leads to reduced complement regulation at the cell 
surface (63). This results in initiation of inflammatory cascade leading to tissue 
damage and ultimately drusen formation in AMD (63). 
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1.9. Amyloid Beta (Aβ) 
 
Recent proteome analysis has demonstrated that amyloid beta (Aβ) deposition 
was specific to drusen from eyes with AMD (47, 68). These deposits may be 
involved in the activation of the complement cascade. Amyloid deposits are 
insoluble, extracellular accumulations of amyloid beta (Aβ) peptides. These 
molecules tend to aggregate and form complexes of varying size: from small 
soluble oligomers, bigger protofibrils and finally insoluble fibres. Aβ peptides vary 
in length from 39 to 43 amino acid residues and are produced by the proteolytic 
processing of amyloid precursor protein (APP) (69, 70). APP is a single membrane 
spanning protein that can be cleaved by 3 enzymes alpha, beta and gamma 
secretase. APP is sequentially cleaved by two membrane–bound endoprotease 
activities, β- and γ-secretase. β-secretase first cleaves APP to release a large 
secreted derivative, sAPPβ. A fragment of 99 amino acids remains membrane 
bound, and is in turn rapidly  cleaved  by γ- secretase to generate Aβ to be released 
in the extracellular space (71). Hence, different forms of Aβ species are formed, but 
those ending at position 40 (Aβ40) are the most abundant, followed by 42 (Aβ42). 
The latter are more hydrophobic and fibrillogenic and therefore confer to the 
peptide the ability to self-aggregate and polymerise into amyloid fibrils and are the 
principal forms deposited in between the Bruch’s membrane and RPE. The term β 
of Aβ indicates its propensity to form partial β- plated sheet structures once it 
aggregates into amyloid fibrils.  
 
Aβ is normally eliminated (i) by cellular mechanisms involving microglia (72, 73); 
(ii) by enzymatic degradation (74, 75); (iii) by transport across the blood retinal 
barrier mediated by the low density lipoprotein receptor-related protein receptor 
and/or (76); (iv) by bulk flow with interstitial fluid along the perivascular drainage 
pathway (77, 78). It is supposed that an overproduction of Aβ or an increase ratio 
of the 42 amino acid form appears sufficient to cause an early onset of AMD (79-
82). The overproduction or the inability to eliminate Aβ may be due to the fact that 
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microglia may lose their neuroprotective properties with advancing age or they 
become dysfunctional with ageing, characterised by structural deterioration and 
increased apoptosis (83). These Aβ deposits might increase oxidative stress and 
inflammation in AMD as they are present in vesicles and co-localise with 
complement suggesting an association with inflammation (84). The interaction of 
these Aβ deposits with cellular membranes could cause damage by mechanical 
blockage of cellular exchange between the neural retina, RPE and the choroidal 
capillaries, thus causing the degeneration of the photoreceptors of the retina and 
RPE cells (85). It has been supposed that Aβ peptides secreted into the 
extracellular space never leave the membrane lipid bilayer and after fibrillation 
modify its electric property and alter ion channels. This could allow lethal amounts 
of calcium to enter into the cell and induce apoptosis (86). 
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2. Abstract 
 
Amyloid beta (A ) accumulates in the ageing central nervous system and is 
associated with a number of age-related diseases, including age-related macular 
degeneration (AMD) in the eye. AMD is characterised by the accumulation of 
extracellular deposits called drusen in which A  is a key constituent. A  activates 
the complement cascade and its deposition is associated with activated 
macrophages. So far, little is known about the quantitative measurements of Aβ 
accumulation and definitions of its relative sites of ocular deposition in the normal 
ageing mouse. 
 
Fundus autofluorescence was examined using confocal scanning laser 
ophthalmoscopy in normal C57Bl/6 of different ages. The morphology was 
assessed and the amount of Aβ was quantified by electron microscopy, 
immunohistochemical methods and Western blotting. It was observed that Aβ is 
not only deposited at Bruch’s membrane and along blood vessels, but 
unexpectedly, it also coats photoreceptor outer segments. While Aβ is present at all 
sites of deposition from 3 months of age, it increases markedly from 6 months 
onward. Progressive accumulation of deposits on outer segments was confirmed 
with scanning electron microscopy (SEM), revealing age-related changes in their 
morphology. A progressive accumulation of Aβ on photoreceptor outer segments 
with age was also confirmed in human retinae using immunohistochemistry. With 
age, macrophages become bloated with cellular debris including Aβ, however, their 
increasing numbers fail to stop Aβ accumulation.  
 
With age, there is a significant accumulation of Aβ rich extracellular deposits in the 
outer segment of photoreceptors and along the Bruch’s membrane of C57Bl/6 
mice. This accumulation of Aβ in the subretinal space results in an age-related 
accumulation of Iba-1+ microglia in normal C57Bl/6 mice. The same accumulation 
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of Aβ was observed in the outer segment of the photoreceptors in human retinal 
tissues and in the outer segment of the photoreceptors of C57Bl/6 mice. The 
present findings suggest that there is an association between macrophage 
response and Aβ deposition both anatomically and in vivo retinal imaging in mice. 
Aβ accumulation is associated with an increase in macrophage numbers. These 
results showed that while retinal Aβ deposition accumulates with age, there is an 
associated response via an increased in macrophage number however this alone is 
inefficient in clearing Aβ deposits. This is because ageing RPE cells and microglia 
cells fail to clear Aβ deposition and other debris and this may contribute to the 
visual deficits seen in ageing mice. 
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2.1. Introduction 
 
Many diseases of ageing such as age-related macular degeneration (AMD) and 
Alzheimer’s disease (AD) are characterised, in part, by the building up of 
extracellular deposits that contribute to their pathogenesis and progression. Age-
related macular degeneration is one of the leading causes of vision loss in those 
over 50 years in industrialized countries (48, 87-89) and is characterised by the 
formation of drusen, extracellular deposits between the retinal pigment epithelium 
(RPE) and the Bruch’s membrane (BM). These deposits are associated with 
atrophy of the RPE, disturbance in transepithelial barrier and photoreceptor cell 
death (44).  
 
One of the key constituents of drusen is amyloid beta (Aβ), a protein also present 
in the brain of Alzheimer’s disease (AD) patients (43, 47, 68, 90). Aβ causes RPE 
alterations and dysfunctions leading to retinal degeneration (91). This deposition 
of Aβ is either due to an overproduction of Aβ by amyloid precursor protein (APP), 
its precursor or a defect in the clearance of Aβ (92). The Aβ is derived by the action 
of two proteases that cleave APP in different steps. There are numerous different 
forms of Aβ that exist, but those ending at position 40 (Aβ40) are the most 
abundant (~80-90%), followed by 42 (Aβ42, ~5-10%)(92). The slightly longer 
forms of Aβ, particularly Aβ42, are more hydrophobic and fibrillogenic, they 
aggregate into clumps called oligomers and are therefore the principal form 
deposited in drusen. 
 
Amyloid fibril formation is a multistep protein misfolding cascade of molecular 
events, wherein a monomeric protein undergoes a conformational reorganisation 
into a number of different oligomeric, β pleated sheet-containing structures that 
ultimately convert into amyloid fibrils (93, 94). Cytotoxicity of Aβ is not only due to 
the ability to form fibrillary aggregates in the extracellular environment, but also 
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to the presence of soluble Aβ oligomers in the intracellular environment. Both 
forms produce different types of damage to the cell membrane and different 
organelles, inducing alteration of physiological pathways and leading to oxidative 
stress, inflammation and, at the end, to cell death via apoptosis (95, 96). 
 
Aβ may be regarded as an activator of the complement cascade and its depositions 
are usually associated with activated microglia cells and astrocytes. The presence 
of reactive astrocytes and microglia cells may indicate cellular clearance of Aβ in 
between the RPE and the photoreceptors (97-100). It has been suggested that Aβ 
in drusen affects the expression of CRALBP and RPE65, two proteins important in 
the visual cycle, and that it may also play a role in the vision impairment (91). 
 
It was shown that Aβ depositions are intimately associated with activated 
microglial cells and astrocytes and a role for inflammatory molecules in Aβ-
induced cytotoxicity (101). Inflammatory and /or immune-mediated processes, 
including the recruitment and maturation of dentritic cells, play an important role 
in drusen formation and, in the etiology of AMD (43). The main function of 
microglia is considered to be immunological defence and repair as they scavenge 
invading microorganisms and dead cells (102, 103). Microglia are capable of rapid 
dynamism and motility, they also synthesise and release multiple cytokines, 
chemokines, neutrophic factors, and neurotransmitters that allow them to interact 
with multiple central nervous system cell types and exert cytotoxic or 
cytoprotective properties depending on the tissue context. They are the principal 
immune effector cells in the retina and undergo a conversion into a reactive 
proinflammatory phenotype after their association with Aβ deposits.  
 
Microglia extend ramified processes into the surrounding tissue and they cluster at 
sites of Aβ deposition. Such clustering is due to chemotactic signalling by Aβ itself 
and by several inflammatory mediators that are associated with Aβ deposition: 
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complement activation fragments, cytokines and chemokines (97). Microglia 
migrate in response to monocyte chemoattractant protein-1 (MCP-1), a 
chemokine, and cease migration upon interaction with immobilized Aβ1-42 (104).  
Activated microglia are associated with virtually every Aβ deposit and are 
concentrated in regions of compact Aβ deposits where they surround and infiltrate 
the Aβ deposits. Microglia may be involved in the conversion of non fibrillar Aβ 
into amyloid fibrils, a role similar to that attributed to peripheral macrophages in 
systemic amyloidosis (105). Microglia may also play a role in the phagocytosing 
and/or degrading deposited Aβ, which suggest that it contributes to the formation 
of drusen (106). An abnormally deposited, chronic, highly insoluble, cross β- 
pleated protein, Aβ aggregate has the properties that lead to phagocytosis. It has 
been shown by Rogers et al. (2002)(107) in Alzheimer’s disease that in culture, 
microglia not only migrate to aggregated Aβ deposits but ultimately remove it.   
 
Much has been done to study Aβ depositions in the brain of mice models of 
Alzheimer’s disease however (108-112), little was done to study its accumulation 
in the retina. Aβ deposition in aged AD transgenic mice was shown in the 
RPE/Bruch’s membrane interface (113, 114), retina (115, 116) and 
retinal/choroidal blood vessels using immunohistochemistry (113).  
 
To date the presence and accumulation of the Aβ in the retina were mostly studied 
in the AD murine models. Hence this is the first comprehensive study on the 
accumulation of Aβ in the retina of a normal ageing mouse. My aim was to 
investigate the relationship between the macrophages and Aβ and to quantitate 
the progressive accumulation of Aβ in normal murine ageing retinae using three 
independent methods to reveal diverse deposition sites. A key site for Aβ 
accumulation was shown here to be on the membrane of the photoreceptor outer 
segments as well as on blood vessels and Bruch’s membrane. These data were 
related with quantitative assessments of macrophage recruitment using both in 
vivo retinal imaging and immunohistochemistry.     
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2.2. Materials and Methods 
 
All animal procedures conformed to the United Kingdom Animal License Act 1986 
(UK) and local ethical regulations. Human eyes were obtained from the eye bank at 
Moorfields Eye Hospital with the Local and National Ethical Approval. 
 
2.2.1. Animals 
C57Bl/6 mice were housed in a temperature-controlled environment with a 12-
hour- day (160 lux) light/dark cycle. Three groups of C57Bl/6 mice were used, 
each containing 8 animals at 3, 6 and12 months (16 eyes per group). An additional 
group of 4 animals was used at 24 months of age (8 eyes); 28 animals were used in 
total. Both eyes were used from each animal. The 3, 6 and 12- months-old animals 
were divided between 5 experiments. The first was the non-invasive imaging of the 
outer retina/RPE undertaken on the right eye prior to sacrifice. Four eyes from 
each group were then used for cryosectioning and antibody staining. Four were 
used for confocal SEM, four were taken for Western blot analysis and four were 
used for whole mounts of the RPE surface. The outer retina and Bruch’s 
membrane/RPE interface were the targeted areas of interest because this is a key 
area for accumulation of age-related deposits [30-32,55]. The 24-months-old 
animals were only used for retinal imaging followed by antibody staining of whole 
mounts of the sub-retinal space and SEM. 
 
2.2.2. In vivo imaging 
Mice were anaesthetised (6% Ketamine, (Fort Dodge, UK) 10% Dormitor, (Pfizer, 
UK) and 84% sterile water at 5ul/g intraperitoneal injection and their pupils were 
dilated (1% tropicamide, MINIMS, Bausch & Lomb, France) 10 to 15 minutes 
before scanning laser ophthalmoscope (cSLO) imaging. Before each image 
sequence, drops of hydroxypropyl methylcellulose (0.3%) were placed on the eye 
to prevent drying. Fundus photographs were taken with a digital camera mounted 
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on a modified confocal Scanning Laser Ophthalmoscope (Heidelberg Retina 
Angiograph, Heidelberg Engineering, Germany) where the pinhole diameter had 
been reduced to 100 µm to improve axial resolution and the laser power increased 
to improve the signal-to-noise ratio. Power at the mouse pupil was measured to be 
1400 µW at 488 nm. 
 
2.2.3. Immunohistochemistry 
All mice were killed by exposure to CO2 .The eyes were removed and fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS), pH 7.4, cryopreserved in 
30% sucrose in PBS and embedded in Optimal Cutting Temperature compound 
(OCT) (Agar Scientific Ltd). Cryostat sections were cut at 10um and thaw-mounted 
onto charged slides. Immunohistochemistry was performed at room temperature. 
 
 The sections of the eye were incubated for 1 hour in a 5% Normal Donkey serum 
in 0.3% Triton X-100 in PBS, pH 7.4, followed by an overnight incubation with the 
primary antibody, mouse monoclonal antibody to amyloid beta 4G8 (1:500, 
Covance) which was made in 1% Normal Donkey Serum in 0.3% Triton X-100 in 
PBS. After primary antibody incubation, the sections were washed three times in 
0.1M PBS and then incubated in a secondary antibody conjugated with Alexa Fluor 
568 (Invitrogen) which was made up in 2 % Normal Donkey Serum in 0.3% Triton 
X-100 in PBS at a dilution of 1:2000, was added to the sections and incubated for 1 
hour at room temperature. Negative controls were done by omitting the primary 
antibody. After the secondary antibody incubation, the sections were washed 
several times and the nuclei were subsequently stained with 4', 6-diamidino-2-
phenylindole (Sigma) for 1 min. Slides were then washed a few times in 0.1 M PBS 
and several washes in Tris buffered Saline (pH 7.5). The slides were mounted in 
Vectashield (VECTOR Laboratories) and coverslipped.  
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Mice retinal sections were processed for immunohistochemistry using the biotin-
avidin horseradish peroxidase complex. The sections of the eye were incubated for 
1 hour in a 5% Normal Donkey serum in 0.3% Triton X-100 in PBS, pH 7.4, 
followed by an overnight incubation with the mouse monoclonal antibody to Aβ 
which was made in 1% Normal Donkey Serum in 0.3% Triton X-100 in PBS. After 
the primary antibody incubation, the sections were washed three times in 0.1M 
PBS and then treated with 0.3% hydrogen peroxide in PBS to quench endogenous 
peroxidase activity. After several washes, the tissues were incubated with a biotin–
SP conjugated secondary antibody against mouse (Jackson ImmunoResearch 
Laboratories, 1:1000) which were made up in 2 % Normal Donkey Serum in 0.3% 
Triton X-100 in PBS, were added to the sections and incubated for 1 hour at room 
temperature. Negative controls were done by omitting the primary antibody. After 
the secondary antibody incubation, the sections were washed several times and 
then incubated in a ready-to-use horseradish peroxidise Streptavidin solution 
(Vector Laboratories) for 30 minutes, followed by a peroxidase substrate solution, 
3,3-diaminobenzidine (DAB) for 1 minute. Slides were mounted in Vectashield 
(VECTOR Laboratories) and coverslipped after several washes in PBS and TBS. 
Sections were viewed and images captured using an Epi-fluorescence bright-field 
microscope (Olympus BX50F4, Japan), where data were captured as 24-bit colour 
images at 3840 x 3072 pixel resolution using a Nikon DXM1200 (Nikon, Japan) 
digital camera. The images were then put together and the integrated density of 
both the outer segment of the photoreceptors and the Bruch’s membrane were 
measured using Adobe Photoshop CS4 extended. 
 
For the flatmounts, the eyes were fixed in 4% paraformaldehyde in PBS and 
washed with PBS. The eyes were dissected and the cornea, lens and retina were 
removed.  To facilitate preparation of the flatmounts, five or more vertical cuts 
were made in the RPE-choroidal tissues. 
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After several washes with PBS, the RPE-choroidal tissues were blocked and 
permeabilised with 5% Normal Donkey serum with 3% (v/v) Triton X-100 in PBS 
for 2 hours. Samples were incubated overnight in a cocktail of primary antibodies:  
mouse monoclonal to Aβ 4G8 (1:500, Covance) and Rabbit polyclonal antibody to 
Iba-1 (1:1000, A. Menarini diagnostics) which were made in 1% Normal Donkey 
Serum in 3% Triton X-100 in 0.1M PBS. After primary antibodies incubation, the 
samples were washed three times in PBS and then incubated in respective 
secondary antibodies which were made up in 2 % Normal Donkey Serum in 0.3% 
Triton X-100 in PBS at a dilution of 1:2000, and incubated for 2 hours at room 
temperature. After the secondary antibodies incubation, the samples were washed 
several times and the nuclei were subsequently stained with 4', 6-diamidino-2-
phenylindole (Sigma) for 1 min. The RPE-choroidal tissues were then washed a 
few times in 0.1 M PBS and several washes in Tris buffered Saline (pH 7.5). The 
flatmounts were mounted in Vectashield (VECTOR Laboratories) and coverslipped. 
The samples were viewed and images captured using an Epi-fluorescence bright-
field microscope (Olympus BX50F4, Japan), where data were captured as 24-bit 
colour images at 3840x3072 pixel resolution using a Nikon DXM1200 (Nikon, 
Japan) digital camera. The images were then put together and Iba-1 positive cells 
were counted using Adobe Photoshop CS4 extended. 
 
Four human eyes were fixed in 10% formalin for at least 24 hours and then 
dissected whereby the lens, the sclera and the RPE were removed and the retina 
were cut into smaller pieces. After several washes in PBS, the retinae were 
cryoprotect in sucrose and then embedded in OCT. 10 μm sections were made and 
thaw-mounted onto charged slides. 
 
Immunohistochemistry was performed at room temperature in the same way as it 
was done with the mice eye sections. 
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2.2.4. Scanning Electron Microscopy 
The retinae were fixed in buffered 2% paraformaldehyde and 2% glutaldehyde in 
phosphate buffered saline for 24 hours, followed by washing in PBS and then post 
fixed in 1% osmium tetroxide in 0.1M PBS for 2 hours. The tissues were then 
thoroughly washed in distilled water and then dehydrated through a graded series 
of ethanol.  The specimens were dried with a critical dry point apparatus (Bal-Tec 
CPD 030 Critical Point Dryer). After drying the samples were coated with platinum 
or gold (Cressington 308R Desktop Advancing Coating Systems) and then 
specimens were analysed using a Carl Zeiss scanning electron microscope (ΣIGMA 
VP– Advanced Analytical Microscopy).  
 
2.2.5. Western Blot 
For Western blot, the eyes were dissected on ice and the retina and RPE-choroidal 
tissues were separated and frozen in liquid nitrogen and stored at -80oC. The 
retina and RPE-choroidal tissues were sequentially extracted. The samples were 
homogenised in 2% SDS with protease inhibitor cocktail (Roche diagnostics), then 
centrifuge at 13,000 X g. The supernatant was then transferred to a new 
microcentrifuge tube and the resultant pellet was then extracted with 70% formic 
acid in water. Then centrifuge at 13,000 X g and the supernatant was transferred 
to the microcentrifuge tube and the pellet discarded. The formic acid in the 
supernatant was then evaporated using a speed-Vac concentrator (The Eppendorf 
Vacuum Concentrator Model 5301, Brinkmann) and the protein pellet was 
reconstituted in 10% dimethyl sulfoxide in 2mol/L Tris-HCl. The protein 
concentration was measured with an absorbance of 450nm and Bovine Serum 
Albumin was used as a standard protein concentration. 
 
 Equal amounts of proteins (5µg/ml) were then separated by a 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically 
transferred onto nylon membranes. The nylon membranes containing the 
transferred proteins were pre-treated with 5% non-fat dried milk in 1M PBS 
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(pH7.4) overnight and then incubated for 1 hour with monoclonal Aβ antibody 
(1:1000, Covance) followed by several washes in 0.05% Tween-20 in 1M PBS. The 
membranes were then incubated with a goat anti mouse IgG peroxidase 
conjugated secondary antibody (1:10,000, Thermo Scientific) for 1 hour. Aβ 
immunoreactivity was visualised by exposing x-ray film to blots incubated with 
ECL reagent (SuperSignal West Pico, Thermo Scientific). The total protein profile 
was determined by staining the gels with Coomassie Blue and to check that the 
extraction of proteins were consistent. The protein bands were then photographed 
and scanned. The absolute intensity of each band was then measured using Adobe 
Photoshop CS4 extended. 
 
The mouse monoclonal antibody to Aβ 4G8 which was used in 
immunohistochemistry and Western blot, is specific for the Aβ ectodomain (amino 
acid sequence 17-24 in human), a sequence that does not overlap with that of 
secreted APP and is identical in human, mouse and rat. Therefore this antibody 
excludes the possibility that the bands obtained in the Western blot and the 
protein expression observed in the immunohistochemistry were degradation 
products of soluble amyloid precursor protein which lacks the mid-domain Aβ 
epitope (Aβ17-24).  
 
2.3. Analysis 
2.3.1. Measurement of the distance between macrophages 
Images of clustered and individual macrophages for 12 and 24 months were 
captured using a 40X objective lens and a 10X eyepieces in JPEG format using Epi-
fluorescence bright-field with 24-bit colour images at 3840 x 3072 pixel resolution 
using a Nikon DXM1200 (Nikon, Japan) digital camera. Images were put together 
using Adobe Photoshop CS4 and the dendrite’s length was measured from the 
centre of the nucleus of the macrophage to the end of dendrites. To determine 
whether macrophages were regularly spaced, small clusters of six cells were 
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photographed as above and the distances between the nucleus of each cell and its 
nearest neighbour were measured. 
 
2.3.2. Counting of macrophages 
Images were captured using a 20X objective lens and a 10X eyepieces in JPEG 
format using the Epi-fluorescence bright-field microscope with 24-bit colour 
images at 3840 x 3072 pixel resolution using a Nikon DXM1200 digital camera. The 
images were then put together by Adobe Photoshop CS4 extended. The iba-1 
positive cells were counted using the count tool. 
 
2.3.3. Measurement of Aβ in RPE and photoreceptor outer segments in 
immunostaining 
 Fluorescence images of the area around the optic nerve head were taken in JPEG 
format using a 40X objective lens and a 10X eyepiece, using an Epi-fluorescence 
bright-field microscope (Olympus BX50F4, Japan) with 24-bit colour images at 
3840 x 3072 pixel resolution using a Nikon DXM1200 (Nikon, Tokyo, Japan) digital 
camera. The pictures were montaged and the integrated density, which is the 
product of the area chosen (in pixels) and the mean gray value (the measurement 
of the brightness) was measured using Adobe Photoshop CS4 extended. The lasso 
tool was used to draw a line all the way around the Bruch’s membrane and the 
integrated density was measured from 2 predefined regions per retinal section and 
5 retinal sections per animal. An average of the 10 readings was recorded. The 
same goes for the outer segments whereby the line was drawn around the outer 
segments of the photoreceptor. 
 
2.3.4. Measurement of Aβ in RPE and retina in Western blot  
The scanned pictures of the protein gel were inverted to grayscale format and the 
mean gray value was measured for each protein band by using the lasso tool to 
draw a line all the way around the edges of the band using Adobe Photoshop CS4 
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extended. The absolute intensity was calculated by multiplying the mean gray 
value and the pixel value.  
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2.4. Results 
2.4.1. Age-dependent accumulation of subretinal microglia in mice 
Fundus autofluorescence images taken using the confocal scanning laser 
ophthalmoscope (cSLO) of the 3, 6, 12 and 24 months showed an age dependent 
increase in the number of hyperautofluorescence spots in the subretinal regions 
(Figure 2.1 A-C).  These spots were variable in number but appeared to increase 
markedly in animals over 6 months of age. To visualise microglial distribution in 
the different age groups of normal mice, the eyes were processed as flatmounts 
and stained for macrophage marker Iba-1 and it was observed that there was a 
tight correlation between the hyperautofluorescence sources in vivo and the Iba-1 
positive cells when the images were overlaid (Figure 2.1 A-C), hence they were 
macrophage/microglia cells, a point also noted by Xu, et al. (106). More than 95% 
of the Iba-1 positive cells contained Aβ (Figure 2.1 A-C). The amount of Aβ in these 
cells appeared to increase with age and hence there is a direct correlation between 
Aβ and macrophages.  As with the hyperautofluorescence point sources, the 
number of microglia increased significantly with age (Figure 2.1D. ANOVA P= 
0.0286).  Changes were, however, less marked between 3 and 6 months, but they 
were significant between these early stages and 12 and 24 months (P< 0.05 in both 
cases). In 6 and 12 months old mice, the number of Iba-1 positive cells increased 
progressively and there was a significant difference between them (P=0.0221). The 
Iba-1 positive cells were morphologically ramified dendriform and they were 
regularly distributed in the subretinal space in a mosaic pattern (Figure 2.2.). The 
distance between these cells when they clustered, did not change over time but 
their dentritic processes shortened (Figure 2.2A, P=0.0082), perhaps suggesting 
that they were less efficient in the removal of cellular debris as they covered less 
surface area. When the Iba-1 positive cells were on their own and not in cluster, 
the length of the dendritic processes did not change (Figure 2.2C). These 
observations showed the ability of microglia to phagocytose Aβ and the ability to 
clear Aβ by degradation via Aβ-degrading enzymes. 
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Figure 2.1 - Retinal imaging and macrophage histology. 
 A. Scanning laser ophthalmoscope images of the retinae of mice taken at 3, 6, 12 and 24 months of age. With 
time there is an accumulation of fluorescent point sources. B. The images are overlaid with the eyecups once they 
have been stained for Iba-1 to reveal macrophages and Aβ. This shows that many of the point sources are 
macrophages containing Aβ. Arrows indicate macrophages containing Aβ. These are arranged in a grid like 
pattern. C. A higher power image of Aβ containing macrophages. D. The number of macrophages present in the 
whole mounts at progressive ages. There are significant increases at 12 and 24 months (see text for statistics).  
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Figure 2.2 - Graphs showing the distance between macrophages and measurement of the dendritic processes. 
 A. Graph showing the distance between macrophages in a cluster of seven cells for the 12 months and six cells 
for the 24 months.  B. Graph showing the length of the dendritic processes of these seven cells of the 12 months 
and six cells of the 24 months (P< 0.01). C. Graph showing the length if the dendritic processes of eight individual 
macrophage cells for the 12 months and four individual cells for the 24 months. 
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2.4.2. Age-dependent accumulation of Aβ in mouse and human eyes 
Immunostaining of the retinal and RPE sections revealed that Aβ expression was 
primarily present along the Bruch’s membrane/RPE interface (Figure 2.3.) and at 
the level of the photoreceptor outer segments (Figure 2.4) and along the retinal 
and choroidal blood vessels of normal C57Bl/6 mice (Figure 2.5) and its 
progressive accumulation with age was observed (Figure 2.4.). At 3 months of age, 
the mice had sparse but detectable Aβ deposits. The accumulation was more 
significant towards the age of 6 months and onwards. By 12 months of age, Aβ 
deposits were distributed along the Bruch’s membrane and throughout the outer 
segment of the photoreceptors. The accumulation of Aβ was presented 
quantitatively with integrated density at the Bruch’s membrane/RPE interface and 
for the photoreceptor outer segments in immunohistochemical preparations 
(Figure.2.4B and C) and using Western blot analysis (Figure 2.4D-G). 
  
Aβ deposition on Bruch’s membrane/RPE interface was increased in stages from 
3-6 months and from 6-12 months in immunostained tissue. The difference over 
the 3 time periods shown in Figure 2.4 was significant (ANOVA P=0.0002). Post-
hoc testing revealed that differences between 3 and 12 months and 6 and 12 
months were significant (P=0.0006; P=0.0026, respectively). Similar patterns were 
found with Aβ deposition over time around photoreceptor outer segments (Figure 
2.4C). Differences in age groups were significant (ANOVA P<0.0001), but post-hoc 
testing revealed that significant differences were between 3 and 12 months and 6 
and 12 months (P<0.0001; P<0.0001 respectively), but not between intermediate 
stages. 
 
Aβ staining of whole mounted retinae also revealed the age-dependent 
accumulation of Aβ in retinal blood vessels. When the tissue was sectioned to 
examine the accumulation of Aβ in other retinal regions it was clear that it also 
accumulated in the choroidal blood supply. Here specific vessels became heavily 
labelled while others appeared to be devoid of Aβ (Figure 2.5). In order to confirm 
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the presence of Aβ in the choroidal vasculation, another method of 
immunohistochemistry was performed using a colorimetric staining to rule out all 
background staining and false positive (Figure2.6). 
 
Western blot analysis was also undertaken to quantify age-related changes in Aβ 
deposition in the mouse retina and at the RPE/Bruch’s membrane interface. The 
results of the RPE/Bruch’s membrane analysis showed a consistent increase of Aβ 
expression over age (Figure 2.4D and 2.4F, ANOVA P = 0.0448). Post-hoc testing 
demonstrated significant differences between 3 and 6 months and 3 and 12 
months (P= 0.0415; P=0.0110 respectively). Differences between 6 and 12 months 
were not significant. In the retina a similar pattern was found (Figure 2.4E and 
2.4G). Overall there was a significant increase in Aβ accumulation (ANOVA P= 
0.0317). Post-hoc testing showed that differences were significant between 3 and 6 
months and 3 and 12 months (P<0.0326; P<0.0057 respectively). The two most 
distinct oligomers of Aβ present in the retina and RPE were the hexamers (22-36 
kDa) and docecamers (50-64 kDa). Figure 2.4 H and I show the quantitative 
accumulation of the two most distinct oligomers of Aβ, the >22kDa and the 
>50kDa, present along the Bruch’s membrane /RPE interface and in the retina. The 
results showed that both the >22kDa and the >50kDa oligomers increased with 
age. These results were largely consistent with that found using 
immunohistochemistry. The differences at the 6-month stages could be due to the 
differences in the volumes of the tissue sampled and their origins, as the Western 
blots included choroidal and retinal blood vessels. If rates of Aβ accumulation in 
these differed from those in the outer retina and at the Bruch’s membrane/RPE 
interface some variation between immunohistochemical and Western blot analysis 
might be expected. 
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Figure 2.3 - Immunofluorescence of a mouse RPE/BM section stained with Aβ. 
The figure shows the presence of Aβ 4G8 (red) along the BM. The nuclei were stained with DAPI (Blue). Scale bar 
= 20µm. 
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Figure 2.4 - Aβ was deposited at the Bruch’s membrane (BM)/RPE interface and among photoreceptor outer 
segments. 
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A. The accumulation of Aβ in sections showing BM/RPE interface and the regions of the outer segments (OS) in 
mice of 3, 6 and 12 months age. Here Aβ label is red and the outer nuclear layer (ONL) is blue. This progressive 
accumulation was quantified with two independent methods at the two sites. First, the integrated density of 
label from immunostained sections was measured. The results of this are shown graphically in B and C. There 
were significant increases at both sites, particularly at 12 months (see text for levels of significance). Second, 
Western blots were run for Aβ at each site shown in D and E. F and G show the measurements at the same three 
time points as in B and C. The amount of Aβ increased significantly over time (see text for levels of significance). 
Differences between B and C and F and G were probably due to the different amounts of tissue sampled, as F and 
G would also include measures derived from inner and outer retinal blood vessels. H and I show quantification of 
the two main distinct oligomers of Aβ, the >22kDa and the >50kDa, present in the retina and the RPE/BM. There 
was an increase in both the >22kDa and >50kDa oligomers at the age of 6 months and onwards. 
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Figure 2.5 - Retinal blood vessels stained for Aβ. 
A. Inner retinal vessels stained for Aβ (red), Iba-1 (green) and neuronal cell bodies (blue) at 24 months. B. Inner 
retinal vessels shown at a higher magnification than A at 24 months. Here the amyloid deposits can be seen to be 
at focal points along the vessel rather than being continuous. C. Choroidal vessels also accumulated Aβ, however, 
the accumulation of this material appeared to be specific to a sub-group of vessels with other showing no sign of 
Aβ accumulation. This was taken from a 12 months old animal. 
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Figure 2.6 - Aβ was deposited on the outer segment of the photoreceptors. 
The accumulation of Aβ in retinal sections of mice of 12 months old. Here the Aβ was stained in brown using the 
ABC-DAB substrate. This is another method of immunostaining to confirm the presence of Aβ in the outer 
segment of the photoreceptors and also in the choroidal blood vessels. Note the absence of staining in the 
negative control where the primary antibody was omitted. 
 
To investigate whether similar patterns of Aβ accumulation were present in the 
photoreceptor outer segments in human tissue, four human retinae spanning from 
31-90 years were immunostained with the same Aβ antibody. A progressive 
accumulation of Aβ with age was observed (Figure 2.7B.). Although only one retina 
at each time point was examined with only one method, the results were very 
similar to that found in mice, with a marked accumulation of Aβ over time. The 
drop observed in the accumulation of Aβ in the 90 years old retina might be due to 
loss and shortening of photoreceptors.  
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Figure 2.7 - Fluorescence images of the accumulation of Aβ in human retinal sections. 
(A) Section of human RPE/BM (10µm thick) of an 87 y/o that has been stained with Aβ 4G8 (red) and C3b (green). 
Druse (*) was positive for Aβ.  (B) Aβ staining in human outer retina from individuals aged 31, 47, 80 and 90 
years. This was undertaken on retinae separated from the RPE. Aβ is red and the outer nuclear layer (ONL) is 
blue. The outer segments (OS) were positive for Aβ but the intensity of the staining increased with age. In spite of 
this, the overall progression of Aβ accumulation here mirrors that found in mice. Scale bar -50μm  
  
* 
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2.4.3. Scanning Electron Microscopy imaging of photoreceptor outer segments 
The results presented above reveal quantitative increases in Aβ deposition with 
age in mouse using immunohistochemistry and Western blots. Although these 
results combined two quantitative methods for measuring Aβ accumulation, the 
presence of this material was unexpected on photoreceptor outer segments. 
Consequently a third method, scanning electron microscopy (SEM), was adopted to 
investigate this deposition in tissue taken at 3, 6, 12 and 24 months (Figure 2.8). 
This analysis revealed an increasing accumulation of highly fragmented material 
on the outer segments with age. This stopped at the inner–outer segment junction 
of the photoreceptor, which reflected the patterns seen using 
immunohistochemistry. 
 
Deposition could be identified at 3 months and it was more prominent along outer 
regions of the outer segment at this stage. The amount of material found here 
increased between 3-6 months (Figure 2.8). Consistent with the immunostaining 
(Figure 2.4A), there was a marked increase in this material at 12 months. At this 
stage the outer segments appeared almost completely wrapped in the material. At 
24 months the outer segments appeared qualitatively different as many had 
enlarged tips (Figure 2.8). This might be indicative of less efficient patterns of 
phagocytosis by RPE cells, which remove the end of the photoreceptors daily to 
compensate for the addition of new photoreceptor disks at the outer segments 
base (9, 117). For such reasons, it was not possible to determine whether more 
debris accumulated on them than at earlier times. At all stages, there was no direct 
proof that the debris that accumulated on outer segments was Aβ but the close 
association between immunostaining patterns and the scanning EM images would 
argue that Aβ was at least an element of such deposits. 
 
There appeared to be not only a gradual increase in material on outer segments, 
but also a marked change in its appearance between that found at 3-6 months and 
that present at 12 months. At the earlier stages, the deposits tended to be spherical 
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or to have rounded edges. At 12 months and after, spherical bodies could also be 
identified. The majority of the deposits, however, now appeared to have a 
fragmented wire like appearance. In many cases, the deposits adopted a 
morphology similar to ruptured spheres, leaving angular edges on the side of a 
distorted hemisphere (Figure 2.9). 
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Figure 2.8 - Scanning electron micrographs of photoreceptor outer segments. 
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They were taken from animals at 3, 6, 12 and 24 months of age. In each case the right hand panel is a higher 
magnification of that on the left and the orientation is such that the RPE would be to the top and the outer 
nuclear layer to the bottom. Even at 3 months of age deposits could be found on outer segments, however they 
were more common towards the tip of the outer segment than the base. They were largely spherical in 
morphology or had rounded edges. By 6 months, their coating had increased and the deposits were present along 
the length of the outer segment.  At 12 months the deposits have thickened, but also appear to have changed 
qualitatively (See Figure 2.9). At 24 months while thick deposits remain, the tips of many outer segments have 
enlarged and those that remain were shorter making direct comparison with earlier stages difficult. n = 4 animals 
per group. 
 
 
Figure 2.9 – Scanning electron micrographs of 3-month and 12-month-old photoreceptor outer segments. 
There appeared to be a qualitative change in the morphology of deposits found on outer segments at 12 months 
of age.  The two panels show higher magnification scanning electron micrographs of debris on outer segments at 
3 and 12 months. At the earlier stage the deposits were largely spherical with thin processes connecting them to 
the wall of the outer segment. At 12 months a very different picture is present. Here the deposits appear as 
ruptured hemispheres that have partially collapsed leaving rough edges.  
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2.5. Discussion 
 
Aβ is a known constituent of drusen (44, 84, 90), which are age-related deposits 
found between the RPE and the Bruch’s membrane of the human eye and are the 
key risk factors for developing AMD (37). In this study, site-specific age-related 
accumulation of Aβ in the mouse retina was demonstrated. This occured primarily 
among the photoreceptor outer segments and on the RPE/Bruch’s membrane 
interface. Two of the independent methods used here, Western blots and 
immunostaining, were quantitative and Aβ specific. The third, the scanning EM, 
provided structural images for the potential Aβ containing elements deposited on 
the outer segments. It was demonstrated in vivo, using the cSLO that in the normal 
ageing mouse retina, there was an age-related accumulation of macrophages that 
internalised Aβ and appeared to establish individual exclusion territories. Aβ 
deposition in the outer segment of the photoreceptors was also examined in 
human retinae using immunostaining, showing that as in mice, Aβ accumulated 
with age.  
 
Age-related accumulation of Aβ rich extracellular deposits along the Bruch’s 
membrane and also in the outer segments of the photoreceptor was observed in 
both human and mouse by immunostaining. It was revealed that photoreceptors 
themselves became increasingly coated with debris.  Western blot results in mouse 
tissue showed that the most abundant types of Aβ present in both the outer 
segment of the retina and in the RPE-choroidal tissues were the 22-36 kDa and the 
50-64kDa oligomers. These oligomers were also found in the brain of AD murine 
model (108). In the brain of an AD transgenic mice was demonstrated that 56kDa 
Aβ oligomers are viable candidates for Aβ assemblies that cause memory deficits 
as they appear at 6 months old when memory deficit starts. The 27 kDa oligomers 
are present before memory impairment and they do not affect memory function. 
Therefore the 50-64kDa bands obtained in this study might be the one that is toxic 
in the retina. Lesné et al. (2006) (108) have also demonstrated that the level of the 
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56kDa remains stable between 6 months and 13 months in the brain and this 
result reflected the same pattern as there was no significant difference in the level 
of Aβ in the mouse retina and at the RPE/Bruch’s membrane between these two 
age groups. 
 
Accumulation of Aβ in the brain has an adverse effect on the recruitment of 
macrophages cells at the site of Aβ deposition. Aβ is a chemotactic factor for 
microglia (97) and production of monocyte chemotactic protein-1 and interleukin-
8 is stimulated by human monocytes and murine microglia (98). Microglia migrate 
in response to the chemokine monocyte chemoattractant protein-1, and 
incorporate Aβ in an internal attempt to remove it (104, 118). Through its 
interaction with C1q, Aβ can activate the complement cascade (100). Aβ alone, or 
in combination with interferon γ, activates nuclear factor-κB and induces the 
secretion of tumour necrosis factor-α (TNF-α) and nitric oxide (99, 119-121). The 
emerging data support the role of Aβ as an immune effector molecule that can 
activate microglial function. In the brains of Alzheimer’s disease patients, activated 
microglia are associated with virtually every amyloid deposit and are concentrated 
in regions of compact amyloid deposits (122) where they surround and infiltrate 
the deposits (123). 
 
In addition to an increase in Aβ deposition over age, there was a marked and 
persistent activation of microglial cells. Once the microglia adhered with the Aβ 
deposition, it became immobilised and started to ingest and degraded it (104) but 
retained a regular distance from each other. Increasing evidence indicates that 
microglia may play a protective role by mediating clearance of Aβ. Retinal 
microglia and choroidal macrophages are important cells responsible for the 
removal of retinal waste materials. Retinal cells such as photoreceptors have high 
metabolic activity (9, 117) and therefore produce a lot of Aβ as waste materials. 
These accumulations of Aβ both in the photoreceptor and on the Bruch’s 
membrane trigger an inflammatory response, which in turn activate microglia 
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cells. Microglia in subretinal space may be more phagocytically active in 
comparison to microglia in other retinal sites. With age, these cells may become 
less capable of digesting phagocytosed waste material, which finally become 
evident as increased lipofuscin deposits (106) and also Aβ and thus become 
‘overloaded’ with waste material. As a result, more and more microglia are being 
recruited to maintain the homeostasis of the retinal environment and hence the 
increase in their number, clustering around the Aβ /lipofuscin sites with age. Early 
microglial accumulation delays disease progression by promoting clearance of Aβ 
before the formation of drusen in the eye.  However, persistent Aβ accumulation 
despite increasing microglial numbers suggests that the ability of microglia to clear 
Aβ may decrease with age and progression of AMD pathology. 
 
In the brain, macrophage numbers have been increased experimentally in an 
animal model of AD where amyloid accumulation is marked. This resulted in not 
only a reduction in amyloid accumulation, but also prevented cognitive decline 
(124). It would be surprising if the same were not the case in the retina. Many 
macrophages seen in older animals appeared bloated with material that included 
Aβ. As they were so bloated, their ability to remove further quantities of Aβ might 
have been compromised. As in the brain, one way around this might be the 
recruitment of new macrophages into the local environment. As we have shown, 
macrophages in the retina do increase with age, but only over a larger retinal area 
with no increase in local density. Once initially established, macrophages appeared 
to maintain exclusion territories that restricted the entry of new cells into their 
matrix. New cells appeared to extend the coverage of the matrix but not its local 
density. 
 
Studies have revealed the presence of Aβ in drusen and nothing has been said 
about its presence in the outer segment of the photoreceptors. Human retinal 
sections were immunostained with Aβ antibody and it was noticed that the amount 
of Aβ accumulated in the outer segment in human sections, plateaued at the age of 
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around 80 and then decreased at around 90 years old and this might be because 
with age, many changes occur in the retina. Approximately 25-30% of rod 
photoreceptors are lost and those that remain shorten by a similar proportion 
(125, 126). These changes are probably associated with the distinct functional 
changes found in the electroretinogram (ERG). Here, the amplitude of component 
waves of the ERG, both receptoral and post receptoral, decline in magnitude (127-
130). The outer retina has the largest metabolic demand in the central nervous 
system (130, 131) and any deposition along Bruch’s membrane/RPE interface 
restricting its access to the choroidal blood supply is likely to be detrimental to 
retinal function, probably contributing to age-related cell loss. More intriguing, is 
the potential impact the outer segment debris is likely to have upon photoreceptor 
function, which is unknown. 
 
In mice, Aβ was present in the vascular network of the inner and outer retina. Here 
the most marked feature was that while inner retinal vessels accumulated Aβ in a 
patchy progressive manner along their length, choroidal vessels were different in 
that some accumulated Aβ deposits while others seemed to remain Aβ free. There 
is a correlation between retinal degeneration and AD (113, 116) and it has been 
demonstrated that AD patients suffer visual disturbances (131-133). One reason 
for this might be because such disturbances arose from the narrowing of retinal 
blood vessels and decreased blood flow (134, 135). Ning et al. (113) have shown 
that in an AD murine model, there is an accumulation of Aβ in the retinal and 
choroidal vasculature, which is consistent with our finding of Aβ deposition in 
vessels. This may explain the narrowing of the retinal blood vessels and the 
decreased blood flow found in AD patients. 
 
In Alzheimer's disease, it has been suggested that microglia continue to produce 
proinflammatory cytokines, but lose their Aβ-clearing capabilities with disease 
progression.  Expression of microglial Aβ receptors and Aβ-degrading enzymes is 
reduced, resulting in reduced Aβ uptake and degradation, and increased Aβ 
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accumulation (136). These data provide evidence to support the paradigm that 
microglia in the eye are recruited to sites of Aβ deposition as part of an attempt to 
clear these neurotoxic peptides. With age, these microglial cells fail to phagocytose 
and digest the Aβ deposition as they become bloated with waste materials. Hence 
more and more microglia are recruited to maintain the homeostasis of the retinal 
environment. Anti-inflammatory therapy that focus on the functions of microglia 
and promotes their ability to clear Aβ, while decreasing their ability to produce 
proinflammatory cytokines, may indeed be very helpful to delay or stop the 
progression of age-related macular degeneration. 
 
This study reveals the presence of extracellular material at the EM level specifically 
on photoreceptor outer segments, which is a novel finding. The material appeared 
to initially accumulate at the apical tip of the outer segment and progress down 
along its length with age, but at no point did this material encroach upon the inner 
segment. This indicated that the focus of the accumulation was at the interface of 
the RPE with the photoreceptor outer segment tip, implying that accumulation of 
debris was in some way related to a decline in the efficiency of the RPE 
phagocytotic process (9, 117). If this is correct, then it would suggest that to fully 
understand the ageing process in the outer retina, the age-related changes in the 
RPE population and shifts in their efficiency must be taken into account. 
 
Significant differences were found in the intensity of the Aβ antibody staining on 
the outer segments around 12 months of age, which coincided with a marked 
change in the appearance of deposits at the EM level. Initially the deposits were 
roughly spherical, but later many appeared to rupture giving the appearance of 
distorted hemispheres with rough sharp edges. 
 
The explanation for this distinct morphological change at this stage remains 
illusive. Given the large number of EM studies undertaken on the outer retina over 
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the years, it is rather surprising that deposition of debris has not been reported 
before on outer segments. The answer to this question probably relates to the 
electron density of the material and the fact that most studies have used relatively 
young animals with transmission EM. However, the images in this study were 
generated by platinum coating a fractured surface of the retina, which would 
reveal 3 dimensional deposits on structures.  Aβ is assumed to be an element of 
these depositions as there is a close association between the immunostaining 
pattern and the scanning EM images. An additional consideration is that when Aβ 
is viewed with transmission EM it tends to be amorphous and as such is commonly 
missed unless specifically targeted (137, 138). Scanning EM has the advantage of 
providing a 3 dimensional picture where extracellular deposition is much more 
obvious. Our lab has undertaken transmission EM studies on aged rodent 
photoreceptors where tissue is viewed in section and failed to identify the 
structures seen here (125), although re-examination of the tissue now has 
revealed amorphous bodies with little structures between the outer segments, 
particularly around their tips (Unpublished observation). 
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3. Abstract 
 
Age-related macular degeneration (AMD) is the most prevalent form of 
irreversible blindness worldwide in the elderly population. It is a late-onset, 
neurodegenerative retinal disease that shares several clinical and pathological 
features with Alzheimer’s disease (AD) including extracellular deposits containing 
amyloid beta (A ) peptides. Immunotherapy targeting the A  protein has been 
investigated as a potential treatment for AD. Recently Ding et al. (114) have shown 
that this approach of targeting A  protein can also be extended to treat AMD. In 
this study, the same approach was used to target A  protein in a mouse model of 
advance ageing by administering systemically a mouse monoclonal anti-A  
antibody. The efficacy of the treatment was examined via systemic delivery both 
prophylactically and therapeutically. Histological and functional measurements in 
treated and control animals were compared and it was shown that there was a 
decrease in the amount of A  and the active form of complement component C3, 
C3b, along the Bruch’s membrane.  
 
This study shows that prophylactic treatment has a significant ability to prevent 
the formation of A  deposits and prevent the onset of inflammatory response, and 
hence, the activation of complement alternative pathway. Both the prophylactic 
and therapeutic treatments decrease the amount of A  deposition along the 
Bruch’s membrane, which is an earlier sign of AMD pathology. Hence, systemic 
delivery of anti-A  in this mouse model of advanced ageing significantly improves 
pathological featured associated with the disease phenotype as it decreases 
deposition of both A  and uncleaved and active forms of C3 along the Bruch’s 
membrane thus restoring control of the activation of the complement alternative 
pathway. 
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3.1. Introduction 
 
Age-related macular degeneration (AMD) is a late-onset neurodegenerative retinal 
disease that manifests as progressive loss of central vision due to dysfunction and 
death of photoreceptor and adjacent retinal pigment epithelial (RPE) cells, 
accumulation of lipofuscin and formation of drusen in the macula. It is the most 
common cause of visual impairment in individuals over the age of 55 in the 
Western world (139). AMD is a blinding disorder that compromises the central 
vision and is characterised by the degeneration of the macular retina and choroid 
by atrophy or detachment and scarring caused by choroidal neovascularisation 
(45, 58). Early clinical manifestation and pathological feature of AMD is the 
development of drusen, extracellular deposits of glycoproteins, lipids, and cellular 
debris located inside Bruch’s membrane and beneath the retinal pigment 
epithelium (43). Drusen size, number, and degree of confluence are significant risk 
factors for the development of AMD.  
 
It has been suggested that drusen as well as other aged-related changes that occur 
near Bruch’s membrane, may lead to the dysfunction and/or degeneration of the 
RPE and retina by inducing ischemia and/or restricting the exchange of nutrients 
and waste products between the neural retina and choroid (58). The thickness of 
drusen deposits have been shown to correlate with the degree of retinal pigment 
epithelium degeneration, reduction of photoreceptor and visual loss (140). With 
age, drusen can further accumulate on either side of the elastin layer in the Bruch’s 
membrane (141). Bruch’s membrane is a connective tissue layer that lies between 
the metabolically active retinal pigment epithelial cells and the choriocapillaries. It 
supplies nutrition to the retinal pigment epithelium cells (142) and regulates ionic 
and metabolic exchange between the retinal pigment epithelium and the 
choriocapillaries (33).  
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Recent findings on the molecular composition of drusen have implicated 
inflammation, and particularly local activation of the alternative pathway (AP) of 
the complement cascade in the retina, in the pathogenesis of AMD (43, 44, 46). A 
number of triggers may initiate these immune events and identification of these 
factors may lead to new therapeutic approaches, indicating that immunological 
factors are involved not only in the pathogenesis of AMD, but also in the treatment. 
 
The complement system may have an important role in the pathogenesis of age-
related macular degeneration, since other factors such as factor B and complement 
components C2 and C3 are also associated with age-related macular degeneration 
(143, 144). Mullins et al. (145) identified the presence of the complement 
component 5 (C5) and the membrane attack complex (MAC) consisting of 
complement components 5b-9 (C5b-9) in drusen from human eyes, including AMD 
eyes. These observations suggest that age-related macular degeneration, like other 
age-related diseases such as Alzheimer’s disease and artherosclerosis, may involve 
a major inflammatory component.  
 
Genetic investigations have shown that polymorphisms in the gene encoding 
complement factor H (CFH) are the most consistent genetic risk factors for AMD 
(146). CFH is a negative regulator of the complement system. It inhibits the 
activation of the alternative pathway either by promoting the inactivation of C3b 
by Factor I-mediated or by displacing Factor Bb from the C3bBb complex (147). 
CFH dysfunction may lead to excessive inflammation and tissue damage and 
contribute to the pathogenesis of AMD (148). Aged transgenic complement factor 
H knockout mice were used for this purpose as they exhibit a number of AMD 
pathologies such as reduced visual acuity and rod responses, accumulation of 
complement component C3 (C3) in the retina and along the Bruch’s membrane, 
secondary C3 deficiency, uncontrolled C3 activation, which may increase 
phagocytic uptake and cause neural damage to the retina (145, 149). There is an 
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accumulation of A  along the Bruch’s membrane and an increase in 
autofluorescent spots and macrophages in the subretinal space.  
 
Studies (47, 68, 84) have shown that in AMD, the substructural elements within 
drusen contain A  peptides and therefore AMD shares several clinical features 
with Alzheimer’s disease (AD). A  deposition in the sub-retinal space may 
contribute to the local inflammatory events involved in drusen formation and 
perhaps to the RPE atrophy, photoreceptor cell death, and choroidal neovascular 
events that are directly responsible for the loss of vision in AMD (47). A  activates 
the alternative pathway by triggering the formation of covalent, ester linked 
complexes of A  with C3b/iC3b, an activation product of the complement C3 (59). 
A  colocalises with activation-specific fragments of complement C3 in unique 
substructural domains, ‘amyloid vesicles’ within drusen (84). A  has also been 
shown to bind to complement factor I, a co-factor of complement factor H, which 
then inhibit the cleavage of activated C3, C3b, into its inactivated form iC3b(150). 
 
 In the treatment of AD, A  has become a major therapeutic target, with various 
anti-A  strategies being pursued. These strategies include decreasing the 
production of A  by inhibiting the enzymes that are involved in the production of 
A , preventing A  aggregation and increasing the rate of A  clearance from the 
brain. Most A  immunotherapy uses anti-A  antibodies, generated following either 
vaccination or introduced passively, to increase the rate of clearance and prevent 
aggregation of this peptide. This approach of targeting A  protein was extended to 
treat AMD by administering systemically an anti-A  antibody in the CFH knockout 
mice.  
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In this study, prophylactic and therapeutic treatments were tested to see whether 
an anti-A  antibody delivered systemically, efficiently deplete A  in homozygous 
CFH knockout mice, which will then ameliorate the disease AMD. 
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3.2. Materials and Methods 
3.2.1. Animals 
Homozygous CFH knockout mice were backcrossed onto the C57Bl/6 genetic 
background for more than 10 generations, were fed lab chow and libitium and 
housed in a temperature-controlled environment with a 12-hour- day (160 lux) 
light/dark cycle. All animal procedures conformed to the United Kingdom Animal 
License Act 1986 (UK) and local ethical regulations. 
 
Two small cohorts of mice aged about 6 months; one cohort of 4 CFH knockout 
mice and the other cohort of 4 wild type C57Bl/6, were first immunostained with a 
mouse monoclonal antibody to amyloid beta 4G8 (1:500, Covance) to compare the 
accumulation of A  along the Bruch’s membrane. It was found that CFH knockout 
mice accumulated more A  along the Bruch’s membrane in comparison to age-
matched wild types as shown in the figure below (Figure 3.1., P<0.0001). Marked 
differences in the accumulation were seen at the age of 6 months and onwards. 
This suggests that CFH knockout mice not only exhibit a number of AMD 
pathologies such as reduced visual acuity and rod responses, accumulation of 
complement C3 in the retina and along the Bruch’s membrane, secondary C3 
deficiency, uncontrolled C3 activation, which may increase phagocytic uptake and 
cause neural damage to the retina (145, 149) but also accumulate A  along the 
Bruch’s membrane at a faster rate than the control group. 
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Figure 3.1 - Representative pictures and graphs of A  along the BM of wild type and CFH knockout mice of 
different ages. 
The graph shows the quantitative results of the amount of Aβ (red) present along the RPE/BM interface. There is 
a significant increase in the accumulation of Aβ at the age of 6 months and onwards in the CFH knockout mice 
(P<0.0001) in comparison with the wild type. (Scale bar = 50 μm; n=3) 
 
The mouse monoclonal anti-A  antibody 6F6, B456-2008, GRITS 32750, 
concentration 4.59mg/ml is a synthetic peptide from a region of the human Aβ  
which recognise the middle portion, 27-38 amino acids of the Aβ peptides  in the 
human sequence, was provided by GlaxoSmithKline (GSK) It was administered by 
intraperitoneal injection to the mice. There were two studies; the first study was 
the prophylactic treatment, which determines the efficacy of preventing the 
accumulation of A  and the second study was the therapeutic treatment which 
determines the efficacy disease amelioration. Time-points for respective treatment 
were determined based on the onset and progression of pathologies in the 
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knockout mouse model. The prophylactic treatment was started when the mice 
were 3-months old before any significant accumulation of A  started and the 
therapeutic treatment was started at the age of 6 months. 
 
The 6F6 anti-A  antibody was administered systemically through intraperitoneal 
(IP) injections of different titrates as 0.4ml dosages in prophylactic study and 
0.5ml dosages in therapeutic study. The prophylactic treatment was done for a 
duration of 3 months and the therapeutic treatment was done for a duration of one 
month and three months. 
 
3.2.2. Prophylactic treatment 
Five groups of three-month-old CFH knockout mice (± 2 weeks), each containing 5 
animals (n= 25) were used for the prophylactic treatment. Three groups were 
given the 6F6-GSK anti-A  antibody, systemically by IP at the following titrates; 
60µg/ml, 300µg/ml and 600µg/ml. Control groups were given sterile phosphate 
buffered saline (PBS), pH 7.4 as negative control and for a positive control, another 
group was given an anti-A  antibody 2286 provided by GSK and is a version made 
by GSK of the C-terminal Rinat antibody to 2H6 (HEK 244 Rinat 2286 mIgG 
2a/mcK, concentration 0.56mg/ml in sterile PBS, EK ELNB N7452-17) used by 
Catherine Bowes Rickman (114) that is known to clear A  accumulation and the 
titrate given was 60µg/ml. Five age-matched control wild type C57Bl/6 mice were 
given titrate of 60µg/ml. For baseline, 5 three-month old CFH knockout mice were 
culled and their eyes were removed and processed for immunostaining. The mice 
received weekly injections of the antibodies for three months. 
 
3.2.3. Four weeks therapeutic treatment 
Five groups of six-month-old CFH knockout mice (± 1 month), each group 
containing 4 animals were used in the one-month therapeutic treatment. One 
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group was used as baseline and they were culled and their eyes were removed and 
processed for immunohistochemistry. Two groups were given the 6F6 anti-A  
antibody at titrations; 60µg/ml and 600µg/ml. A fourth group was used as 
negative control and was given sterile PBS. The last group was used as a positive 
control and were injected with the anti-A  antibody 2286. One group of 4 wild 
type C57Bl/6 six months old mice were injected with the 6F6 anti-A  antibody at a 
concentration of 600µg/ml. The mice were injected every week for one month.  
 
3.2.4. Twelve weeks therapeutic treatment 
Four groups of six-months-old CFH knockout mice (± 1 month), each group 
containing 4 animals, were used in the three months therapeutic treatment. Two 
groups were treated with the 6F6 anti-A  antibody at a concentration of 60µg/ml 
and 600µg/ml. One group was injected with PBS and the last group was used as 
the positive control and was treated with the anti-A  antibody 2286. The mice 
received weekly injections of the antibodies for three months. 
 
3.2.5. Immunohistochemistry  
After the prophylactic and the one-month therapeutic treatment, the mice were 
culled by an overdose of anaesthetic. Both eyes of each animal were used in this 
study. The eyes were removed and fixed in 4% paraformaldehyde in phosphate 
buffered saline (PBS), pH 7.4 for 1h. They were then cryopreserved in 30% sucrose 
and embedded in optimal cutting temperature compound (OCT, Agar Scientific 
UK). Cryostat sections were cut at 10μm and thaw-mounted onto charged slides. 
Immunohistochemistry was performed at room temperature. 
 
The sections of the eye were incubated for 1 hour in a 5% Normal Donkey serum in 
0.3% Triton X-100 in PBS, pH 7.4, followed by an overnight incubation with the 
following primary antibodies; Mouse monoclonal antibody to Aβ 4G8 (1:500, 
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Covance) and Rat monoclonal antibody to mouse C3b/iC3b/C3c (1:50, Hycult 
biotechnology) were made in 1% Normal Donkey Serum in 0.3% Triton X-100 in 
PBS. After primary antibodies incubation, the sections were washed three times in 
0.1M PBS and then incubated in respective secondary antibodies conjugated with 
either Alexa Fluor 488 or 568 (Invitrogen) which were made up in 2 % Normal 
Donkey Serum in 0.3% Triton X-100 in PBS at a dilution of 1:2000, were added to 
the sections and incubated for 1 hour at room temperature. Negative controls were 
undertaken by omitting the primary antibody. After the secondary antibody 
incubation, the sections were washed several times and the nuclei were 
subsequently stained with 4', 6-diamidino-2-phenylindole (Sigma) for 1 min. Slides 
were then washed a few times in 0.1 M PBS and several washes in Tris buffered 
Saline (pH 7.5). The slides were mounted in Vectashield (VECTOR Laboratories) 
and coverslipped. Sections were viewed using an Epi-fluorescence bright-field 
microscope (Olympus BX50F4, Olympus, Japan) and the degree of expression of A  
and C3b/iC3b/C3c was measured using a grading system, which is as follows: 
I. Grade 0, No expression 
II. Grade 1, Fragmented expression/deposition or < 10% 
expression along the Bruch’s membrane 
III. Grade 2, Segmental expression/deposition or 10-50% 
expression along the Bruch’s membrane 
IV. Grade 3, Close to continuous expression/deposition, or 50-
75% along the length of the Bruch’s membrane 
V. Grade 4, a continuous expression, or > 75% along the Bruch’s 
membrane. 
Representative images were captured as 24-bit colour images at 3840 x 3072 pixel 
resolution using a Nikon DXM1200 (Nikon, Japan) digital camera. 
 
The Aβ expression was quantified by setting an intensity threshold, which was set, 
based upon visual reviewing of microscopic slides of the negative control of each 
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group of treated CFH knockout mice and was used consistently throughout the 
analysis to discriminate nonspecific staining.  
 
A rat monoclonal antibody, which is specific for cleaved complement component 
C3 fragments C3b, iC3b and C3c and activated C3 was used in this experiment to 
identify potential sites of complement activation on the Bruch’s membrane and 
outer segment of the photoreceptors. C3b, iC3b and C3c become bound to 
complement activating surfaces as a normal consequence of the complement 
activation cascade, and thus distinguish sites of activation.  
 
 
Figure 3.2 - Representative images of the grading protocol for the Immunohistochemistry in the eyes. 
A. Grade 0, no expression along the Bruch’s membrane;B. Grade 1, fragmented expression/deposition or < 10% 
expression along the Bruch’s membrane;C. Grade 2, Segmental expression/deposition or 10-50% expression 
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along the Bruch’s membrane;D. Grade 3, Close to continuous expression/deposition, or 50-75% along the length 
of the Bruch’s membrane. Grade 4 was not shown because a continuous expression of A  was not seen in any of 
the mice. Arrows indicate A  deposition on the Bruch’s membrane. 
 
3.2.6. Optokinetic head tracking 
Optokinetic head tracking was used to evaluate the visual acuity of the CFH 
knockout mice that were treated systemically for 12 weeks. Optokinetic head 
tracking is a non-invasive technique, widely used for visual functional evaluation in 
rodents and requires no training and can be induced repeatedly with minimal 
fatigue or adaptation (151). It involves measuring an animal’s ability to track a 
moving stimulus and is based on an optokinetic test devised by Cowey and 
Franzini (152). The optokinetic head-tracking response is compensatory eye 
movement that reduces movement of image across the retina (153) and therefore 
is an efficient way to test the visual acuity of an animal by measuring its ability to 
track moving stimuli at a series of spatial frequencies. Animals with normal vision 
exhibit this automatic reflex, tracking a moving stimulus by repeatedly turning 
their heads in the direction of the movement (154). Measurement of the length of 
time an animal spends tracking the moving stimulus has been shown to be a 
reliable method for quantifying the level of visual function. The protocol yielded 
independent measures of the acuities of right and left eyes based on the unequal 
sensitivities of the two eyes to pattern rotation, the left eye is more sensitive to 
clockwise rotation and the right eye is more sensitive to anti-clockwise rotation. In 
this study, clockwise and anti-clockwise tracking times were pooled due to the fact 
that the treatment was systemic. 
 
Mice that have undergone therapeutic treatment for 3 months were tested for the 
optokinetic head tracking. The mouse was placed in the centre of a rotating vertical 
cylinder in which the inside was covered with vertical black and white stripes. 
Three gratings with increasing spatial frequencies were used in this experiment; 
0.0625, 0.125 and 0.25 cycles/deg. The vertical cylinder was alternately rotated 
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clockwise and anti-clockwise for 90 seconds, interspaced by a 30 seconds pause. 
Each mouse was only tested at one grating frequency per day. A video camera 
mounted above the cylinder was used to record head movements and the readout 
was used for analysis. The rotation speed of the cylinder was 12 degrees/second 
and the mean illuminance at the surface of the grating was 1000 lux. Each animal 
was tested three times, one time for each grating frequency, on consecutive days. 
The time the test groups spent following the different gratings in each direction 
was pooled, quantified and compared against the negative control group. 
 
 
Figure 3.3 –Schematic diagram of the optokinetic head tracking as tested in the treated mice. 
The mouse was placed into a drum into which a square wave grating was placed. The drum was then slowly 
rotated clockwise and anticlockwise and the times spent following the gratings were then noted. Three gratings 
of different spatial frequencies are used: (a) 0.0625 (b) 0.125 and (c) 0.25 cycles/deg. Images are from Lund et al., 
2001 (154).  
 
After the optokinetic head-tracking test, the mice were culled by an overdose of 
anaesthetic and the eyes were removed and processed for immunohistochemistry 
as mentioned above. 
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3.2.7. Immunohistochemistry in renal sections 
Accumulation of Aβ and C3 were also examined in the kidneys to check the 
systemic effect of the 6F6 antibody other than the eyes. Kidneys of the 12 weeks 
therapeutically-treated mice were removed and processed in the same way as the 
eyes for immunohistochemistry.  The cryostat sections were immunostained with 
the mouse monoclonal antibody to Aβ 4G8 (1:500, Covance) and a Rabbit 
polyclonal antibody to complement component C3 (1:20, Abcam). Sections were 
then viewed and images captured using Epi-fluorescence and bright-field. 24-bit 
colour images were captured at 3840x3072 pixel resolution. 
 
The amount of Aβ and C3 expression in the glomerulus was measured using a 
grading system according to the degree of expression as follows; 
Grade 0, No expression  
Grade 1, < 10% expression 
Grade 2, 10-50% expression 
Grade 3, 50-75% expression 
Grade 4, <75% expression. 
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Figure 3.4 - Representative images of the grading protocol of C3 expression for immunohistochemistry in the 
glomeruli of the kidney. 
Green fluorescence shows C3 expression. A. Grade 0, no expression in the glomerulus; B. Grade 1, < 10% 
expression in the glomerulus; C. Grade 2, 10-50% expression in the glomerulus; D. Grade 3, 50-75% expression in 
the glomerulus. E. Grade 4, >75% expression of C3 in the glomerulus. F. Schematic diagram of the structure of a 
glomerulus. DAPI stains the nuclei blue. (Scale bar = 50μm) 
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Figure 3.5 - Representative images of the grading protocol of Aβ in the glomeruli of kidneys for 
immunohistochemistry. 
Red fluorescence shows Aβ expression. A. Grade 0, no expression along the glomerular basement membrane; B. 
Grade 1, fragmented expression/deposition or < 10% expression along the glomerular basement membrane; C. 
Grade 2, Segmental expression/deposition or 10-50% expression along the expression along the glomerular 
basement membrane; D. Grade 3, Close to continuous expression/deposition, or 50-75% expression along the 
glomerular basement membrane; E. Grade 4, > 75% expression of Aβ along the glomerular basement membrane. 
DAPI stains the nuclei blue. (Scale bar = 50μm). 
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3.3. Results 
3.3.1. Immunohistochemistry of the prophylactic treatment 
Prophylactic treatment was performed in young CFH knockout mice for three 
months and the efficacy of the treatment in the prevention of the onset of disease 
by inhibiting A  deposition along the Bruch’s membrane in the retina was 
evaluated using immunohistochemistry.  
 
The effect of the antibody 6F6 on the deposition of A  was demonstrated in 
micrographs of retinal sections obtained from the treated CFH knockout mice. 
Deposition of A  along the Bruch’s membrane was seen to increase significantly 
over age in CFH knockout mice. The expression intensity of the A  (green) was 
quantified by the grading system and showed a consistent and significant 
reduction in its expression along the Bruch’s membrane with increased 
concentration when compared with the group that was injected with only PBS (P< 
0.0001, ANOVA) (Figure 3.6 and 3.7). There is a significant increase in the 
accumulation of A  from the baseline group which are 3 months old and the 
control PBS treated group, 6 months old (P= 0.0007) but the expression of C3b was 
not significantly reduced (P= 0.9346). Test groups that were treated with anti-A  
antibody either the 6F6 or the 2286-60µg/ml, when compared with the control 
PBS treated group, the expressions of both A  and C3b are significantly reduced 
(P< 0.0001, P<0.0001). For the group that was treated with 6F6-60µg/ml, the 
average grading of the expression of A  was around 1.2 while for the control PBS 
group, the expression was around 2.1 (P= 0.0003). The C3b expression for the 
group treated with 6F6-60µg/ml was significantly decreased in comparison with 
the control group (P=0.0425). Comparing the group tested with 6F6-300µg/ml and 
the control group, the grading of A  expression was around 0.9 (P<0.0001) and is 
significantly different from the control group. The C3b expression was also 
significantly different (P=0.0004). For the group that was treated with the 6F6-
600µg/ml, both the expression of A  and C3b are markedly reduced in comparison 
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with the control group (P<0.0001 and P< 0.0001). The expressions of A  and C3b 
were also decreased in the group that were treated with the anti-A  antibody 2286 
(P<0.0001 and P=0.0020). 
 
 
 
Figure 3.6 - Representative fluorescence images of the prophylactically-treated mouse retina. 
Aβ detection on the retinae using 4G8 anti-Aβ antibody and the secondary antibody used is an Alexa Fluor 488 
(green). A. 3-month-old baseline. B. CFH-/- treated with PBS. C. CFH-/- injected with 60µg/ml of the anti-Aβ 
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antibody, 6F6. D. CFH-/- injected with 300µg/ml of the anti-Aβ antibody 6F6. E. CFH-/- injected with 600µg/ml of 
the anti-Aβ 6F6. F. CFH-/- injected with 60µg/ml of the anti-Aβ 2286. The images show the efficacy of the 
treatment on preventing the deposition of Aβ along the Bruch’s membrane. Very strong positive staining of Aβ 
(green) was detected along the Bruch’s membrane in the CFH-/- vehicle (PBS) injected control retina, but less in 
antibody tested CFH-/- mouse retina. 
 
Figure 3.7 - Graphs showing summary and statistical results of the accumulation of Aβ and C3b along the Bruch’s 
membrane. 
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A. Right eye. B. Left eye. C. Overall performance of both the right and left eye of each group in the prophylactic 
test groups. The density of the deposition was graded from 0-4 (refer to text). Prophylactic treatment of young 
CFH knockout mice showed that it efficiently prevents the building up of both Aβ (red) and C3b (green) along the 
Bruch’s membrane. It was noted that 6F6 antibody was more efficient at higher concentration. (Each group 
consists of 5 animals). 
 
3.3.2. Immunohistochemistry of 4-week therapeutic treatment 
The efficiency of the therapeutic treatment in preventing and reducing age-related 
macular degeneration like pathologies in aged transgenic CFH knockout mice was 
observed and quantified using immunohistochemistry. Animals were culled at two 
time points; after 4 weeks’ of systemic treatment and after 12 weeks’ treatment. 
The morphology of the retina was the same in all the groups apart from the A  and 
C3b deposition. There is an increase in A  and C3b deposition between the 6-
month- old baseline and the control PBS treated group after 4 weeks of treatment 
(Figure 3.8 and 3.9) but the increase in the accumulation of A  was not significant 
(P=0.0944) but the increase in the deposition of C3b was significant (P= 0.0128).  
 
The efficacy of the anti-A  antibody in prevention of Aβ and C3 deposition along 
the Bruch’s membrane in the retina of ageing CFH knockout mice was quantified 
and compared between the different test groups. Grading of immunohistochemical 
staining patterns in the retina showed a significant reduction of basal A  and C3b 
along the Bruch’s membrane of the group that were treated with a higher 
concentration of the 6F6 (6F6-600ug) anti-A  antibody as compared with the 
control vehicle group (P=0.0284 for both A  and C3b) as illustrated in figure 3.8 
and figure 3.9. On average, the control PBS treated group had a grading of 2.5 for 
the A  in comparison with the 6F6-600µg/ml, which had a grading of 1.5. A 
reduction of C3b and A  expressions was also observed with the group treated 
with the antibody 2286-60µg/ml (P=0.0530 and P=0.4047, respectively) but the 
decrease were not significant. There was no significant decrease in the level of 
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expression of A  and C3b in the group that was treated with 60µg/ml of the 6F6 
anti-A  antibody (P= 0.2076, P= 0.0955 respectively). 
 
            
 
Figure 3.8 - Representative images of 4-week therapeutically-treated eyes of CFH knockout mice. 
The eyes were immunostained with a monoclonal antibody to Aβ 4G8 (red) and a rat monoclonal to C3b (green). 
CFH-/- knockout mice treated with PBS, CFH-/- knockout mice treated with 60µg/ml of anti-Aβ 6F, CFH-/- 
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knockout mice treated with 600µg/ml of anti-Aβ 6F6 antibody, CFH-/- knockout mice treated with 2286-60µg/ml 
and baseline mice (6 months old). After 4 weeks of therapeutic treatment of 6F6 anti-Aβ antibody, there was a 
significant decrease in the expression of Aβ (P=0.0010) and C3b (P=0.0114) along the Bruch’s membrane. After 
post-hoc testing, there is a significant decrease in Aβ expression between the PBS treated group and the 6F6-
600µg/ml treated group (P= 0.0284) but not in the other treated groups. 
 
 
 
Figure 3.9 - Graphs showing the grading of the expression level of A  and C3b along the Bruch’s membrane of the 
retina of the 4-week therapeutic test groups. 
There is a significant decrease in the deposition of both A  and C3b between the control PBS treated group and 
the group treated with 6F6-600µg/ml (P=0.0284 for both, n=24). 
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3.3.3. Optokinetic head tracking 
The efficiency of the therapeutic treatment in removing and preventing age-related 
pathologies in CFH knockout mice was monitored by assessment of the optokinetic 
head tracking performance. However, the results were variable between all the 
treated groups after 12 weeks of treatment. All the animals were able to track all 
the grating stimuli but it was noted on average when considering left and right eye 
together that the group treated with the 6F6-600µg/ml show an increase in time 
tracking the higher spatial frequency grating, 0.25 cycles/deg and therefore 
performed better than the control PBS treated group but the difference was not 
significant (Figure 3.10). This group showing more head turns, might suggest that 
they have better visual acuity than the rest of the test groups. The group that were 
treated with 6F6-60µg/ml did not show any significant difference in any of the 
spatial frequency gratings but it was shown that there is a decrease in the head 
turns at higher spatial frequency. There is also an improvement in the head turns 
from the 0.0625 and 0.125 gratings but then decreases at higher grating, 0.250, in 
the group treated with the 2286-60µg/ml. Therefore head tracking failed to reveal 
significant differences in all the treated groups in comparison with the control 
group.  
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Figure 3.10 - Graphs showing optokinetic head tracking to increasing spatial frequency. 
Graphs A and B show the total amount of time the differently treated groups spent tracking a moving square-
wave grating in seconds over a period of 6 minutes after 12 week of systemic 6F6 treatment in a clockwise and 
anti-clockwise direction. Graph C plots combined data of the clockwise and anticlockwise head turning of the test 
groups over the total time spent tracking the moving square wave grating in seconds. The results showed that 
there is an improvement in the head tracking in the group that was treated with the highest concentration of the 
6F6 anti-Aβ antibody (n=16). 
  
C 
Chapter Three - Immunotherapy using an anti-Amyloid Beta antibody in an AMD model 
103 
 
3.3.4. 12-week therapeutic treatment 
The retina of treated CFH knockout mice were immunostained with an anti-Aβ 
(4G8) and C3b antibodies and the level of expression of both Aβ and C3b were 
quantified using the same grading system as the one used for the prophylactic 
treatment. The morphology of the retina in all the test groups is the same. Most of 
the diffuse deposits were absent in the mice treated with the 6F6 antibody at 
600µg/ml compared to those in the control PBS group. The results (Figure 3.11 
and 3.12) showed that there is a significant decrease in the expression of Aβ and 
C3b with increasing concentration of the 6F6 antibody (P <0.0001 for both Aβ and 
C3b). There is a marked reduction in the level of expression of Aβ which has a 
grading of around 1.2 in aged CFH knockout mice treated with the anti-Aβ 
antibody, 6F6-600µg/ml (P=0.0007) in comparison with the control PBS treated 
mice which has a grading of 2.5 but the level of expression of C3b was not 
significantly reduced (P=0.0838), indicating that the level of inflammation was not 
decreased. The control aged-CFH knockout mice treated with PBS and the test 
group that was given the antibody 2286-60µg/ml showed the presence of Aβ along 
the Bruch’s membrane with a grading of around 2.5 and there is no significant 
difference between these two groups (P= 0.8592). The level of C3b expression 
along the Bruch’s membrane of the group treated with the anti-Aβ antibody 2286-
60µg/ml shows a significant increase as compared with the control group 
(P=0.0043), suggesting an increase in inflammatory response. There is a significant 
decrease of Aβ in the group treated with the 6F6-60µg/ml (P=0.0061) but no 
significant decrease in the level of C3b expression (P= 0.1836) when compared 
with the control group. These preliminary findings demonstrate that retinal 
function is preserved as demonstrated by the optokinetic head tracking of the mice 
treated with the 6F6 anti-Aβ antibody at dosage of 600µg/ml and its efficacy in the 
reduction of Aβ deposition in the mouse retina and hence a reduction in 
inflammatory response. 
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Figure 3.11 - Aβ and C3b in 12-week therapeutically-treated retina. 
Representative sections through the retina of treated CFH knockout mice; PBS, 6F6-60µg/ml, 6F6-600µg/ml and 
2286-60µg/ml, stained with an anti Aβ 4G8 (red) and C3b (green) antibodies showing that both Aβ and C3b 
expression decreased in aged CFH knockout mice treated with the anti-Aβ antibody, 6F6 (6F6-60µg/ml and 6F6-
600µg/ml). Control aged CFH knockout mice show the presence of Aβ and C3b deposits along the Bruch’s 
membrane. The mice, which were treated with the anti-Aβ 2286 antibody, also show the presence of Aβ and C3b 
deposits along the Bruch’s membrane. (n=20). 
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Figure 3.12 - Graph showing the expression level of Aβ and C3b along the Bruch’s membrane of the 12-week 
treated mice. 
There is a significant increase in A  and C3b deposition between the baseline and the control-PBS treated mice 
after 3 months of treatment (P= 0.0175 and P=0.0175). There is a significant decrease in the deposition of Aβ 
between the control groups (PBS) and the group that was treated with the 6F6-600µg/ml (P<0.0007) but the level 
of C3b expression was not significantly decreased (P=0.0838). (n=20). 
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3.3.5. Immunohistochemistry of kidneys treated therapeutically over a 12-week-
period 
In order to examine the systemic effect of the 6F6 antibody, kidney sections from 
treated CFH knockout mice were immunostained with the anti-Aβ (4G8) and C3 
antibodies and the level of their expression were quantified using a grading system 
(Figure 3.13 and 3.14). The results show that the level of Aβ expression on the 
glomerular basement membrane in the treated groups significantly decrease in 
comparison with the control group which was treated with PBS (P< 0.0001). The 
Aβ deposition in the 6F6-600µg/ml significantly reduced (P<0.0001) after the 12 
weeks treatment when compared with the control group while the C3 expression 
is not significantly reduced (P=0.0520). There is also a significant decrease in the 
expression of Aβ along the glomerular basement membrane in the group that was 
treated with 6F6-60µg/ml (P=0.0002) but the expression of C3 is not significantly 
decreased (P=0.1467). The 2286 antibody was also efficient in clearing amyloid 
beta deposition along the glomerular basement membrane as there is a significant 
decrease in its expression (P=0.0219) but there is no significant decrease in the C3 
expression (P=0.2211). 
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Figure 3.13 - Aβ and C3 in 12-week therapeutically-treated kidneys. 
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Representative sections through the kidneys of treated CFH knockout mice stained with an anti Aβ 4G8 (red) (A, 
C, E and G) and C3 (green) antibodies (B, D, F and H) showing that Aβ expression decrease in aged CFH knockout 
mice treated with the anti-Aβ antibody, 6F6 (6F6-60µg/ml and 6F6-600µg/ml). Control aged CFH knockout mice 
treated with PBS show the presence of Aβ and C3 depositions along the glomerular basement membrane. The 
mice, which were treated with the anti-Aβ 2286 antibody, also show the presence of Aβ depositions along the 
glomerular basement membrane. (n=20). (Scale bar = 50μm). 
 
 
 
Figure 3.14 - Graph showing the expression level of Aβ and C3 along the glomerular basement membrane of the 
12-week treated mice. 
There is a significant decrease in the level of expression in A  deposition between the 6F6-600µg/ml treated 
groups and the control-PBS treated mice after 3 months of treatment (P< 0.0001) but there is no significant 
decrease in the expression of C3 (P=0.0520). There is a significant decrease in the deposition of Aβ between the 
control groups (PBS) and the group that was treated with the 6F6-60µg/ml (P=0.0002) but the level of C3 
expression was not significantly decreased (P=0.1467). There is a significant decrease in the expression of Aβ in 
the group treated with the 2286 antibody (P=0.0219) but no significant decrease in the C3 expression (P=0.2211). 
(n=20). 
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3.4. Discussion 
 
This study has shown that administering of an antibody against A  peptide 
reduced the extent of A  deposition along the Bruch’s membrane of a mouse model 
of AMD. Even though age-related macular degeneration is not widely considered as 
a disease caused by amyloid, previous studies (145, 155) have localised Aβ peptide 
derived amyloid within sub-RPE deposits and choroidal neovascularisation in 
human AMD eyes, implicating Aβ in AMD pathogenesis. Amyloid-lowering 
therapies, such as Aβ immunotherapy, represent one of the most promising 
approaches for the treatment of AD. Immunotherapies have shown to lower 
amyloid deposits and improve cognition in AD mouse models (156, 157) and an 
AMD mouse model (114). This approach of targeting A  protein was extended in 
this study to treat AMD by administering systemically a mouse monoclonal anti-A  
antibody administering systemically an anti-A  antibody in a mouse model of 
advanced ageing, the CFH knockout mice. In the prophylactic study, the anti-Aβ 
antibody 6F6 following immunisation prevented the accumulation of Aβ along the 
Bruch’s membrane which lead to a decrease in the inflammatory response. This 
prevents the onset of the disease and therefore demonstrated the potential of 
preventing the pathogenesis of AMD. 
 
The 6F6 antibody directed at Aβ peptide is being used to promote the clearance of 
Aβ on the Bruch’s membrane and reducing the inflammatory response caused by 
this deposition. In the therapeutic study, the effects of the systemic injection of the 
6F6 anti-Aβ antibody in aged CFH knockout mice prevented the accumulation of 
more Aβ and presumably led to a reduction in established Aβ depositions. This 
systemic effect of the 6F6 antibody was also observed to be efficient in the kidneys 
of the 12 weeks treated mice as the level of expression of Aβ is seen to decrease 
along the glomerular basement membrane.  Systemic delivery of the 6F6 antibody 
in young animals prevented the accumulation of Aβ along the Bruch’s membrane, 
the same antibody given to aged animals was less effective in clearing well-
Chapter Three - Immunotherapy using an anti-Amyloid Beta antibody in an AMD model 
110 
 
established depositions along the Bruch’s membrane at low dosage, 60µg/ml, but 
very effective in higher dosage, 600µg/ml. 
 
There are several mechanisms that can explain how antibodies directed at A  
promote the clearance of this peptide. First, Solomon et al. (158, 159) showed that 
there is a possibility that Aβ antibodies cross the blood-brain barrier (BBB), bind 
to Aβ deposits and cause their disaggregation and clearance and also Aβ antibodies 
may bind soluble Aβ and prevent it from forming fibrillar aggregates. Another 
probable mechanism that has been suggested by Bard et al. (160) involves Fc-
mediated phagocytosis of Aβ by microglial cells. They suggested that when anti-Aβ 
antibodies cross the BBB and target aggregated Aβ deposits, they form immune 
complexes Aβ antibody bound to Aβ protein, the Fc portion of the antibodies will 
then bind to the Fc-receptors on microglia, inducing phagocytosis of these 
complexes. However, it was observed that microglia activation may be a transient 
effect of Aβ immunisation. An alternate mechanism that has been observed in 
mouse model of AD is that a long term administration of a mouse monoclonal 
antibody results in an increase in plasma A  which leads to a disruption in A  
equilibrium, resulting in an increase efflux of A  out of the brain, into the 
periphery where it is degraded and therefore reduction in the amyloid deposition 
(161). The latter hypothesis is supported by the fact that the A  immunotherapy 
seems to be much more efficient in younger mice with less A  deposits than older 
mice with extensive deposits and this hypothesis was reflected in this study 
whereby the A  immunotherapy was much more efficient in the younger 3-month-
old CFH mice than the older 6-month-old. 
 
The efficacy of the treatment was then examined by behavioural assessment, 
which did not show any conclusive results, as the optokinetic head tracking for 12-
week therapeutic treated mice were variable. However, the group that was treated 
with a higher dosage of the 6F6 antibody showed a trend with higher head turns 
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when compared to the control PBS treated group suggesting a better visual acuity. 
The wide variance in the performance of the treated CFH knockout mice in the 
behavioural analysis can be explained by the fact that several findings (162-164) 
suggested that Aβ peptides have an important role in developmental or synaptic 
plasticity, notably in neurite outgrowth and regulation of intraneuronal Ca2+ level. 
Other studies (165, 166) have shown that A  mediates memory formation and its 
monomers are neuroprotective.  
 
An important question to be addressed is why A , and in particular A  (1-42), 
which is mainly known to cause memory impairment can mediate memory 
formation and enhancement. One likely explanation is the relative concentration of 
A . Low physiologically regulated concentrations of A  would play a critical role in 
mediating learning and memory, while pathological disruptions of this regulation 
with consequent accumulation or chronic exposure of soluble A  would lead to 
synaptic dysfunction and loss (167). Therefore depleting Aβ peptides to a very low 
concentration might have a negative effect on the body and would lead to long 
term potentiation as well as spatial and avoidance learning and memory (168-
170). A  should not only be regarded as a toxic factor that has to be eliminated but 
its physiological roles should be taken into consideration in therapies aiming at 
reducing its accumulation.  
 
Even though immunotherapy is an effective way of reducing A  deposition, some 
adverse effects have been observed. One of them is an autoimmune inflammatory 
response to the injected antibodies whereby several pathways could be involved. 
Inflammation reaction may be triggered by the T-lymphocyte activation after 
immune system stimulation with A . T-cell epitopes to A  have been reported to 
reside in the mid-to-carboxy-terminal region of the peptide (171). A  deposited as 
insoluble aggregates requires phagocytosis by reactive microglia. This process 
causes an activation of the inflammatory pathway resulting in a widespread 
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inflammatory response. However, only the removal of aggregated A , but not 
uptake of soluble A , is associated with an inflammatory response.  
 
These findings, though preliminary, contribute to the understanding of the 
underlying pathways of pathology related to the role of amyloid in the sub-RPE, 
from its formation and how it leads to retinal changes in AMD. This study suggests 
that immunotherapy can be used as a way to prevent and treat AMD. 
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4. Abstract 
 
The most important and frequent ocular degenerative diseases including age-
related macular degeneration are likely to be caused by the interplay of genetic 
and environmental factors. Despite this, gene-disease associations are frequently 
investigated using models that focus solely on a marginal gene effect, ignoring 
environmental factors entirely. Failing to take into account a gene-environmental 
interaction can weaken the apparent gene-disease association, leading to loss in 
statistical power and, potentially, inability to identify genuine risk factors.  
 
Many studies have been performed with the aim of evaluating which factors are 
involved in the etio-pathogenesis of these ocular diseases. As a result, it is now 
clear that a large number of environmental and genetic factors play an important 
role in common eye pathologies. The aim of this study is to overview how gene and 
environment interact in the pathogenesis of age-related macular degeneration in 
an established murine model. Two cohorts of a mouse model of aged-related 
macular degeneration (AMD) which both have a genetic knockout of the 
complement factor H (CFH) were used in this study as polymorphisms in this gene 
are the most consistent genetic risk factors for AMD. Factor H is part of the 
complement system and therefore these mice are immunocompromised. 
 
One cohort was bred in an environment, which contained relatively very few 
pathogens, a barriered environment, while the other cohort was bred in an 
environment rich in pathogens, an open environment. The eyes were examined 
using a confocal Scanning Laser Ophthalmoscope (cSLO) and the morphology of 
the eyes was assessed by immunohistochemistry. It was found that the cohort that 
was from the barriered environment has significantly less inflammatory response 
in comparison with the cohort that was from the open environment. A reduction in 
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the number of cells in the outer nuclear layer of the retina, indicating 
photoreceptor cell loss was also observed in mice from the open environment.  
 
This study explores the possible epidemiologic association between progression of 
AMD and exposure to pathogen and that genetic mutation or polymorphism is not 
the only factor that triggers the onset of AMD but also environmental risk factors 
must be taken into account in future therapies. 
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4.1. Introduction 
 
The most important and frequent ocular degenerative diseases including cataract, 
glaucoma and age-related macular degeneration (AMD) are caused by multiple 
factors. These pathologies are responsible for visual impairment and blindness and 
bear great epidemiologic relevance. Many studies have been performed with the 
aim of evaluating which factors are involved in the etio-pathogenesis of these 
ocular diseases (172-175). As a result it is now clear that complex diseases such as 
AMD are likely to be caused by the interaction between genes and the environment 
but only the role of genes in causing disease is often investigated and little or no 
environmental exposure data is collected and joint effects of genetic and 
environmental exposures are ignored in the analysis. 
 
AMD is a highly complex disease with demographic, environmental, and genetic 
risk factors. Among demographic and environmental factors associated with AMD, 
such as age, gender, race, diet, smoking, education and cardiovascular disease, 
studies have shown that the most established factors are advanced age, cigarette 
smoking, diet and race (176, 177). Common genetic polymorphisms predispose to 
complex diseases as well. It is not clear why some individuals with a given 
polymorphism acquire a disease while others remain unaffected but one 
hypothesis is that in genetically susceptible people, exposure to an organism could 
lead to an inappropriate, poorly regulated inflammatory response, which 
ultimately results in AMD. It seems reasonable that environmental effects may be 
under genetic control, or that environmental risk factors may trigger the disease in 
genetically susceptible subjects (178-180) thus establishing a typical gene-
environment interaction for AMD development. These environmental risk factors 
not only trigger the expression of genes involved in the pathogenesis of the disease 
process, but also trigger adverse inflammatory response. The age-associated 
increase in AMD risk might be mediated by gradual, cumulative damage to the 
retina from daily oxidative stress and inflammation.  
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The factor that seems to form an umbrella over all the environmental risk factors 
for AMD (43) is inflammation as there is evidence to support this from 
histopathological signs of chronic inflammation, disruption and the presence of 
macrophages, lymphocytes and mast cells at Bruch’s membrane (181). 
Inflammation is a highly complex phenomenon that may be either beneficial 
and/or detrimental to the host and is considered to be a response set by tissues in 
response to injury caused by trauma or infection (182), which helps to destroy, 
reduce or sequester both the harmful agent and the wounded tissue. It is a 
complex network of molecular and cellular interactions that facilitates a return to 
physiological homeostasis and tissue repair.  
 
The inflammatory response is composed of both local events and systemic 
activation mediated by cytokines. If tissue health is not restored or in response to 
stable low grade irritation, inflammation becomes a chronic condition that 
continuously damages the surrounding tissues and eventually lead to cell death 
(182, 183). This occurs when tissues are unable to overcome the effects of the 
harmful agent (182). However, the inflammation process is not a negative 
phenomenon it is the response of the immune system to pathogens. One of the 
inflammatory responses is the attraction of phagocytes and their movement to the 
inflammatory sites where they make contact with the harmful agent and develop 
an oxidative burst. The phagosome fuse with the lysosome and degranulation of 
the lysosomal contents takes place which then leads to death and degradation of 
the agent (183). Inflammation clearly occurs in pathologically vulnerable regions 
of the retina and it does so with the full complexity of local peripheral 
inflammatory responses. Depositions of highly insoluble materials such as Aβ 
proteins, which are involved in drusen formation, provide obvious stimuli for 
inflammation (47). Amyloid deposits are associated with reactive astrocytes and 
activated microglia cells. Aβ peptides promote and exacerbate inflammation by 
inducing glial cells to release immune mediators. 
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Recent studies (182, 184) suggest that the reduction in lifetime exposure to 
sources of inflammation, contributes to a decline in old-age mortality, suggesting 
long-life pathogen burden as most important factor for age-related inflammation. 
Inflammation, in AMD, causes the formation of abnormal extracellular matrix; 
basal laminar deposit and basal linear deposit, which then results in altered 
behaviour of RPE and choriocapillaris and ultimately leads to atrophy of retina, 
RPE and choriocapillaris, which is paralleled by neovascularisation of the choroid 
(185). Macrophages and other cells secreting inflammatory proteins such as C-
reactive proteins can activate the complement system and increase the activation 
of macrophages (186). 
 
Studies of AMD suggest that macrophages play an important role in promoting the 
disease (187, 188). Evidence for a disease-promoting role for macrophages in 
neovascular AMD, which is the development of abnormal blood vessels underneath 
the retina, derives from studies in a mouse model showed systemic depletion of 
macrophages using clodronate-filled liposomes blocked neovascularisation (187, 
188). Combadiѐre et al. (189) have shown that macrophages accumulated under 
the retina of a mouse model of AMD elicit photoreceptor degeneration and 
exacerbated neovascularisation. They observed that prolonged contact of 
macrophages with lipid-rich outer segment was associated with intracellular lipid 
accumulation in the macrophages and that these subretinal microglial foam cells 
were the origin of drusen-like deposits in mice. 
 
Activation of the complement system generates a proteolytic cascade that releases 
proinflammatory anaphylatoxins to mediate recruitment of inflammatory cells, 
and causes the production of membrane-attack complex (MAC), which leads to cell 
lysis and death (60, 190). Complement activity is important for the immune 
responses against pathogens or dying cells. Dysregulation of the cascade can result 
in complement over activation-mediated damage to nearby healthy tissue. 
Complement factor H (CFH) is an important inhibitor of the complement pathway 
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as it binds and inactivates complement component C3b, and prevents the 
production of C3 convertase and progression of the cascade (62). CFH dysfunction 
may lead to excessive inflammation and tissue damage. The association between 
CFH and AMD suggests that triggering the complement cascade in genetically 
predisposed individuals promotes development of AMD. 
 
Factor H knockout mice have distinctive ocular phenotype, showing age-related 
degenerative changes of retina and is a mouse model for AMD (149). In this study 
the question of how the environment i.e. exposure to pathogens, affects age-related 
changes and the progression of disease in these immunodeficient AMD mouse 
model and how the pathogens drive degenerative changes to the retina by 
maintaining these mice from birth in either a barriered or an open environment 
are being investigated. The level of inflammatory response and the accumulation of 
Aβ in the retina, were examined and compared in the two groups of mice having 
the same genetic background, given the same diet and under the same light 
regimes but were exposed to different pathogen loads, using confocal scanning 
laser ophthalmoscope and immunohistochemical examination of retinal sections 
with different inflammatory markers.  
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4.2. Materials and Methods 
4.2.1. Animals 
Ten mice, aged around 9 months, were used in this experiment and they were 
homozygous CFH knockout mice and were backcrossed onto the C57Bl/6 genetic 
background for more than 10 generations, were fed the same lab chow and 
libitium and housed in a temperature controlled environment with a 12-hour day 
(160 lux) light/dark cycle. One cohort of 5 mice was given by GlaxoSmithKline and 
the mice were housed in an environment that has few pathogens (barriered 
environment) and the other cohort of 5 mice was in an environment that contained 
far more pathogens (open environment) as shown in the health report. Both 
cohorts come from the same original source (kind donation from Matthew 
Pickering, Imperial College, UK). All animal procedures conformed to the United 
Kingdom Animal License Act 1986 (UK) and local ethical regulations. 
 
4.2.2. In vivo imaging 
Mice were anaesthetised (6% Ketamine, (Fort Dodge, UK) 10% Dormitor, (Pfizer, 
UK) and 84% sterile water at 5ul/g intraperitoneal injection and their pupils were 
dilated (1% tropicamide, MINIMS, Bausch & Lomb, France) 10 to 15 minutes 
before scanning laser ophthalmoscope (cSLO) imaging. Before each image 
sequence, drops of hydroxypropyl methylcellulose (0.3%) were placed on the eye 
to prevent drying. Fundus photographs were taken with a digital camera mounted 
on a modified confocal Scanning Laser Ophthalmoscope (Heidelberg Retina 
Angiograph, Heidelberg Engineering, Germany) where the pinhole diameter had 
been reduced to 100 µm to improve axial resolution and the laser power increased 
to improve the signal-to-noise ratio. Power at the mouse pupil was measured to be 
1400 µW at 488 nm. 
 
All mice were sacrificed by neck dislocation and their eyes and kidneys were 
removed and fixed in 4% paraformaldehyde in phosphate buffered saline (PBS), 
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pH 7.4.  One eye of each animal from both groups was processed for cryosections 
and therefore cryopreserved in 30% sucrose in PBS and embedded in OCT 
compound (Agar Scientific Ltd). Cryostat sections were done at 10um and thaw-
mounted onto charged slides. The other eye was processed for flatmounting. 
Immunohistochemistry was performed at room temperature. 
 
4.2.3.  Immunofluorescence staining 
The sections of the eye were incubated for 1 hour in a 5% Normal Donkey serum in 
0.3% Triton X-100 in PBS, pH 7.4, followed by an overnight incubation with the 
following primary antibodies; mouse monoclonal antibody to Aβ 4G8 (1:500, 
Covance), a rat monoclonal antibody to C3b/iC3b/C3c (1:50, Hycult 
biotechnology) and a goat polyclonal to complement C3d (1:100, R&D systems), 
were made in 1% Normal Donkey Serum in 0.3% Triton X-100 in PBS. After 
Primary antibodies incubation, the sections were washed three times in 0.1M PBS 
and then incubated in respective secondary antibodies conjugated with either 
Alexa Fluor 488 or 568 (1:2000, Invitrogen) which were made up in 2 % Normal 
Donkey Serum in 0.3% Triton X-100 in PBS and added to the sections and 
incubated for 1 hour at room temperature. Negative controls were done by 
omitting the primary antibody. After the secondary antibody incubation, the 
sections were washed several times and the nuclei were subsequently stained with 
4', 6-diamidino-2-phenylindole (Sigma) for 1 min. Slides were then washed a few 
times in 0.1 M PBS and several washes in Tris-buffered Saline (TBS, pH 7.5). The 
slides were mounted in Vectashield (VECTOR Laboratories) and coverslipped. 
Sections were viewed and images captured using an Epi-fluorescence bright-field 
microscope (Olympus BX50F4, Olympus, Japan), where data were captured as 24-
bit colour images at 3840 x 3072 pixel resolution using a Nikon DXM1200 (Nikon, 
Tokyo, Japan) digital camera. The images were then put together and the gray 
value, which is a measurement of brightness whereby all images is internally 
converted to grayscale using the default grayscale profile, of both the outer 
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segment of the photoreceptors and the Bruch’s membrane were measured using 
Adobe Photoshop CS4 extended. 
 
For the flatmounts, the eyes were fixed in 4% paraformaldehyde in PBS and 
washed with PBS. The eyes were dissected and the cornea, lens and retina were 
removed. To facilitate preparation of the flatmounts, five or more vertical cuts 
were made in the RPE-choroidal tissues. 
 
After several washes with PBS, the RPE-choroidal tissues were blocked and 
permeabilised with 5% Normal Donkey serum with 3% (v/v) Triton X-100 in PBS 
for 2 hours. Samples were incubated overnight in a cocktail of primary antibodies:  
mouse monoclonal to Aβ 4G8 (1:500, Covance) and Rabbit polyclonal antibody to 
Iba-1 (1:1000, A. Menarini diagnostics) which were made in 1% Normal Donkey 
Serum in 3% Triton X-100 in 0.1M PBS. After Primary antibodies incubation, the 
samples were washed three times in PBS and then incubated in respective 
secondary antibodies which were made up in 2 % Normal Donkey Serum in 0.3% 
Triton X-100 in PBS at a dilution of 1:2000, and incubated for 2 hours at room 
temperature. After the secondary antibody incubation, the samples were washed 
several times and the nuclei were subsequently stained with 4', 6-diamidino-2-
phenylindole (Sigma) for 1 min. The RPE-choroidal tissues were then washed a 
few times in 0.1 M PBS and several washes in Tris buffered Saline (pH 7.5). The 
flatmounts were mounted in Vectashield (VECTOR Laboratories) and coverslipped. 
The samples were viewed and images captured using an Epi-fluorescence bright-
field microscope (Olympus BX50F4, Olympus, Japan), where data were captured as 
24-bit colour images at 3840x3072 pixel resolution using a Nikon DXM1200 
(Nikon, Tokyo, Japan) digital camera. The images were then put together and Iba-1 
positive cells were counted using Adobe Photoshop CS4 extended. 
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4.2.4. Immunohistochemistry 
The sections of the eye were incubated for 1 hour in a 5% Normal Donkey serum in 
0.3% Triton X-100 in PBS, pH 7.4, followed by an overnight incubation with a 
Rabbit polyclonal antibody to Calcitonin (1:100, Abcam, UK) which was made in 
1% Normal Donkey Serum in 0.3% Triton X-100 in PBS. After the primary antibody 
incubation, the sections were washed three times in 0.1M PBS and then treated 
with 0.3% hydrogen peroxide in PBS to quench endogenous peroxidase activity. 
After several washes, the tissues were incubated with a biotinylated secondary 
antibody against rabbit (Jackson ImmunoResearch Laboratories, 1:1000) which 
were made up in 2 % Normal Donkey Serum in 0.3% Triton X-100 in PBS, were 
added to the sections and incubated for 1 hour at room temperature. Negative 
controls were done by omitting the primary antibody. After the secondary 
antibody incubation, the sections were washed several times and then incubated in 
a ready-to-use horseradish peroxidise streptavidin solution (Vector Laboratories) 
for 30 minutes, followed by a peroxidase substrate solution, 3,3-diaminobenzidine 
(DAB) for 1 minute. Slides were mounted in Vectashield (VECTOR Laboratories) 
and coverslipped after several washes in PBS and TBS. Sections were viewed and 
images captured using an Epi-fluorescence bright-field microscope (Olympus 
BX50F4, Olympus, Japan), where data were captured as 24-bit colour images at 
3840 x 3072 pixel resolution using a Nikon DXM1200 (Nikon, Tokyo, Japan) digital 
camera. The images were then put together and the mean gray value of the 
ganglion cell layer, the inner plexiform layer, the outer plexiform layer and the 
outer segment of the photoreceptors were measured using Adobe Photoshop CS4 
extended. 
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The kidneys from the two different cohorts were processed for immunostaining in 
the same way as the eyes. Immunohistochemistry and immunofluorescence 
staining were done on the renal sections using the monoclonal antibody to Aβ 
(1:500, Covance), a goat polyclonal anti-mouse complement component C3d 
(1:100, R&D systems) and a rabbit polyclonal antibody to calcitonin (1:100, Abcam 
UK).  
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4.3. Results 
4.3.1. In vivo imaging and accumulation of subretinal macrophages in CFH 
knockout mice 
Fundus autofluorescence of the mice was performed to examine the number of 
hyperfluorescence spots between the two cohorts and it was revealed that the 
mice from the open environment had numerous hyperfluorescence spots in the 
subretinal space of the retina while the retina of the mice from barriered 
environment had less (Figure 4.1A). To characterise and quantify in more detail 
these hyperfluorescence spots, the eyes of the mice were flatmounted after the 
removal of the neural retina, exposing the RPE layer and they were immunostained 
with a microglia/macrophage marker, Iba-1. All the hyperfluorescence spots 
overlapped precisely with the iba-1 positive cells. The results showed that there 
was a higher number of Iba-1 positive cells present in the flatmounts of mice that 
were bred in an open environment while mice that were bred in the barriered 
environment had very few number of Iba-1 positive cells as shown in figure 4.1B 
(P=0.0012), showing an increase in macrophage recruitment in the former group, 
an indication of a higher inflammatory response.  
Chapter Four - External pathogens trigger retinal disease in a model of AMD 
126 
 
 
 
Figure 4.1 – Fundus images and graphs showing the number of Iba-1 positive cells of mice from two different 
environments. 
A.Representative fundus images of the retinae of mice from the two different environments. The open 
environment animals had significant increase in the number of autofluorescence spots when imaged in vivo. B. 
Graph showing the number of Iba-1 positive cells in both the open environment and the barriered environment. 
There was a significant increase in the number of Iba-1 positive cells in the group that was in the open 
environment in comparison with the group from barriered environment (P=0.0012).  
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4.3.2. Levels of calcitonin in the retina 
The level of inflammation was next analysed by immunohistochemistry of the 
retinal sections with a rabbit polyclonal antibody to calcitonin, which is a known 
systemic biomarker for inflammation (191, 192). It was revealed that calcitonin 
was present mainly in four different regions of the retina; the ganglion cell layer, 
the inner plexiform layer, the outer plexiform layer and in the photoreceptor layer. 
When the level of expression was quantified, it was found that there was a 
noticeable difference in the amount of calcitonin between the two groups. The 
retinae from the open environment mice had an increased expression of calcitonin 
in the photoreceptor, the inner plexiform layer and the outer plexiform layers 
(Figure 4.2), when compared with the retinae of mice from the barriered 
environment, suggesting a higher level of inflammation. As the Bruch’s membrane 
is sandwiched between the RPE and the choriocapillaris, which contain brown 
melanin pigments, an accurate measurement of the level of calcitonin expression 
was not possible when using the DAB chromogen, which is brown.  
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Figure 4.2 – Representative images and graphs of calcitonin expression in retinal sections of mice from two 
different environments. 
A.Light micrographs of retinal sections of mice from the two different environments immunostained with a 
polyclonal antibody to calcitonin. Calcitonin was stained using the peroxidase substrate 3,3-
diaminobenzidine (DAB). B. Graphs that show the level of calcitonin in the ganglion cell layer (GCL), the inner 
plexiform layer (IPL), the outer plexiform layer and the outer segment (OS) of the photoreceptor layer in the 
retina by measurement of the DAB stained pixels. There was a significant difference between the levels of 
calcitonin between both groups (P < 0.001 in all three layers). The level of expression of calcitonin along the 
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BM was not measured as pigments in the RPE and choriocapillaris will interfere with the reading. (Scale bar - 
50μm). 
 
4.3.3. Structural differences between the two cohorts 
The morphology and structure of the retina were examined and it was observed 
that mice from the open environment showed marked degeneration of the outer 
retina, most precisely in the outer nuclear layer, indicating photoreceptor cell loss. 
Quantification of the number of cells in the outer nuclear layer showed a slight but 
significant decrease in mice bred from the open environment in comparison with 
mice from barriered environment (P=0.0079). The thickness of the outer nuclear 
layer was the same in both groups even though the number of cells was fewer in 
the open environment group as shown by the graphs in figure 4.3. 
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Figure 4.3 – The outer nuclear layer – Image and measurements. 
A.Retinal section showing the outer nuclear layer stained with DAPI. B. Graphs showing measurement of the 
thickness of the outer nuclear layer. There was no significant difference between the thickness of the outer 
nuclear layer (P= 0.2222) in both groups but there was a significant decrease in the number of cells in the retina 
of the mice from the open environment in comparison with the retina from the barriered environment 
(P=0.0079). (Scale bar- 50μm). 
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4.3.4. Accumulation of Aβ and activated complement C3 in the retina 
Retinal sections were immunostained with a mouse monoclonal antibody to Aβ, a 
rat monoclonal to C3b/iC3b/C3c and a goat polyclonal anti mouse complement 
component C3d, to evaluate whether there was a difference in the accumulation of 
Aβ and activated forms of complement component C3 and its fragments in the 
photoreceptor layer and along the Bruch’s membrane. The results did not show 
any significant difference in the accumulation of Aβ peptides along the Bruch’s 
membrane (P = 0.9530) and in the photoreceptor layer (P=0.3102) of both groups 
(Figure 4.4) and this suggested that mice from both groups were ageing at the 
same rate as Aβ was deposited at the same rate. There was a significant difference 
in the accumulation of C3b/iC3b/C3c in the retina between both groups (Figure 
4.5). The mice from the barriered environment had an increase in the 
C3b/iC3b/C3c expression along the Bruch’s membrane (P<0.0001) and in the 
photoreceptor layer (P<0.0001) in comparison with the mice from the open 
environment as shown in figure 4.5. The staining with the complement C3d along 
the Bruch’s membrane (P= 0.0635) and in the photoreceptors (P = 0.2857) did not 
show any significant difference between the two groups when a comparison using 
Mann-Whitney U test was done (Figure 4.6). 
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Figure 4.4 – Fluorescence images and graphs showing the expression of Aβ in retinae of mice from open and 
barriered environments. 
A.Representative images of the immunohistochemistry of the retinae of both mice from open and barriered 
environment. Retinal sections of the mice were stained with a monoclonal antibody to Aβ 4G8 (red) and the 
nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) (Blue). B. Graphs showing the amount of 
Aβ present along the Bruch’s membrane (BM) and in the photoreceptor layer respectively. There was no 
significant difference in the accumulation of Aβ between the two groups (P = 0.9048 for both). Outer nuclear 
layer (ONL), outer segment in the photoreceptor (OS/PR). (Scale bar = 50μm). 
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Figure 4.5 - Fluorescence images and graphs showing the expression of C3b/iC3b/C3c in retinae of mice from 
open and barriered environments. 
A.Representative images of retinal sections immunostained with a rat monocolonal antibody to C3b/iC3b/C3c 
(green) and the nuclei were counterstained with DAPI. B. Graphs showing the amount of C3b/iC3b/C3c 
accumulates along the Bruch’s membrane (BM) and in the photoreceptor layer There was a significant difference 
between the two groups (P<0.0001 for both). Inner nuclear layer (INL), Outer nuclear layer (ONL), Outer segment 
in the photoreceptor (OS/PR). (Scale bar = 50μm). 
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Figure 4.6 - Fluorescence images and graphs showing the expression of C3d in retinae of mice from open and 
barriered environments. 
A.Retinal C3d staining showing that C3d was present in the inner plexiform (IPL) , outer plexiform (OPL), in the 
photoreceptor layer (PR) and along the Bruch’s membrane (BM) in both groups. B. Graphs showing quantitative 
immunofluorescence for the level of C3d expression along the BM and in the photoreceptors. There was no 
significant difference of the expression of C3d in both locations in both groups (P = 0.0635 in the BM and P= 
0.2857 in the photoreceptors) (scale bar = 50μm) 
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4.3.5. Accumulation of Aβ and complement component C3d and the level of 
inflammation in the kidneys of CFH knockout mice 
To examine whether the inflammatory response to pathogens were either systemic 
or local, renal sections were immunostained with Aβ, complement component C3d 
and calcitonin antibodies to examine whether there was a difference in their levels 
of expression in both groups. It was observed that Aβ was strongly expressed on 
the basement membrane of the glomeruli in the renal sections of mice from the 
open environment while the basement membrane of the glomeruli of renal 
sections from the barriered environment were very weakly expressed as shown in 
figure 4.7. Immunostaining with inflammatory response proteins; complement 
component C3d and calcitonin in both groups did not show a striking difference in 
the degree of expression in the glomeruli. C3d deposition was seen along 
glomerular capillary walls of both groups. Quantification of the expression of Aβ, 
calcitonin and complement component C3d in the immunostaining was not 
possible on these retinal sections as it was difficult to define an area of 
measurement. 
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Figure 4.7 - Representative fluorescent images of renal sections of mice from open and barriered environments. 
A and B are glomeruli from open and barriered environments immunostained with Aβ using a DAB-peroxidase 
staining, C and D are glomeruli immunostained with complement component C3d (red) using 
immunofluorescence staining and E and F are renal sections immunostained with calcitonin. There was a strong 
expression of Aβ along the basement membrane of the glomeruli of the mice from the open environment while 
the basement membrane of the glomeruli of the mice from the barriered environment has a weak expression. 
The degree of expression of complement component C3d and calcitonin in the glomeruli of both cohorts did not 
show significant differences. (Scale bar = 50μm). 
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4.4. Discussion 
 
In this study, it was shown that there was a strong relationship between the CFH 
gene and the environment; this provided a possible hypothesis for the underlying 
mechanisms in the progression of AMD in a murine model. This study was initiated 
because it was observed that animals from a barriered environment did not 
present any pathology of AMD while animals that came from an open environment 
developed rapidly retinal phenotype associated with AMD. Animals from both 
environments showed the presence of hyperfluorescence spots when examined 
using the confocal scanning laser ophthalmoscope but the retina of those from the 
open environment contained more than the retina from the barriered 
environment.  
 
In order to confirm these results, the eyes were flatmounted and immunostained 
with Iba-1 antibody, it was seen that these subretinal macrophages were filled 
with lipofuscin and that the number of macrophages in the cohort bred in the 
barriered environment was significantly lower than the other group. This showed 
that less macrophages were being recruited in the subretinal space of the 
barriered animals and this could be explained by the fact that the immune 
response involving the recruitment and activation of macrophages in these 
animals was not triggered and therefore less macrophages were being recruited in 
the subretinal space to clear the apoptotic cells as well as damaged or modified 
self-molecules to maintain tissue homeostasis. 
 
On the other hand, mice from the open environment had an increased number of 
macrophages as they were being recruited in the subretinal space of the eye to 
maintain homeostasis of the retina by engulfing dying cells and accumulation of 
debris as they age despite incessant attack from both intrinsic and extrinsic 
stimuli/antigens. These potentially harmful proinflammatory cytokines and other 
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inflammatory mediators produced by the innate immune system at a later stage of 
life might act antagonistically to the beneficial role they had in an earlier stage of 
life and lead to chronic inflammation and thus emergence of diseases. 
 
Numerous clinical and experimental studies suggest a role for inflammation, 
especially macrophages in the pathogenesis of AMD (188, 193, 194). In eye 
research, microglia in the retina reside mostly in the inner and outer plexiform 
layers in mouse (195). Upon activation and recruitment, microglia might initially 
migrate to the subretinal space to support the RPE in the clearance of age-
dependent debris. However, if trapped in this region, microglia might also form 
‘crystallisation’ points for cellular deposits and complement-containing immune 
complexes. These activated immune cells in the vicinity of the RPE very likely 
influence RPE cell function (196). This can in turn cause RPE cells to secrete 
products that stimulate further microglial migration and activation.  
 
Immunohistochemical analyses of retinas from various animal models 
demonstrated that excessive and prolonged microglial activation may lead to 
chronic inflammation and is associated with and often precedes severe 
pathological side effects resulting in retinal degeneration and photoreceptor 
apoptosis (197-199). When the morphology of the retina between the two groups 
was examined, it was found that the number of cells in the outer nuclear layer was 
significantly less in the open environment group but the thickness remained the 
same. This could be explained by prolonged presence of macrophages in the 
subretinal space might lead to photoreceptor cell death as retinal degeneration 
could be seen in the mice from open environment. 
 
The increase in macrophage number in the subretinal space implies that there 
might be an inflammatory response in the retina of the open environment mice. To 
examine the level of inflammation in the retina, retinal sections were 
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immunostained with calcitonin, a protein that is not involved in the complement 
system, which is a recognised acute phase protein, used as a biomarker for 
inflammation. It is shown that the level of inflammation between both groups of 
animal is significantly different. The level of calcitonin expression was higher in the 
group that was bred in the open environment.  
 
Calcitonin is a 32-amino-acid peptide hormone which is produced mainly by the 
parafollicular cells of the thyroid gland in response to increases in extracellular 
calcium concentrations, binds to the calcitonin receptor and regulates calcium 
concentrations via bone resorption in osteoblasts. Calcitonin and its related 
peptides also act as chemoattractant, inducing monocyte migration and this 
phenomenon is dosage dependent (200). Recent work by Chen et al. (201) has 
shown that calcitonin receptors were present in the retina and that they are up-
regulated in ageing retina, which may reflect a low grade chronic proinflammatory 
state associated with age. Therefore calcitonin may represent a tissue biomarker of 
ageing, as well as have a physiological role in regulation of para-inflammation. 
Hence, in this study the level of calcitonin expression, which was higher in the 
animals from the open environment, might be due to a low-grade chronic 
proinflammatory state associated with constant exposure to pathogens. 
 
To examine whether the accumulation of Aβ and the deposition of activated C3 
were the same in both cohorts, retinal sections were immunostained with an Aβ 
and activated complement C3 antibodies. There was no significant difference in the 
accumulation of Aβ between the two groups implying that they both displayed a 
normal age-related accumulation of Aβ in the outer retina. This suggested that 
both groups were ageing at the same rate as accumulation of Aβ increased with 
age. Even though in previous chapters, it was shown that the accumulation of Aβ 
peptides contribute to the formation of drusen and is a factor that trigger the onset 
of AMD. 
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  In this experiment, this concept was being ruled out as here both groups of animal 
accumulated Aβ at the same rate but the degree of inflammation were different in 
the two, hence the only variable that was different were the environmental 
conditions. There was a significant difference in the level of C3b/iC3b/C3c in the 
outer segment of the photoreceptors and along the Bruch’s membrane when the 
two groups were compared. The level of expression of C3b/iC3b/C3c was 
significantly higher in barriered animals in comparison with animals from the 
open environment. This might be due to the fact that this antibody used in this 
study was specific for cleaved C3 fragments C3b, iC3b, and C3c, and for activated 
C3. In case of chronic inflammatory conditions minimal activity with this antibody 
occurred because the C3dg product, which was not recognised by the antibody 
used here, resided at the place of inflammation while C3c was being cleared. 
 
The synthesis of C3 is tissue-specific and is modulated in response to a variety of 
stimulatory agents. C3 is the most abundant protein of the complement system. 
Upon activation, the complement system produced unstable protease complexes, 
named C3b (61). C3b becomes attached to immune complexes such as C3b 
convertases and is further cleaved by a serine protease called factor I in the 
presence of appropriate cofactors to render C3b inactive by degrading the 
molecule into iC3b, C3c, C3dg and C3f. C3d is a 35kDa, protease resistant fragment 
of C3dg which interact with complement receptor 2, and constitutes the domain 
within C3b that interacts with CFH (202, 203). C3dg binds to complement receptor 
2, found on B cells and is part of a co-receptor complex that powerfully amplifies 
antibody responses. The complexes that the antibody makes with the antigen and 
C3dg produce a more potent antigen, leading to more efficient B-cell activation and 
antibody production (61).  
 
C3dg was shown by Johnson et al. (204) to be a component of drusen. The 
activation of C3 at a lower level would reduce the detection of the C3 fragments 
C3b, iC3b and C3c. Hence, this might suggest that mice bred in the open 
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environment had a chronic inflammation in the retina, while mice bred in a 
barriered environment had either local or acute inflammation. To answer this 
question, mice retina were then immunostained with a complement C3d antibody 
to examine the level of iC3b being converted to C3d and investigate whether the 
animals from the open environment had either chronic inflammation or 
acute/local inflammation. The results obtained were not conclusive as there was 
no significant difference between the two groups tested. This might be because this 
murine model is immunodeficient in complement factor H, the immune response 
involving the complement system was compromised as CFH-/- mice developed 
uncontrolled complement C3 activation.  
 
C3b degradation is mediated by Factor H which regulates the alternative pathway 
by acting as a cofactor for cleavage of C3b to iC3b by factor I (205, 206), 
accelerating the decay of the C3 convertase C3bBb (205, 207) and competing with 
factor B for binding to C3b (208). Factor H promotes the dissociation of these C3 
convertases once they have formed (207). It was very difficult to investigate and 
compare the level of inflammation in those mice using molecules from the 
complement system as markers of inflammation as the immunodeficient in factor 
H might compromise the results obtained. 
 
To investigate whether the inflammation was local or systemic, sections of the 
kidneys were immunostained with the same panel of antibodies as the retinal 
sections. The results were quite confusing and different from that obtained from 
the eyes. The expressions of Aβ deposits in the kidneys of both cohorts were 
significantly different. The kidneys of mice from the open environment strongly 
expressed the presence of Aβ along the basement membrane of the glomeruli 
while the kidneys from the barriered animals expressed weaker staining. 
Immunostaining using inflammatory markers C3d and calcitonin did not show any 
striking difference between the two groups, implying that the level of expression of 
calcitonin in the kidneys were almost the same in both groups. For the kidneys, 
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C3b was not used as inflammatory marker as the main C3 deposition along the 
glomerular basement membrane was in the form of C3d. These results suggested 
that mice from the open environment displayed chronic inflammation only in the 
eyes and not in the kidneys and hence it was a local inflammation. 
 
Chronic inflammation is considered to be involved in the pathogenesis of all age-
related diseases. Inflammaging, i.e. the up-regulation of a variety of anti-stress 
responses at the cellular and molecular level, is the consequence of the body’s 
ability to counteract and modulate the effects of a variety of stressors, which cause 
the accumulation of molecular and cellular scars (182, 209). The two cohorts used 
in this experiment had the same genetic background, the same diet regime and 
light exposure and were immunodeficient in factor H but they had strong 
asymmetries in the exposition of pathogens and susceptibility to diseases.  
 
Barriered mice were exposed to relatively fewer pathogens and therefore their 
immune system was not challenged at all and as a result of their contained 
exposure to pathogens, the onset of diseases was either delayed or did not appear 
at all. It was shown in human by Vasto et al. (210) that people who are genetically 
predisposed to a weak inflammatory activity have less chance to develop age-
related disease and therefore have better chance for a long-life in a modern 
environment with reduced load and improved control of severe infections by 
antibiotics. Chronic inflammatory mechanisms carry the imprint of early-life 
infections into later life morbidity and mortality. The process of life for the 
individual is the struggle to preserve its biological and immunological integrity. 
However, the preservation of the integrity of the organism comes with the price of 
responsiveness to systemic inflammation (211) which must be finely tuned 
otherwise dysregulation becomes a damaging accompaniment. Increased exposure 
to infectious agents could trigger the innate immune system to become over 
activated. 
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The retinal differences between the two groups were most likely to be due to the 
degree of exposure to pathogens. Here, the primary aim was to assess the impact 
of pathogens on disease progression. There was no attempt to exhaustively search 
for one specific pathogen in the open environment that will trigger AMD, but 
Pasteurella pneumotropica, and parasites such as Syphacia obvleata, Entamoeba 
and Trichichomas were present in the open environment. Further studies on this 
field would open the way for new treatment. It is possible, before clinical 
manifestation appear that anti-inflammatory or other treatments might play a 
desicive role in preventing or significantly retarding the manifestation of age-
related disease. 
 
 Exposure to pathogens could result in chronic low level of inflammation capable of 
triggering diseases that might not arise otherwise. It is now clear that such factors 
are likely to be significant in coronary heart disease (212). One study by Cadwell et 
al. (213) demonstrated that a specific virus interacted with a mutation in Crohn’s 
disease susceptibility gene Atg16L1 induced intestinal pathologies in mice. Other 
clinical studies have suggested the association of cytomegalovirus or Chlamydia 
pneumonia in the progression of AMD (214-216). Focus on clarifying a specific 
pathogen, which contributes to the onset of AMD, might help to the discovery of 
new drugs but it might also be that the onset of AMD is not entirely due to a 
specific pathogen but to the load of pathogen one is exposed to. This study 
reinforced the important concept that there were situations in which concomitant 
collection of environment data could help in identifying gene-disease association 
and it showed that genetic mutation or polymorphism was not the only factor that 
triggered the onset of AMD but environmental risk factors must also be taken into 
account in future therapies. 
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5. Abstract 
 
Mechanisms of complement regulation are crucial for understanding disease 
pathology and for enabling the development of diagnostic tools and therapies for 
complement-associated diseases. Complement C3 is the central component of the 
complement system and a key inflammatory protein activated in age-related 
macular degeneration (AMD). AMD is associated with polymorphisms of 
complement factor H, which is thought to result in uncontrolled activation of C3.  
Consequently, inhibiting C3 activation is a target strategy in AMD treatment. 
 
 In this study, the target strategy of inhibiting C3 activation and complement 
activation in treating AMD is questioned by examining an aged mouse model 
where both the complement factor H and component C3 have been knocked-out 
(CFH-/-.C3 -/-). These were compared with age-matched CFH -/- alone and normal 
C57Bl/6 wild type (WT) to address the role of C3 in age-related ocular disease and 
to investigate the impact of C3 deficiency in the factor H deficient mouse model of 
AMD. Retinal functions of all mice were assessed using electroretinogram (ERG) 
and the eyes were examined using a confocal scanning electron microscope. The 
retinal morphology of the eyes was analysed using resin-embedded histochemical 
methods and scanning electron microscope (SEM). The accumulation of Aβ along 
the retinal pigment epithelium /Bruch’s membrane (RPE/BM) interface and in the 
outer segment of the photoreceptors was assessed and compared with age-
matched wild type and complement factor H knockouts (CFH-/-) using 
immunohistochemistry and Western blotting.  
 
It was found that CFH-/-.C3-/- accumulated Aβ along the RPE/BM to a greater extent 
than the other groups. However, unlike the other groups they failed to accumulate 
this material on their outer segments. They also had significantly fewer subretinal 
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macrophages than the other groups. The ERG of CFH-/-.C3-/- animals displayed a 
more sever a and b-wave reduction than found in CFH-/- or WT animals, 
particularly at higher stimulus intensity, suggesting compromised rod and cone 
functions. Histological analysis show significant photoreceptor loss in CFH-/-.C3-/- 
animals when compared with the other two groups. 
 
It is thought that C3 impacts negatively on the retina. However, C3 deficiency in 
CFH knockout mice resulted in an increased amyloid accumulation on RPE/BM, 
elevated photoreceptor loss and inflammation and reduced retinal function. 
Contrary to expectation, these results point to a beneficial/protective role of C3 in 
this AMD mouse.  
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5.1. Introduction 
 
The complement system is a major non-cellular component of the innate immunity 
and is important for cellular integrity, tissue homeostasis and modifying the 
adaptive immune response (60, 190). Complement activation provides an effective 
host defence mechanism against foreign organisms by generating effector 
molecules, which are involved in cell death and inflammatory responses (217). 
Complement can be activated through three pathways; the classical pathway (CP), 
the mannose-binding lectin pathway, and the alternative pathway (AP). The 
alternative pathway in serum is initiated by the proteolytic activation of 
Complement component C3 (C3) to C3b through the cleavage of small 
anaphylatoxin C3a. The central complement component C3 is the point of 
convergence of three complement pathways (218) and thus plays a critical role in 
biological processes mediated by complement activation.  
 
The key difference between different pathways rests on how the enzymes C3 and 
C5 convertases are formed. C3 is the most important protein of the complement 
system and plays a central role in the immune response. It is capable of forming a 
covalent linkage with the target of complement activation, and genetic deficiency 
of C3 is associated with impaired host resistance to bacterial infection and perhaps 
an increase of diseases that may be immunologically mediated. Its activation 
results in the cleavage of C3 by the convertase C3bBb, which is formed by C3b and 
factor B, to smaller proinflammatory molecules, C3a and C3b. C3a aids in the 
recruitment and activation of innate immune effector cells and also has 
antimicrobial and antifungal activity (219). If activation progresses, C3b is 
deposited close to the site of generation and, on formation of surface-bound 
convertases, amplifies the cascade.  
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While complement can be triggered by antibody-antigen complexes, it also has its 
own intrinsic capability for recognising foreign organisms. This recognition 
system, the alternative pathway, operates by continuously generating small 
amounts of activation products derived from C3 (220). The invading organism 
becomes coated with C3b, leading to it being attacked by phagocytic cells and the 
terminal components of the complement system (220). On the surface membrane 
of intact host cells, C3b deposition is prevented by regulators and further 
progression is blocked; by contrast, on microbial surfaces or on modified self cells 
activation can progress. C3b opsonises the biological surfaces and the latter, are 
then cleared by phagocytosis in a non-inflammatory manner. 
 
C3b is further cleaved by factor I, in the presence of appropriate cofactor to release 
C3f and iC3b. Factor I further degrades iC3b into C3dg and C3c. These degradation 
products, iC3b and C3dg are involved in complement-mediated cytolysis, 
opsonisation, immune regulation, and the inflammatory responses (221). C3 is 
synthesised mainly by the liver and in small amounts by activated monocytes and 
macrophages (222).  The functions of C3 activation products include virus particle 
neutralisation (C3b), inflammation (C3a), improving the clearance and 
solubilisation of immune complexes (C3b), vasopermeability and smooth muscle 
contraction (C3a), regulating the proliferation and/or differentiation of 
lymphocytes and leucocytes (C3dg) and aiding in the clearance of pathogenic 
microorganism through complement-mediated lysis and opsonisation (C3b, iC3b). 
Immobilised C3 fragments facilitate the cooperation between immunocompetent 
cells as they are involved in antigen processing and presentation (222) and are co-
stimulatory molecules in T- and B-cell activation and T-cell proliferation and 
differentiation (223, 224), probably as a result of their ability to promote cell-cell 
adhesion. Soluble C3 products inhibit lymphocyte proliferation (225). 
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In addition to these three well-known pathways, complement is also activated by a 
bypass pathway that acts independently of C3 to bypass the C3 convertase and is 
mediated by direct thrombin action on the C5 convertase (226). 
 
The eye is an immune-privileged site that contains a number of 
immunosuppressive factors that protect it from potentially dangerous immune and 
inflammatory reactions. There is a low degree of complement activation that exists 
in the eye under normal physiological conditions (227), which increases with age 
(196, 228). Although plasma complement components can easily reach ocular 
tissues lacking a tight blood tissue barrier, such as sclera and choroid, the retina is 
relatively closed off to the immune system due to the blood-retinal barrier, yet 
retinal complement activation occurs even under normal ageing conditions (196). 
The eye is also able to regulate complement activation by producing complement 
components such as C3 and complement regulatory proteins such as complement 
factor H (CFH) and complement factor B (CFB) locally (228-233). 
 
The immune mechanism and cellular interactions in AMD are similar to those seen 
in other diseases characterised by the accumulation of extracellular deposits, such 
as atherosclerosis and Alzheimer’s disease (AD) (204). Recent studies in the last 
decades suggest that age-related macular degeneration may be a consequence of a 
chronic inflammatory process (43, 44, 204, 234). AMD has shown particularly 
strong ties to complement. After several complement components were detected 
in subretinal drusen (46, 145), the genome-wide association studies identified 
polymorphisms in the factor H gene as major risk factors for AMD (64-67). 
Meanwhile, additional polymorphisms and deletions that mostly affect the 
alternative pathway including C3 and factor B (143, 235), have been discovered, 
suggesting that disruption of the delicate balance between complement activation 
and regulation in the subretinal tissue might contribute to the progression of AMD.  
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Given the strong association between AMD and complement and the high 
prevalence of the disease, it is not surprising that considerable complement-
targeted drug development efforts are being directed towards AMD. Complement 
inhibitors are among the few promising options for treating the early, dry form of 
AMD and potentially preventing vision loss (236). Compstatin is a synthetic C3 
cyclic peptide inhibitor that acts by binding to C3 preventing its activation and 
therefore is a blocker of the activation of complement at a crucial step (237). 
Compstatin has been discovered for more than 10 years by phage-display libraries 
in the search for C3b-binding peptides (238). Potencia pharmaceuticals is 
developing an intravitreal therapeutic delivery of a compstatin analog (POT-4) for 
the treatment of AMD and this is under clinical trials. 
 
The study of inherited deficiencies of complement proteins in vivo offers insights 
into the physiological activities of the complements system that are not readily 
available from in vitro analysis. Deficiency of complement function is associated 
with an increased tendency to pyogenic infection (239). Deficiency in factor H 
results in an inability to catabolised C3b, leading to uncontrolled amplification of 
cleavage of C3 by an unregulated C3bBb C3 convertase. Deficiency in C3 seriously 
impairs immune homeostasis and predisposes to immune complex disease (239). 
Ghannam et al. (2008)(240) demonstrated that in addition to a defective B cell 
memory, human C3 deficiency may be associated with important functional defects 
of dendritic and regulatory T cells therefore highlighting the importance of C3 as a 
key regulator of cell-mediated immunity. 
 
Thus C3 is the pivotal factor in all complement activation pathways and is 
necessary for the complement activation. However, the question to be addressed is 
whether inhibiting the activation of C3 will be beneficial in the treatment of AMD. 
In this study, factor H knockout AMD murine model, deficient in C3 (C3-/-) was 
used to investigate the in vivo role of complement C3 and the effect of inhibiting 
complement activation in AMD. The results suggest a beneficial role of complement 
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C3 in AMD and the general neuronal health in the retina, particularly with ageing 
and pathogenesis. 
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5.2. Materials and Methods 
5.2.1. Animals 
Twelve to fourteen-month-old complement factor H (CFH-/-) knockout and double 
knockouts of CFH and complement component 3 (CFH-/-.C3-/-) (kind donation from 
Matthew Pickering, Imperial College, UK) and age-matched wild-type C57Bl/6 
(C57) mice (8 animals per group) were fed lab chow ad libitium and housed in a 
temperature controlled environment with a 12-h day (160 lux)-night cycle. All 
experimental procedures complied with and were carried out under the United 
Kingdom Animals (Scientific Procedures) Act 1986. 
 
5.2.2. Electroretinogram (ERG) 
Electroretinography (ERG) was used to assess retinal function in response to full-
field flash stimuli under scotopic and photopic conditions. The eyes of the mice are 
stimulated with a bright light source such as a flash produced by a strobe lamp. 
The intense flash of light elicits a biphasic waveform recordable at the cornea 
whereby an electrode is placed.  The resulting signal is displayed showing the time 
course of the signal’s amplitude (voltage) (241).The mice were dark-adapted 
overnight for scotopic measurements and then they were anaesthetised with 6% 
Ketamine, (Fort Dodge, UK) 10% Dormitor, (Pfizer, UK) and 84% sterile water at 
5ul/g intraperitoneal injection. The pupils of the mice were dilated (1% 
Tropicamide, MINIMS, Bausch & Lomb, France) 10 to 15 minutes prior to ERG 
recordings. Procedures were carried out under a red-light condition. Only the left 
eye of each mouse was subjected to ERG recording via a platinum loop electrode 
placed on the cornea. A ground electrode was placed subcutaneously through the 
skin at the back of the mouse and a reference electrode was placed under its 
tongue.  The mouse was placed on a heated pad (370C) to keep the temperature of 
the body constant. ERG was carried out under both scotopic and photopic 
conditions by subjecting the animals to flash stimuli (10μs to 1 ms in duration, 
repetition rate of 0.1-1 Hz; log intensity of -6.1 to +2.7). The pulse time for the 
scotopic conditions were 33 ms and the cycle time were 20 secs, 30 secs and up to 
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110 secs. After the series of scotopic stimulation, mice were adapted to a 20cd/m2 
background for 20 minutes, after which photopic responses to flash stimuli and 
flicker (up to 40 Hz for a duration of 30 secs for each frequency) were recorded. 
The cycle time for the photopic condition was 1 sec and there were 30 repetitions 
for each stimuli. The pulse time was 10ms. An average of five readings was taken 
for each intensity. Statistical differences between groups were evaluated by using 
random ANOVA. 
 
5.2.3. In vivo imaging 
Under the same anaesthetic, scanning laser ophthalmoscope (cSLO) imaging was 
performed. Before each image sequence, drops of hydroxypropyl methylcellulose 
(0.3%) were placed on the eye to prevent drying. Fundus photographs were taken 
with a digital camera mounted on a modified confocal Scanning Laser 
Ophthalmoscope (Heidelberg Retina Angiograph, Heidelberg Engineering, 
Germany) where the pinhole diameter had been reduced to 100 µm to 
improve axial resolution, and the laser power increased to improve signal-to-
noise ratio. Power at the mouse pupil was measured to be 1400 µW at 488 nm. 
 
5.2.4. Immunohistochemistry 
All mice were killed by exposure to CO2 .The eyes were removed and fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS), pH 7.4, cryopreserved in 
30% sucrose in PBS and embedded in OCT compound (Agar Scientific Ltd). 
Cryostat sections were cut at 10um and thaw-mounted onto charged slides. 
Immunohistochemistry was performed at room temperature. 
 
The sections of the eye were incubated for 1 hour in a 5% Normal Donkey serum in 
0.3% Triton X-100 in PBS, pH 7.4, followed by an overnight incubation with a 
mouse monoclonal antibody to Aβ 4G8 (1:500, Covance) which was made in 1% 
Normal Donkey Serum in 0.3% Triton X-100 in PBS. After the primary antibody 
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incubation, the sections were washed three times in 0.1M PBS and then incubated 
in a secondary antibody conjugated with Alexa Fluor 568 (Invitrogen) which was 
made up in 2 % Normal Donkey Serum in 0.3% Triton X-100 in PBS at a dilution of 
1:2000 and added to the sections and incubated for 1 hour at room temperature. 
Negative controls were done by omitting the primary antibody. After the 
secondary antibody incubation, the sections were washed several times and the 
nuclei were subsequently stained with 4', 6-diamidino-2-phenylindole (Sigma) for 
1 min. Slides were then washed a few times in 0.1 M PBS and several washes in 
Tris buffered Saline (pH 7.5). The slides were mounted in Vectashield (VECTOR 
Laboratories) and coverslipped.  
 
Retinal sections were also immunostained to reveal levels of retinal inflammation 
with calcitonin (1:100, Abcam) and visualised with 3,3-diaminobenzidine. 
 
For the flatmounts, the eyes were fixed in 4% paraformaldehyde in PBS and 
washed with PBS. The eyes were dissected and the cornea, lens and retina were 
removed.  To facilitate preparation of the flatmounts, five or more vertical cuts 
were made in the RPE-choroidal tissues. 
 
After several washes with PBS, the RPE-choroidal tissues were blocked and 
permeabilised with 5% Normal Donkey serum with 3% (v/v) Triton X-100 in PBS 
for 2 hours. Samples were incubated overnight in a rabbit polyclonal antibody to 
Iba-1 (1:1000, A. Menarini diagnostics) which were made in 1% Normal Donkey 
Serum in 3% Triton X-100 in 0.1M PBS. After primary antibody incubation, the 
samples were washed three times in PBS and then incubated in a secondary 
antibody, Alexa Fluor donkey anti rabbit 488,  which were made up in 2 % Normal 
Donkey Serum in 0.3% Triton X-100 in PBS  at a dilution of 1:2000, and incubated 
for 2 hours at room temperature. After the secondary antibody incubation, the 
samples were washed several times and the nuclei were subsequently stained with 
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4', 6-diamidino-2-phenylindole (Sigma) for 1 min. The RPE-choroidal tissues were 
then washed a few times in 0.1 M PBS and several washes in Tris buffered Saline 
(pH 7.5). The flatmounts were mounted in Vectashield (VECTOR Laboratories) and 
coverslipped. The samples were viewed and images captured using an Epi-
fluorescence bright-field microscope (Olympus BX50F4, Japan), where data were 
captured as 24-bit colour images at 3840x3072 pixel resolution using a Nikon 
DXM1200 (Nikon, Japan) digital camera. The images were then put together and 
Iba-1 positive cells were counted using Adobe Photoshop CS4 extended. 
 
Immunohistochemistry was performed at room temperature in the same way as it 
was done with the mice eye sections. 
 
5.2.5. Western Blot 
For Western blot, the eyes were dissected on ice and the retina and RPE-choroidal 
tissues were separated and frozen in liquid nitrogen and stored at -80oC. The 
retina and RPE-choroidal tissues were sequentially extracted. The samples were 
homogenised in 2% SDS with protease inhibitor cocktail (Roche diagnostics), then 
centrifuged at 13,000 X g. The supernatant was then transferred to a new 
microcentrifuge tube and the resultant pellet was then extracted with 70% formic 
acid in water. Then centrifuge at 13,000 X g and the supernatant was transferred 
to the microcentrifuge tube and the pellet discarded. The formic acid in the 
supernatant was then evaporated using a speed-Vac concentrator (The Eppendorf  
Vacuum Concentrator Model 5301, Brinkmann) and the protein pellet was 
reconstituted in 10% dimethyl sulfoxide in 2mol/L Tris-HCl. The protein 
concentration was measured with an absorbance of 450nm and Bovine Serum 
Albumin was used as a standard protein concentration. 
 
Equal amounts of proteins (5µg/ml) were then separated by a 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically 
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transferred onto nylon membranes. The nylon membranes containing the 
transferred proteins were pre-treated with 5% non-fat dried milk in 1M PBS 
(pH7.4) overnight and then incubated for 1 hour with monoclonal Aβ antibody 
(1:1000, Covance) followed by several washes in 0.05% Tween-20 in 1M PBS. The 
membranes were then incubated with a goat anti mouse IgG peroxidase 
conjugated secondary antibody (1:10,000, Thermo Scientific) for 1 hour. Aβ 
immunoreactivity was visualised by exposing x-ray film to blots incubated with 
ECL reagent (SuperSignal West Pico, Thermo Scientific). The total protein profile 
was determined by staining the gels with Coomassie Blue and to check that the 
extraction of proteins were consistent. The protein bands were then photographed 
and scanned. The absolute intensity of each band was then measured using Adobe 
Photoshop CS4 extended. 
 
The mouse monoclonal antibody to Aβ 4G8 which was used in 
immunohistochemistry and Western blot, is specific for the Aβ ectodomain (amino 
acid sequence 17-24 in human), a sequence that does not overlap with that of 
secreted APP and is identical in human, mouse and rat. Therefore this antibody 
excludes the possibility that the bands obtained in the Western blot and the 
protein expression observed in the immunohistochemistry were degradation 
products of soluble amyloid precursor protein which lacks the mid-domain Aβ 
epitope (Aβ17-24).  
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5.2.6. Resin embedded histology 
The retina were fixed in buffered 2% paraformaldehyde and 2% glutaldehyde in 
phosphate buffered saline for 24 hours, followed by washing in PBS and then post 
fixed in 1% osmium tetroxide in 0.1M PBS for 2 hours. The tissues were then 
thoroughly washed in distilled water and then dehydrated through a graded series 
of ethanol. Then the tissues were infiltrated, polymerised and embedded in 
Technovit 7100 historesin solution (Taab Laboratories equipment, UK).  Resin 
sections were cut at 5 μm and mounted in Depex mounting medium and then 
coverslipped. 
 
5.2.7. Scanning Electron Microscopy 
The retina were fixed in buffered 2% paraformaldehyde and 2% glutaldehyde in 
phosphate buffered saline for 24 hours, followed by washing in PBS and then post 
fixed in 1% osmium tetroxide in 0.1M PBS for 2 hours. The tissues were then 
thoroughly washed in distilled water and then dehydrated through a graded series 
of ethanol.  The specimens were dried with a critical dry point apparatus (Bal-Tec 
CPD 030 Critical Point Dryer). After drying the samples were coated with platinum 
or gold (Cressington 308R Desktop Advancing Coating Systems) and then 
specimens were analysed using a Carl Zeiss scanning electron microscope (ΣIGMA 
VP– Advanced Analytical Microscopy).  
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5.3. Analysis 
5.3.1. Counting of macrophages 
Images were captured using a 20X objective lens and a 10X eyepieces in JPEG 
format using the Epi-fluorescence bright-field microscope with a 24-bit colour 
images at 3840 x 3072 pixel resolution using a Nikon DXM1200 digital camera. The 
images were then put together by Adobe Photoshop CS4 extended. The iba-1 
positive cells were counted using the count tool. 
 
5.3.2. Measurement of Aβ in RPE and photoreceptor outer segments and 
calcitonin in the retina by immunostaining 
Fluorescence images of the area around the optic nerve head were taken in JPEG 
format at  X400, using an Epi-fluorescence bright-field microscope (Olympus 
BX50F4, Japan) with a 24-bit colour images at 3840 x 3072 pixel (px)resolution 
using a Nikon DXM1200 (Nikon, Tokyo, Japan)  camera. The pictures were 
montaged and the integrated density, which is the product of the area chosen (in 
pixels) and the mean gray value (the measurement of the brightness) of 118.11px 
X 11.811px (31.65µm X 3.17µm) box for the RPE and 118.11 px X 118.11px (31.65 
µm X 31.65 µm ) box for the outer segments at 5 predefined regions per retinal 
section and 5 retinal sections per eye were measured and averaged using Adobe 
Photoshop CS4 extended. Measurement of calcitonin was done in the same way 
with a box of 118.11px X 11.811px (31.65µm X 3.17µm) for the outer plexiform 
layer and 118.11 px X118.11px (31.65 µm X 31.65 µm) box for the GCL/IPL and 
outer segments. The scale was reversed as measurement of the brownness was 
used and not the brightness (255- mean gray value). 
 
5.3.3. Measurement of Aβ in RPE and retina in Western blot  
The scanned pictures of the protein gel were inverted to grayscale format and the 
mean gray value was measured for each protein band by using the lasso tool to 
draw a line all the way around the edges of the band using Adobe Photoshop CS4 
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extended. The absolute intensity was calculated by multiplying the mean gray 
value and the pixel value. 
 
5.3.4. Statistical analysis 
The Mann-Whitney U test was used for comparison of two groups, whilst for 
analysis of three or more groups Bonferroni’s multiple comparison test was used. 
Data were analysed using GraphPad Prism version 5.0 for windows (GraphPad, San 
Diego, USA). 
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5.4. Results 
5.4.1. C3 deficiency in AMD model results in photoreceptor dysfunction 
Electroretinography (ERG) was used to assess retinal functions in response to full-
field flash stimuli under scotopic (relatively low luminance) (Figure 5.1 and 5.2) 
and photopic conditions (relatively high luminance)(Figure 5.3 and 5.4). 
Responses to light stimuli from C57, CFH-/- and CFH-/-.C3-/- mice were recorded. 
ERGs were comprised of clear a- and b- wave components and oscillatory 
potentials on the rising slope of the b-wave. Recordings were performed under 
scotopic conditions, in which rod-mediated responses predominate and photopic 
conditions whereby responses are cone-mediated. Under scotopic conditions, the 
CFH-/-.C3-/- animals displayed lower a-wave amplitudes at all stimulus intensities 
and especially at higher intensities; 9 (P<0.05) and 10 (P<0.01) (Figure 5.2). There 
was no significant difference in the b-wave amplitude among the three groups but 
a trend was seen in the b-wave of CFH-/-.C3-/-, which lowered at intensity 8 and 
onwards. This change in the a- and b- wave amplitude, but particularly the a-wave 
suggests that photoreceptor cell death as well as photoreceptor dysfunction occur 
in the CFH-/-.C3-/- mice. 
 
The a-wave and b-wave of the CFH-/- mice also showed a small decrease in 
amplitudes but it was not significant. It was seen that the b-wave of these animals 
was almost entirely devoid of the oscillatory potential indentation in the scotopic 
responses (Figure 5.1), indicating that the retinal vasculature is compromised.  
 
The a-wave latencies for CFH-/-.C3-/- and CFH-/- mice were shorter at intensity 5 
(P<0.001 for both CFH-/-.C3-/- and CFH-/-) and 6 (P< 0.01 for both CFH-/-.C3-/- and 
CFH-/-) (Figure 5.2) in comparison with that of the C57 mice suggesting that the 
response to the stimulus was faster or enhanced at these two intensities while b-
wave was almost similar in all three groups. The CFH-/- mice also showed a 
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significantly shorter response latencies at intensities 5 (P<0.001) and 6 (P<0.01). 
These results still remain unclear and no plausible explanation can be provided. 
 
After adaptation to photopic conditions, CFH-/-.C3-/- mice showed a lower response 
in the a-wave amplitude than the other two groups (Figure 5.3 and 5.4). At 
intensities 3 (P <0.01), 4 and 5 (P<0.001 for both 4 and 5), CFH-/- .C3 -/- mice 
showed lower responses when compared to wild-type and at intensities 4 (P<0.01) 
and 5 (p<0.01) when compared to CFH-/- mice (Figure 5.4). There were no 
significant differences in b-wave amplitude among all the three groups in the 
photopic conditions but the CFH -/- mice showed a trend in reduced amplitude 
when compared to the other two groups. The b-wave of the CFH-/- mice also 
showed the absence of oscillatory potential and this further supported the results 
obtained from the scotopic conditions, which reflected that the CFH-/- mice have 
compromised vasculature in the retina (Figure 5.3).  
 
There was a significant shortening of the a-wave latency in the CFH-/-.C3-/- mice at 
all intensities (1; P<0.01, 2-5; P<0.001) while the CFH-/- mice showed also a 
significantly shorter response latency at intensity 1 (P<0.001) in comparison with 
the C57 mice, suggesting an enhanced response to increasing intensity of the 
stimulus (Figure 5.4). There was no significant difference in the latency b-wave 
among all the three groups but the CFH-/-.C3-/- mice showed a slower response to 
the stimulus in comparison with the other two groups. The results obtained from 
the latency response of the CFH-/-.C3-/- mice are still unclear and no explanation 
can be provided. 
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These ERG data demonstrate that rod and cone photoreceptor function is impaired 
in the CFH-/-.C3-/- mice as a result of photoreceptor cell death, as shown by the 
lower amplitude a-waves in both scotopic and photopic recordings. There was also 
the absence of oscillatory potentials along the b-waves in the CFH-/- mice when 
compared to the C57 mice. 
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Figure 5.1 - Electrophysiological assessment of retinal function under scotopic condition in in age-matched wild 
type C57, CFH
-/-
 and CFH
-/-
.C3
-/-
 mice. 
Representative examples of recorded evoked responses comprising clear a- and b- wave components and 
oscillatory potentials in scotopic conditions of neural retina responses to flash stimuli of increasing log intensity. 
Chapter Five - Complement C3 deficiency leads to neurodegeneration and retinal dysfunction in an AMD murine model 
164 
 
 
Figure 5.2 - Graphs showing combined A- and B- waves of the average performance of all the four animals in each 
group under scotopic conditions. 
CFH
-/-
.C3
-/-
 mice exhibited a significant reduction in the amplitude a-wave and latency a-wave with increasing 
stimulus intensity in comparison with age-matched wild type and the CFH
-/-
, indicating that function of rods and 
cones of the photoreceptor are impaired. B-wave in all three groups has no significant difference among them. 
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Figure 5.3 - Electrophysiological assessment of retinal function under photopic condition in in age-matched wild 
type C57, CFH
-/-
 and CFH
-/-
.C3
-/-
 mice. 
Representative examples of recorded evoked responses comprising clear a- and b- wave components and 
oscillatory potentials in photopic conditions of neural retina responses to flash stimuli of increasing log intensity. 
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Figure 5.4 - Graphs showing combined A- and B- waves of the average performance of all the four animals in each 
group under photopic conditions. 
CFH
-/-
.C3
-/-
 mice exhibited a significant reduction in the amplitude a-wave and latency a-wave with increasing 
stimulus intensity in comparison with age-matched wild type and the CFH
-/-
, indicating that function of rods and 
cones of the photoreceptor are impaired. B-wave in all three groups has no significant difference among them. 
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5.4.2. CFH-/-.C3-/- aged mice exhibit less subretinal autofluorescence spots and 
macrophages 
Using in vivo imaging techniques (cSLO), images of the retina of all the three 
groups of mice were taken and it was shown that there are less autofluorescence 
spots in both the CFH-/-.C3-/-, and CFH-/- when compared to the wild type C57Bl/6 
(Figure 5.5). As previously shown in chapter two, there was a tight correlation 
between the autofluorescence spots from the cSLO and macrophages. Therefore 
the imaged eyes were then processed histologically and quantification of the 
activated macrophages in the subretinal area by Iba-1 specific immunoreactivity of 
the CFH-/-.C3-/- CFH-/- and wild type was performed by counting the number of Iba-
1 positive cells. It is revealed that the CFH-/-.C3-/- and CFH-/- mice have less Iba-1 
positive cells in the subretinal space when compared to the C57 mice (P=0.0051 
and P=0.0177 respectively). This suggests that transgenic mice did not have a 
widespread activation and recruitment of macrophages in the subretinal space. 
Chapter Five - Complement C3 deficiency leads to neurodegeneration and retinal dysfunction in an AMD murine model 
168 
 
 
 
Figure 5.5 - cSLO images and graph showing the number of Iba-1 positive cells in C57, CFH
-/-
 and CFH
-/-
.C3
-/-
 mice. 
A. Representative cSLO images of the three test groups; C57, CFH
-/-
 and CFH
-/-
.C3
-/-
 mice. B. Flatmounts of the 
three test groups immunostained with the antibody Iba-1 (green). C. A close up image of the Iba-1 positive cells 
of the C57 flatmount and D. is the graph which shows the number of Iba-1 positive cells in RPE-choroidal 
flatmounts of mice.  There are significant difference in the number of Iba-1 positive cells between the wild type 
C57Bl/6 mice and either the CFH 
-/- 
mice (P= 0.0177) or CFH
-/-
.C3
-/-
 mice (P=0.0051) but no significant difference 
between the CFH-/-mice and the CFH
-/-
.C3
-/-
 mice (P= 0.3984). n= 4 in each group. (Scale bar = 500μm). 
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5.4.3. CFH-/-.C3-/- aged mice expressed more calcitonin, an inflammatory marker, 
in the retina 
Microglia and macrophages reactivity in the subretinal space decreased with CFH 
and C3 knockouts and this may suggest a reduction in the secretion of 
inflammatory factors. To test whether the observed decrease in activated 
macrophages led to a reduction of inflammatory factors, retinal sections are 
stained with calcitonin, which is recognised as an acute-phase protein and used as 
a biomarker of inflammation using the peroxidase detection method. When the 
pixel intensity was measured, the results showed calcitonin expression in the CFH-
/-.C3-/- aged mice is higher (P<0.0001 in all the three retinal layers) than the other 
two groups of mice as shown in figure 5.6. This indicates that even though the CFH-
/-.C3-/- mice have a lower number of macrophages being recruited and activated, 
they have a higher level of inflammation than the age-matched wild type and CFH-/- 
mice. Calcitonin is expressed in the ganglion cell layer, inner plexiform layer, the 
outer plexiform layer and in the photoreceptor layer in the retina. Calcitonin 
expression in the retina of CFH-/- aged mice was not significantly different when 
compared to the aged wild type mice (GCL/IPL; P= 0.5148, OPL; P=0.1220 and 
photoreceptor layer; P= 0.1728).  
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Figure 5.6 - Expression of calcitonin in retinal sections of C57, CFH
-/-
 and CFH
-/-
.C3
-/- 
mice. 
 A. Representative images of calcitonin expression in the retinal sections of the wild type C57, CFH 
-/- 
and CFH
-/-
.C3
-/-
mice (Calcitonin is expressed as the brown staining). B. Graphs showing the level of calcitonin in different 
areas in the retina; in the ganglion cell and inner plexiform layer, the outer plexiform layer and in the 
photoreceptor layer. Calcitonin is significantly higher in the CFH
-/-
.C3
-/-
mice when compared with the CFH
-/-
mice 
and the wild type C57 (P< 0.0001) in all the three layers measured. There is no significant difference between 
CFH
-/-
 and wild type C57 mice. (n=4 in each group). (Scale bar = 50μm). 
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5.4.4. CFH-/-.C3-/- aged mice have increased Aβ deposition along the RPE/BM but 
not in the outer segment of photoreceptors 
To study how deficiency of complement C3 affects the accumulation of Aβ along 
the RPE/Bruch’s membrane (RPE/BM) interface and on the outer segments of the 
photoreceptor, immunohistochemical analysis of retinas from the different 
transgenic mice and the wild type were performed with an Aβ antibody and 
immunoreactivity was analysed by measuring the integrated density. Analysis 
showed that the outer segments of the photoreceptor of the CFH-/-.C3-/- mice has 
significantly less (P= 0.0002 when compared with the wild type and P= 0.0001 
when compared to CFH-/-) Aβ among the three groups but significantly higher 
along the RPE/BM interface (P=0.0001 when compared with wild type and P= 
0.0001 when compared to CFH-/-) as it is shown on figure 5.7. The expression of Aβ 
along the RPE/BM was very strongly expressed in the CFH-/-.C3-/- mice and the 
deposition appeared thicker than the two other groups. The CFH-/-.C3-/- mice failed 
to accumulate Aβ in the outer segment of the photoreceptors. This absence of Aβ in 
the outer retina suggests that photoreceptors failed to secrete Aβ locally, in the 
absence of complement C3, indicating the dysfunctioning of the photoreceptors.  
Hence, it is shown here that Complement C3 is important for the general health of 
the retina. When the Aβ accumulation of the CFH-/- mice were compared to the 
wild type, it is observed that there was a significantly higher deposition along the 
RPE/BM interface but no significant difference in the photoreceptor outer 
segments of  the CFH-/- mice. 
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Figure 5.7 – Expression of Aβ in retinal sections of C57, CFH
-/-
 and CFH
-/-
.C3
-/- 
mice. 
A. Representative micrographs of retinal sections showing Aβ deposition along the RPE/Bruch’s membrane 
interface and the outer segment of the photoreceptor of the different mice groups. Here Aβ is in red and the 
nucleus stained with DAPI (blue). B. Graphs showing the quantitative measurement of the expression of Aβ in the 
RPE/BM interface and in the photoreceptors.  It is shown that Aβ are present along the RPE/BM interface of all 
the three groups of mice but there was a stronger expression along the RPE/BM of the CFH
-/-
.C3
-/-
 mice in 
comparison with the wild type C57Bl/6 (P=0.0001) or when compared with CFH
-/-
 mice (P= 0.0001).  Aβ was 
significantly more in the CFH
-/-
 mice when compared to the wild type (P= 0.0002). Aβ expression in the 
photoreceptor of the CFH
-/-
.C3
-/-
 mice was weakly expressed when compared to the other two groups. (Wild type, 
P= 0.0002 and CFH-/-, P= 0.0001). n= 4 mice in each group. * and ** showing that the difference is significant. 
(Scale bar = 50μm). 
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To further quantify the amount of Aβ present in the RPE/BM and the retina of all 
three groups of mice, Western blot analysis was undertaken (Figure 5.8). This 
revealed that the two most noticeable oligomers present in either the RPE/BM or 
the retina are the 22-36kDa hexamers and the 50-64kDa docecamers.  It is clear 
that the accumulation of Aβ along the RPE/BM of CFH-/-.C3-/- mice is higher than 
that of the wild type but lower than that found in CFH-/- mice. In the retina of the 
CFH-/-.C3-/- mice, the accumulation of Aβ is lower than that of the two other groups. 
The most distinct oligomer present in the retina of the CFH-/-.C3-/- mice is the 50-
64kDa docecamers as shown in figure 5.8C which are thought to be one of the 
possible candidate for Aβ assemblies that cause memory deficits in mouse model 
of Alzheimer’s disease (108) Therefore this 50-64kDa band may be the one that is 
toxic in the retina. These results are largely consistent with that obtained using 
immunohistochemistry, however, the differences in the accumulation of Aβ 
between the two methods especially the results obtained from the CFH-/-.C3-/- and 
CFH-/- mice in the RPE/BM may be due to the differences in tissue sampled as for 
the Western blot, the tissue sample includes the choroidal and retinal blood 
vessels. The impairment in the functions of rods and cones may be explained by 
the increased accumulation of Aβ along the RPE/BM of the CFH-/-.C3-/- mice as this 
deposition prevent transepithelial transportation of nutrients and ions between 
the choriocapillaris and the RPE and this may cause atrophy of the RPE and 
photoreceptor cell death and hence degeneration of the retina. 
Chapter Five - Complement C3 deficiency leads to neurodegeneration and retinal dysfunction in an AMD murine model 
174 
 
 
Figure 5.8 – Western blot analysis of Aβ accumulation in retinae of C57, CFH
-/-
 and CFH
-/-
.C3
-/- 
mice. 
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A. Aβ protein bands obtained from Western blot analysis. B. Graphs showing the quantification of Aβ present in 
the RPE/BM and in the retina. The tissue samples were pooled for the Western blot analysis. It is observed that 
Aβ is present in the RPE/BM of all the three groups. The retina of CFH
-/-
.C3
-/-
 has significantly less Aβ when 
compared with the retina of CFH
-/-
 and wild type C57.C. Graphs showing the quantification of individual 
oligomers,>22kDa and >50kDa. The most distinct oligomer of Aβ present in the retina of CFH
-/-
.C3
-/-
 was the 50-
64kDa while 22-36kDa oligomers were merely present. Differences between the quantification of the 
immunostaining and the Western blot analysis are probably due to the different amounts of tissue sample as 
measurement for the Western blot includes Aβ present in the inner and outer retinal blood vessels but the same 
trend for less Aβ accumulation in the retina of the CFH
-/-
.C3
-/-
 is seen in both experiments. (n= 4 mice in each 
group). 
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5.4.5. CFH-/-.C3-/- aged mice display ultrastructural changes in the retina and 
accumulate debris on the outer segment of photoreceptors 
A detailed ultrastructural examination of the outer retina from the CFH-/-.C3-/-, 
CFH-/- and wild-type mice were undertaken to investigate whether the morphology 
of the retina varies with the different genotypes. Resin sections revealed normal 
histology for wild-type and CFH-/- mice but the CFH-/-.C3-/- mice exhibited a 
significant decrease in the thickness of the outer nuclear layer and in the number 
of nuclei as shown in figure 5.9. In the photoreceptor layer, it is seen that the outer 
segments of the photoreceptor are loosely packed together as there are big gaps in 
between them and therefore they are less dense while the outer segments of the 
photoreceptor of the wild type and CFH-/- are very densely packed together.  
 
The thickness of the outer nuclear layer is thinner in the CFH-/-.C3-/- mice when 
compared to the other two groups. The number of outer segments of the 
photoreceptor was then counted and it is found that there is a significant reduction 
in the number of outer segments of the photoreceptors indicating that there is a 
significant photoreceptor cell loss.  The thickness of the outer nuclear layer in all 
three groups was measured and the number of nuclei was counted. The results 
revealed a significant decrease in the thickness and a lower number of nuclei in the 
ONL (P< 0.0001 and P<0.0001 respectively) of the CFH-/-.C3-/- mice when 
compared to the age-matched C57 and CFH-/- mice. These results support the fact 
that there is significant photoreceptor cell loss and these abnormalities are 
consistent with the recorded changes and impairment in retinal function. 
 
Ultrastructural analysis of the photoreceptor outer segments (Figure 5.10) shows 
that there is an accumulation of highly fibrillary material on the outer segments of 
both CFH-/-, wild-type and CFH-/-.C3-/- retina. This stops at the inner-outer segment 
junction of the photoreceptor, which correlates with the patterns seen in 
immunohistochemistry of CFH-/- and wild type. A closer look at the deposits at 
higher magnification reveal that the accumulated material on the outer segments 
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of the wild type C57 appear as ruptured hemispheres that have partially collapsed 
leaving rough edges while the debris on the outer segment of the CFH-/- mice 
appear to be spherical with some that look like ruptured spheres while the outer 
segments of the CFH-/-.C3-/- are completely coated with very dense filaments which 
have globular nodules at the extremities and the outer segments look shorter than 
the other two groups.  
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Figure 5.9 - Representative images of resin-embedded retinal sections of the three groups of mice. 
A. Micrographs of photoreceptor layer at X40 magnification. B. Micrographs of photoreceptor layer at X100 
magnification. C. Graphs showing the quantification of the number of nuclei in the outer nuclear layer and its 
thickness and the number of photoreceptors within a 100μm area. It is observed that the thickness of the outer 
nuclear layer is thinner and there is less nuclei in the CFH
-/-
.C3
-/-
 mice when compared to the wild type (P<0.0001 
for both the thickness and number of nuclei) and the CFH
-/-
 (P<0.0001 for both the thickness and number of 
nuclei) mice and this is due to significant cell loss in the retina. The number of outer segments of photoreceptor is 
significantly less in the CFH
-/-
.C3
-/-
 mice (P<0.0001 when compared with the wild type and P< 0.0001 when 
compared with CFH
-/-
). (n= 4 mice in each group). (Scale bar = 50μm for the top panel and scale bar = 20μm for 
the bottom panel). 
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Figure 5.10 - Scanning electron micrographs of photoreceptor outer segments taken from C57, CFH
-/-
 and the CFH
-
/-
.C3
-/-
 mice. 
In each case the lower panel is a higher magnification of the outer segment of the photoreceptors and the 
orientation is such that the inner segment (IS) would be to the left and the outer segment (OS) would be to the 
right. It appeared that there are qualitative differences in the morphology of deposits between the three groups 
of animals. The outer segments of the CFH
-/-
.C3
-/-
 are coated with very dense globular nodules and are shorter 
than the other two groups.    The debris on the outer segments of the wild type C57 appear as ruptured 
hemispheres that have partially collapsed leaving rough edges while the debris on the outer segment of the CFH
-/- 
mice appeared to be spherical with some that look like ruptured spheres. Both the CFH
-/-
.C3
-/-
 and CFH
-/-
 mice 
photoreceptor outer segments are completely covered with this debris. (Scale bars = 2 μm; n=4). 
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5.5. Discussion 
 
To reveal the role of complement C3 in the pathogenesis of age-related macular 
degeneration, a double knockout of complement component C3 and factor H 
transgenic mouse was analysed biochemically and neuropathologically and 
compared with CFH knockout and wild-type C57Bl/6 mice. There was a significant 
decrease in retinal function of the CFH-/-.C3-/- mice when this was assessed by ERG. 
The CFH-/-.C3-/- animals displayed lower a-wave amplitudes with increasing 
stimulus intensity suggesting that there was photoreceptor cell loss and 
dysfunction in these animals. There were no significant differences in b-wave 
amplitude between the three groups but a trend was seen in the b-wave of CFH-/-
.C3-/- which decreased with increasing intensity. This significant reduction in the a-
wave amplitude of the CFH-/-.C3-/- mice was not mirrored in the b-wave amplitudes 
and this was because there is more variability in the amplitude of the b-wave and 
changes in the a-wave may be too small to be reflected in the b-wave. To observe 
significant changes in the b-wave amplitude a change of up to a 20% and more in 
a-wave amplitude may be required.  
 
The a-wave and b-wave of the CFH-/- mice also showed a small decrease in 
amplitudes but it was not significant; the ERG of the CFH-/- mice however showed 
an ascending limb of the b-wave that was almost entirely devoid of the typical 
oscillatory potential indentation in both scotopic and photopic conditions. 
Oscillatory potentials are originally presented as small, high-frequency 
components, superimposed on the ascending b-wave of the ERG (242). They are 
understood to be generated by amacrine cells and their temporal interactions. It 
has been shown that reduced amplitudes of the oscillatory potentials are also 
known to indicate development of soft exudates and non-perfused areas and thus a 
compromised microcirculation in patients suffering from diabetes mellitus (243). 
Other studies show that patients with occlusion of the retinal artery have low 
amplitude or extinguished oscillatory potentials (244, 245). Hence, the absence of 
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oscillatory potentials suggests an occlusion of the retinal artery of the CFH-/- mice, 
impairing the blood flow to the retina. Oscillatory potential response at the onset 
of a vascular occlusion in the retina seems to provide information on the severity 
of retinal damage and the risk of developing neovascularisation. 
 
This occlusion in the vasculature of the CFH-/- mice was also reflected in the b-wave 
responses under scotopic and photopic conditions as it had lower amplitudes than 
normal wild type. The results obtained from the ERG correlate with the findings of 
Lundh et al. (2009) (246). The latter demonstrated that the CFH-/- mice have 
vascular pathologies which are the result of complement component C3 and its 
active fragments being deposited on retinal vessels, leading to occlusion of the 
blood vessel and a reduction of retinal blood supply.  
 
When the C3 knockout was combined with the CFH knockout, the oscillatory 
potentials reappeared on the b-wave of the CFH-/-.C3-/- mice. A possible 
explanation is that with the increased loss of photoreceptor outer segments, the 
demand of blood supply to the retina is less and easily met thereby re-establishing 
a ‘normal’ balance of supply and demand even with occlusion of the blood vessels. 
Alternatively, it could also be explained that in the complete absence of 
complement component C3, there were no deposition of any complement 
component and its active fragments along the walls of the retinal blood vessels and 
therefore no occlusion occurred. 
 
The a-wave amplitudes for both the scotopic and photopic conditions were lower 
in the CFH-/-.C3-/- mice than the CFH-/- and wild-type mice. As the a-wave responses 
reflect the general physiological health of the photoreceptors in the outer retina, 
the results obtained here suggest that the photoreceptors of the CFH-/-.C3-/- mice 
have suffered a greater deficit than that found in the other two groups.  
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Both the cones and rods of the CFH-/-.C3-/- mice were affected as a-wave responses 
of scotopic and photopic conditions were significantly lower than the age-matched 
wild type and CFH-/- mice. The a-wave latency for both scotopic and photopic ERGs 
of the CFH-/-.C3-/- mice were shorter than that of the wild type suggesting a faster 
response to increased intensity of the stimulus. These results still remain unclear 
and no explanation can be provided. 
 
Together the in vivo data and the flatmounts immunostained with 
macrophage/microglia marker Iba-1 revealed a significant 10-fold decrease in the 
number of autofluorescence spots /macrophages in the subretinal space. CFH-/-.C3-
/- and CFH-/- mice showed a significant increase in both immunohistochemistry and 
Western blot data in total Aβ deposits in the RPE/BM interface in comparison with 
the wild-type but  CFH-/-.C3-/- mice showed a significantly lower expression of Aβ 
deposits in the outer segment of the photoreceptors as the immunohistochemistry 
and Western blot data revealed. 
 
Ultrastructural analysis demonstrated a quantifiable photoreceptor cell loss in the 
absence of complement component C3 when compared to the factor H knockout 
alone or with the wild type. This may be explained by the dual role of complement 
in possessing both beneficial and pathologic functions (60). 
 
Macrophages/microglia are known to synthesise and to secrete virtually all 
components of the classical and alternative pathways (247) Local biosynthesis of 
complement components by inflammatory macrophages is thought to be one of 
many regulatory and/or effector mechanisms in inflammatory processes (248). 
Microglia/macrophages possess cellular receptors for C3 fragments such as C3a, 
C3b, iC3b and C3d, through which signalling and macrophage activation may occur 
in response to free or particle-bound C3 fragments (249). This is in agreement 
with the results obtained here as significantly fewer numbers of activated 
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microglia/macrophages were found in the subretinal space of the CFH-/-.C3-/- mice, 
implying that in the absence of complement component C3, free or particle-bound 
C3 fragments were not present and this result in microglia/macrophages not being 
activated to respond to these inflammatory proteins.  
 
Microglia are involved in the clearing of Aβ protein deposits in the brain (123) and 
in the retina (250). Multiple studies (59, 251) have shown that different forms of 
aggregated Aβ activate and become bound by complement opsonins such as C3b, 
which are then phagocytosed by complement receptor 3-mediated phagocytosis 
(252). Therefore, it might be possible that the increased accumulation of Aβ along 
the RPE/BM interface in the CFH-/-.C3-/- mice might be attributable to less efficient 
phagocytosis of Aβ deposits in the absence of C3 due to the lack of C3b- or iC3b-
mediated opsonisation and less macrophage recruitment and activation. It was 
also possible that the presence of C3 might be necessary for anti-inflammatory 
cytokines to stimulate microglial phagocytosis of accumulated Aβ.  
 
Mantovani et al. (2004)(253) and Morgan et al. (2005)(254) showed that in the 
absence of C3, there is a shift of microglia/macrophage response toward an 
alternative M2 activation (anti-inflammatory) phenotype. M2-type 
microglia/macrophage are often found in association with apoptotic cells to 
scavenge debris and promote tissue repair, which is in agreement with the 
increased neurodegeneration observed here in the photoreceptor layer. It was 
possible that the complete absence of C3 might have additional effects on 
microglial function and/or molecules that normally suppress microglial activation 
along the phagocytic and cytotoxic pathways. 
 
 It is possible that C3 also plays a role in suppressing aggregation and 
accumulation of Aβ in which case its lack would result in reduced soluble Aβ in the 
retina and increased accumulation of insoluble Aβ along the RPE/BM. CFH-/-.C3-/- 
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mice might be more vulnerable to the cytotoxic effects of Aβ, suggesting a role of 
complement C3 in neuronal survival and health. Tony Wyss-Coray et al. (2002) 
(255) showed that complement activation products may be protective against Aβ-
induced toxicity and reduce the accumulation or promote the clearance of amyloid 
and degenerating neurons and further showed that certain inflammatory defence 
mechanisms may be beneficial in neurodegenerative disease. The results obtained 
here clearly demonstrate that in the complete absence of central C3 in an AMD 
murine model, there is an acceleration of AMD-like pathologies with an increased 
accumulation of Aβ on the RPE/BM and an increased loss of photoreceptors. 
 
Inflammation leads to a series of reactions harmful to cells and it is thought that 
reducing inflammation may improve regeneration and functional recovery (256). 
Hence, in knocking out complement component C3 in a complement factor H 
deficient mouse, it would have been predicted that there would be less 
inflammation.  It has been shown that inflammation can activate the complement 
system, which in turn augments the inflammatory process and aggravates the 
situation (257). Next, the level of inflammation was investigated by 
immunostaining the retinal sections with the inflammatory marker calcitonin and 
it was found that the CFH-/-.C3-/- mice expressed a higher level of calcitonin than 
the age-matched factor H knockout alone and the wild type, indicating a low-grade 
chronic proinflammatory state. In this state, proinflammatory cytokines are 
upregulated and it has been demonstrated by Koenigsknecht-Talboo et al. (2005) 
(258) that chronic inflammation in brains of Alzheimer’s disease patients 
suppresses activation of phagocytic machinery and affects the ability of microglial 
cells to mount a phagocytic response, thereby inhibiting normal microglial 
clearance of Aβ. Hence, it was possible that proinflammatory cytokines lessened 
the efficiency of microglial phagocytosis leading to an accumulation of Aβ along the 
RPE/BM.  
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Aβ not only has a potential pathological role in Alzheimer’s disease and AMD but it 
also has a role in the normal physiology of the central nervous system as Aβ 
activity is required for the essential modulation of synaptic activity and neuronal 
survival (259, 260). It must be remembered that the proteolytic cleavage of 
amyloid precursor protein into Aβ is a physiological process, only when net Aβ 
levels become excessive can this process be regarded as pathological. There was a 
marked reduction, lower than under normal physiological level, of Aβ present on 
the outer segments of the photoreceptors and this could be explained by the fact 
that there were significantly fewer outer segments of the photoreceptor in the 
CFH-/-.C3-/- mice. This low level of Aβ present in the outer segments of the 
photoreceptor could also indicate that the functions of the photoreceptors were 
impaired.  
 
The antibody anti-Aβ 4G8 used, recognises the total Aβ produced and accumulated 
as it recognises both the diffuse and fibrillary forms. The most distinct form of Aβ 
present in the outer segment was the >50kDa docecamers as in the absence of C3, 
there was a reduction in soluble Aβ in the retina and increased accumulation of 
insoluble Aβ in the outer segment of photoreceptors, hence the presence of 
>50kDa molecules which were the bigger and insoluble form. Therefore the 
marked reduction of Aβ suggested that the functions of the photoreceptor were 
compromised and the presence of the >50kDa forms of Aβ in the outer segments of 
the photoreceptor led to neurodegeneration and photoreceptor loss, which was 
reflected in a reduced ERG. Increased accumulation of Aβ along the RPE/BM 
interface prevented the transepithelial transportation of nutrients and ions 
between the choriocapillaris and the photoreceptors and this would cause atrophy 
of the RPE and photoreceptor cell death and hence degeneration of the retina. This 
study demonstrates that in the absence of complement activation, retinal damage 
occurs. 
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Ultrastructural examination of the retina of the three groups of mice showed that 
CFH-/-.C3-/- mice had photoreceptor cell loss associated with an increased Aβ 
deposition on the RPE/BM. Scanning electron microscopy revealed that the 
morphology of the outer segments of the CFH-/-.C3-/- mice were markedly different 
from that seen on the outer segment of the C57 and the CFH-/- mice. The outer 
segments of CFH-/-.C3-/- mice were shorter than the two other groups and were 
completely coated with some kind of debris that had long filament with globular 
nodules at the extremities. These abnormalities were consistent with the recorded 
changes in retinal functions. There was no direct proof that the debris that 
accumulated on outer segments of both CFH-/- and wild type C57 was Aβ, but the 
close association between immunostaining patterns and the scanning EM images 
would argue that Aβ was at least an element of such deposits. Using the same close 
association between the immunostaining patterns of Aβ on the outer segments of 
the photoreceptor of the CFH-/-.C3-/- mice and the scanning EM images, Aβ was not 
one of the elements comprising the debris and the origin of the latter is unknown 
but it is suggested that these debris on the outer segment of the photoreceptor of 
CFH-/-.C3-/- mice might be either blebs or scar tissues resulting from photoreceptor 
cell death and chronic inflammation. Further investigation is required to identify 
its nature and origin.  
 
There are potential therapeutic methods that target the complement pathway, 
particularly the alternative pathway amplification loop against AMD. Many 
biopharmaceuticals such as Potencia Pharmaceuticals are currently developing 
complement–targeted therapies with the aim of treating early AMD and these 
include inhibition of C3 activation, inhibition of C3 convertase assembly, 
promotion of C3 convertase decay promotion of factor–I mediated C3b proteolysis 
and inhibition of C3 convertase activities.  
 
Compstatin/ POT-4, a synthetic peptide developed by Potentia Pharmaceuticals, is 
a C3-peptide inhibitor, which is currently being used under clinical trials for 
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intravitreal use for geographic atrophy in AMD eyes (236, 237). It effectively 
inhibits the central step of the complement cascade by binding to C3 molecules and 
inhibits the cleavage of C3 to its active forms, C3a and C3b. Other preclinical 
development for possible use in the treatment of AMD include an anti-properdin 
antibody, that would destabilise the C3 convertase, sCR1 which is a soluble form of 
endogenous complement receptors 1 that promotes the degradation of active C3 
convertase (236).  
 
This study demonstrates that the complete absence of complement component C3 
in an AMD mouse model, led to a significantly fewer recruitment and activation of 
microglia/macrophages, which failed to phagocytose and hence cleared Aβ 
deposits along the RPE/BM interface. This significant increase in the accumulation 
of Aβ along the RPE/BM which comprised one of its toxic forms, the >50kDa 
oligomers, led to significant photoreceptor cell loss and reduced retinal functions.  
 
Together, these in vivo data demonstrate that complement component C3 is 
critically required for the health of the murine retina. The initial hypothesis was 
that the genetic deficiency of C3 would likely be protective against the 
development of AMD in CFH-/- mice by preventing the inflammatory response and 
cellular damage mediated by complement activation. Contrary to expectation, 
these results pointed to a beneficial and neuroprotective role of C3 in the retina of 
this AMD mouse model and although the results obtained here were in a model in 
which complement component C3 was developmentally rather than conditionally 
depleted and should thus be cautiously extrapolated. Therefore attempts at 
treating AMD using complement-targeting therapies in patients with 
polymorphism in any of the complement genes should take into account the roles 
of complement component C3 and whether inhibiting C3 activation would be 
beneficial or detrimental to the retina of AMD patients for their future therapies. 
 
 
 
 
 
 
 
-  
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6. Final Discussion 
 
In the second chapter of this thesis, it is shown that there is an age-related 
accumulation of Aβ in the retina of a normal mouse at specific sites. This 
accumulation occurs primarily on the outer segments of the photoreceptor and 
along the RPE/BM interface. This was shown using immunohistochemistry to 
detect and understand the distribution and localisation of Aβ in the retina and 
Western blot to quantify it.  
 
The Western blot results shows that the >50kDa oligomers are the most prominent 
along the RPE/BM interface and that a stronger protein band is seen at 6 months 
while in the retina both the 22-36kDa oligomers and the >50kDa are present. This 
results reflect the same observation as Lesné et al. (2006)(108) and suggest that 
the >50kDa docecamers are those that may be toxic to the retina and may lead to 
the onset of AMD.  
 
A third method, scanning electron microscopy, was used to analyse the 
morphology of the outer segment with this potential Aβ containing elements 
wrapping around them. It was shown that the photoreceptors become increasingly 
coated with a form of extracellular debris and these debris correlates with the 
immunostaining results suggesting that Aβ is an element of this debris. This 
material appears to accumulate at the apical tip of the outer segment and progress 
down along its length with age, but at no point does this material accumulate on 
the inner segments. The accumulation of this material on the outer segments may 
be related to a decline in the efficiency of the RPE to phagocytose the tips of 
photoreceptors. 
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There are obvious differences in the appearance of the extracellular material with 
age. At a younger age, the material was roughly spherical and with age, it appears 
as distorted hemispheres with rough sharp edges. It will be important to further 
investigate and identify the nature and origins of this material that accumulates in 
the outer segments of the photoreceptor that may have a negative impact on the 
function of the RPE and photoreceptors themselves by immunogold staining in 
transmission electron microscopy. This age-related accumulation of Aβ on the 
outer segments of photoreceptor is also present in the human retina.  
 
The accumulation of Aβ in the retina was also associated with an increase of 
microglia/macrophages in the subretinal space. These microglia/macrophages 
internalise Aβ suggesting their role in clearing the latter.  These data provide 
evidence that microglia/macrophages in the eye are recruited to site of Aβ 
deposits to clear these neurotoxic peptides, but with age these 
microglia/macrophages fail to do so as they become bloated with waste materials. 
Therefore more and more microglia/macrophages are recruited to maintain the 
homeostasis of the retinal environment. 
 
Another experiment that is worth investigating is whether it is the RPE cells or the 
macrophages that clear the subretinal debris. Studies (261-263) have shown that a 
laser burn at the level of the RPE at a very low intensity may help in the clearing of 
drusen in the eye. Whether it is the new regenerated RPE cells or the recruited 
macrophages that clear the drusen present in the area is still unknown. Therefore 
two groups of CFH knockout mice, which is a known AMD mouse model and in this 
thesis have shown to accumulate more Aβ along the RPE/BM interface at an earlier 
stage than normal mice, should be used for the study. The retinae of the mice will 
be lasered with a low energy burn and one group will be treated with a 
proinflammatory cytokines such as TNFα and IL-1β as it was demonstrated that 
they attenuate the microglial phagocytosis (258), while the other group will be left 
healing normally.  
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The retinal function and visual acuity will be examined in vivo and the amount of 
Aβ will then be quantified. If the mice treated with the proinflammatory cytokines 
have less Aβ than the other group, then it is the RPE cells that are clearing Aβ and 
debris in the eye but if they have more, then it is the macrophages. 
 
The third chapter shows one approach of targeting Aβ using immunotherapy as a 
potential treatment for AMD. A mouse monoclonal antibody against Aβ was 
administered systemically in an AMD murine model, the complement factor H 
knockout mice, and the efficacy of the treatment was examined both 
prophylactically and therapeutically. The results show that administering the 
antibody reduced the extent of Aβ deposition along the RPE/BM interface. 
 
The therapy aimed at promoting the clearance of Aβ along the RPE/BM interface 
and also reducing the inflammatory response caused by the deposition. In the 
therapeutic treatment, injection of the anti-Aβ antibody prevented further 
accumulation of Aβ and presumably led to a reduction of established Aβ deposition 
while in the prophylactic treatment, accumulation of Aβ along the RPE/BM 
interface was prevented.  
 
The kidneys of these mice were also examined to investigate the systemic effect of 
the antibody and it was found that the antibody reduce Aβ along the basement 
membrane of the glomeruli. However, optokinetic head tracking did not show any 
conclusive results about their visual acuity after the 12 weeks therapeutic 
treatment, but the group treated with the higher dosage of the antibody showed a 
trend with higher head turns when compared with the control PBS group 
suggesting a better visual acuity. A longer treatment, about 6 months and above, 
might be more efficient and may give better and significant results on the 
behavioural assessment than the 3 months therapeutic treatment. 
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Although many differences between the treated and control groups reported here 
were statistically significant, the data could be highly variable. The wide variance 
in the performance of the treated groups may also be due to the fact that Aβ 
peptides have normal physiological roles in the development or synaptic plasticity, 
memory formation and are neuroprotective (162-164) and it is only when there is 
an excess in the production or the failure of removing the peptides that they 
become pathological. Therefore depleting Aβ to a very low concentration might 
have a negative effect on the body. The level of Aβ at which it is not pathological 
should be determined and taken into consideration in immunotherapies aiming at 
reducing its accumulation. 
 
The factor H knockout mouse has a distinctive ocular phenotype, showing age-
related degenerative changes of the retina and is a model of AMD (149). It was 
found that the complement factor H knockout mice failed to develop a pathological 
phenotype when they are raised in a pathogen free environment while those that 
are raised in open environment rapidly developed AMD-like features.  
 
Therefore, in chapter four, the strong relationship and complex interactions 
between the CFH gene and the environment was studied. The question of whether 
within a homogeneous population, external pathogens can drive degenerative 
changes in the retina by maintaining two different groups of mice with the same 
genetic background, from birth in two different environments, one in a barriered 
specific pathogen-free environment and the other open. Among all the pathogens 
that the mice in open environment were exposed to, Pasteurella pneumotropica, 
and parasites such as Syphacia obvleata, Entamoeba and Trichichomas were 
present.  
 
The results obtained showed that the animals from the open environment have 
more autofluorescence spots when the retina was examined in vivo and hence 
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more macrophages/microglia than the animals from barriered environment. 
Exposure to pathogens can result in chronic low level of inflammation capable of 
triggering disease and this is reflected by the high level of calcitonin, a biomarker 
of inflammation that is independent of the complement system, in the retina of 
mice from the open environment. Both groups of animal show the same age-
related accumulation of Aβ, however, macrophage numbers and levels of 
inflammation in the open environment mice were higher which was associated 
with outer retinal cell loss. Renal sections were also examined with inflammatory 
markers and it was found that kidneys from the open environment accumulate 
more Aβ than the barriered animals but there was no elevated expression of 
inflammatory markers. 
 
It is established that there is a strong relationship between the onset of diseases 
and inflammation. Studies (264, 265) on cardiovascular disease have shown that 
raised levels of C-reactive protein (CRP) are linked to the disease. Another study 
showed that a specific virus interacted with a mutation in Crohn’s disease 
susceptibility gene induced intestinal pathologies in mice (213). 
 
Other studies have gone further and investigated which pathogen might be 
associated with AMD. One of the key candidates has been Chlamydia pneumoniae 
(214, 215). For this study, no attempt was made to exhaustively search for a 
specific pathogen that could trigger AMD. Pasteurella pneumotropica present in the 
open environment colony is known to induce ocular inflammation in rodents and it 
is rare in human and unlikely to be a trigger for human AMD (266). Likewise, 
Chlamydia pneumoniae, which has been suggested as a potential pathogen for 
human AMD is not common in rodents unless experimentally induced (267). It is 
probable that pathogen load is the risk factor in disease progression and not one 
specific pathogen and hence it is important to highlight that reducing pathogen 
exposure in individuals who are susceptible to diseases may help to delay the 
onset of disease. This study focus on the important concept that genetic mutation 
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or polymorphism is not the only factor that triggers the onset of AMD but 
environmental risk factors must also be taken into account in future therapies. 
 
Chapter five address the role of complement component C3 in the pathogenesis of 
AMD. It is thought that complement component C3 is the key inflammatory protein 
activated in AMD and therefore one of the target strategies in AMD treatment is to 
aim at inhibiting C3 activation. A double knockout of complement component C3 
and complement factor H transgenic mouse was used to investigate the role of 
complement component C3 in AMD pathology. The results showed that in the 
complete absence of complement component C3, there is significant decrease in 
retinal function as revealed by their ERG results.  
 
Significant photoreceptor cells loss was found in the retinae of these mice and the 
photoreceptor outer segments are completely coated with extracellular material. 
The morphology of the extracellular material in the CFH-/-.C3-/- mice are different 
from the one observed in the wild type mice or the CFH-/- mice. These deposits on 
the outer segment of photoreceptors of the CFH-/-.C3-/- mice are thought to be 
either blebs or scar tissues as a result of photoreceptor cell death and chronic 
inflammation but further investigation is required to identify these deposits. 
 
Aβ not only has a potential pathological role in Alzheimer’s disease and AMD but it 
also has a role in the normal physiology of the central nervous system as Aβ 
activity is required for the essential modulation of synaptic activity and neuronal 
survival (259, 260). It must be remembered that the proteolytic cleavage of 
amyloid precursor protein into Aβ is a physiological process, only when there is an 
overproduction or failure to remove it that it becomes pathological. 
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Immunostaining of the retinae of these mice showed that there was a marked 
reduction in the Aβ accumulation in photoreceptor outer segments of CFH-/-.C3-/- 
mice but a significant increase along the RPE/BM. The reduced expression of Aβ in 
the photoreceptor outer segments implies that their functions are impaired. 
Increased accumulation of Aβ along the RPE/BM interface may prevent the 
exchange and metabolic traffic from the neural retina and the RPE to the choroidal 
capillaries and may lead to atrophy of the RPE and photoreceptor cell death and 
hence degeneration of the retina. 
 
Western blot results again showed that the >50kDa oligomers were the most 
abundant form of Aβ in the retina. >50kDa is considered to be toxic to neurons and 
therefore its presence in the retina will lead to neurodegeneration.  
 
With the presence of increased accumulation of Aβ in the RPE/BM interface, there 
is an increase in the level of inflammation, which is marked by the high expression 
of calcitonin in the retina. It has been demonstrated by Koenigsknecht-Talboo et al. 
(2005) (258) that chronic inflammation suppresses activation of phagocytic 
machinery and affects the ability of microglial cells to mount a phagocytic 
response. This reflects the results obtained when confocal scanning laser 
ophthalmoscope images of the retina of CFH-/-.C3-/- mice, revealed that the mice 
had significantly fewer microglia/macrophages present in the subretinal space.  
 
In the complete absence of complement component C3, microglia/macrophages 
are not activated because the cellular receptors for C3 fragments on the 
microglia/macrophages do not respond to free or particle-bound C3 fragments as 
C3 fragments are absent. Without the recruitment of microglia/macrophages, 
accumulated Aβ is less efficiently phagocytosed and removed from the retinal 
environment. 
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All the results obtained in this study converge towards the conclusion that the 
complete absence of complement component C3 will lead to significant 
photoreceptor loss and significant decrease in retinal function. Attempts at 
inhibiting C3 activation in complement-targeting therapies are underway, 
biopharmaceuticals such as Potencia pharmaceuticals have developed a C3-
peptide inhibitor, compstatin/POT-4, which binds to C3 and prevent its activation. 
This peptide is currently being used under clinical trials for intravitreal use for 
geographic atrophy in AMD eyes (236, 237). It effectively inhibits the central step 
of the complement cascade by binding to C3 molecules and inhibits the cleavage of 
C3 to its active forms, C3a and C3b. Other preclinical development for possible use 
in the treatment of AMD include an anti-properdin antibody, that would destabilise 
the C3 convertase, sCR1 which is a soluble form of endogenous complement 
receptors 1 that promotes the degradation of active C3 convertase (236). 
  
The question to be answered is whether the inhibition of complement component 
C3 activation will be beneficial or detrimental to the retina as complement 
component C3 has many crucial roles in the maintenance of retinal homeostasis.  
 
Although the results obtained were in a model in which complement component 
C3 was developmentally rather than conditionally depleted and should thus be 
cautiously extrapolated. Further investigation is required in young CFH-/-.C3-/- mice 
to examine whether they present the same pathological features as the aged mice. 
If they do so then complement component C3 is detrimental to the development of 
the outer retina.  
 
The animal model used here is a double knockout and it would be interesting to 
know whether it is the combination of complement factor H and complement 
component C3 knock out that is causing the dysfunction of the outer retina and 
photoreceptor cell death and not the complement component C3 knockout alone. 
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Age-matched mice deficient in complement component C3 alone should be tested 
in vivo and in vitro for their retinal functions and morphology to examine whether 
they have the same features as the double knockouts, CFH-/-.C3-/- mice.  
 
Another experiment that can be performed to test the hypothesis that it is the 
deficiency in complement component C3 is the one responsible for the dysfunction 
of the outer retina is to experimentally inhibit the activation of C3 in adult normal 
mouse and CFH knockout mouse, using the complement receptor 1-related 
gene/protein y (Crry). Crry is a potent membrane complement regulator that 
inhibits complement C3 activation by both classical and alternative pathways in 
rodents (268). The retinal functions and morphology will be examined to see 
whether inhibiting C3 activation will lead to neurodegeneration and retinal 
dysfunction. 
 
Collectively these data show that inflammation is the one factor that forms an 
umbrella for the onset and progression of AMD. However, the inflammation 
process is not a negative phenomenon and it is the response of the immune system 
to pathogens or injury made by trauma. Aβ deposition and pathogen load are 
factors that will trigger an inflammatory response in the tissue. Therefore further 
understanding in the relationship between the factors that promote inflammation 
and the inflammatory response is required for future therapies and ways to 
control inflammatory response to a physiological level and subsequently removing 
the factor causing the inflammation without affecting the homeostasis of the tissue 
will be a step forward in treating AMD. 
 
Ageing has been defined as the progressive accumulation of changes with time that 
are associated with or responsible for the ever-increasing susceptibility to disease 
and death which accompanies advancing age (269). With ageing, the sensitivity of 
the peripheral field of vision in humans declines more rapidly than that of the 
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central field. Scotopic vision is more greatly affected than photopic vision (270, 
271) indicating that rods are more affected than cones. Electrophysiological 
studies report a significant increase in implicit times and a decrease in the 
amplitudes of a waves and b waves in the elderly (272, 273).  
 
One of the characteristics of ageing in the human retina is an overall thinning due 
to neuronal loss and shortening of the photoreceptor cells. The number of ganglion 
cells in the fovea and peripheral retina also decreases (28, 29) and astrocytes 
display higher levels of glial fibrillary acidic protein and more cytoplasmic 
organelles (30) during ageing. The RPE specifically is known to undergo several 
structural changes, including loss of melanin granules, increase in the number of 
residual bodies, accumulation of lipofuscin in the RPE, accumulation of basal 
deposits on or within BM, formation of drusen, calcification and thickening of the 
BM, RPE microvilli atrophy and disorganisation of basal infolding (274). 
 
Age-related diseases are often considered to be distinct pathologies rather than an 
inevitable part of ‘normal’ ageing. The quest for therapies in an attempt to treat 
most age-related diseases has failed to deliver an unequivocal clinical 
breakthrough. We seek genes and other factors that raise our susceptibility to 
diseases, but these age-related diseases are the price we pay for the way we cope 
with physiological stresses, such as infections and perhaps also our lifestyle. 
Infections and age-related diseases are linked by oxidative stress, which is an 
imbalance in the production and elimination of free radicals. Oxidative stress is 
only one factor among many that contribute to ageing and is the primary cause of 
age-related diseases.  
 
A key question to be asked here is why should one person suffer from one age-
related disease and the other one from nothing at all, while both age at much the 
same rate? To answer this question, Nick Lane (2003) (275) stressed the free 
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radical theory of ageing. Free radicals are produced during metabolism. The rate of 
ageing generally varies with metabolic rate (276). The theory argues that there is a 
trade-off between oxidative stress as a critical redox signal that marshals genetic 
defences against physiological stress and oxidative stress as a cause of ageing and 
age-related disease. 
 
A susceptibility factor underlying age-related neurodegeneration may be the 
increased presence of damaged DNA with age (277). The importance of 
mitochondria in both ageing and age-related disease was demonstrated by Tanaka 
et al. (1998)(278) who showed that people with a mitochondrial gene variant have 
fewer mitochondrial DNA mutations and therefore they live longer. 
 
Macular photoreceptors are exposed to light, including short wavelength light, 
which damages mitochondrial DNA (mtDNA). Mitochondria are critical for ocular 
function as they represent the major source of a cell’s supply of energy and play an 
important role in cell differentiation and survival (279). Mitochondria synthesise 
adenosine triphosphate (ATP), which includes the photoreceptor-specific ATP-
binding cassette transporter, a key agent in the retinoid cycle between the RPE and 
photoreceptors, through oxidative phosphorylation. mtDNA mutations 
progressively accumulate in photoreceptors with age, particularly in the foveal 
region (280). MtDNA instability is an important factor in mitochondrial 
impairment culminating in age-related changes and pathology, and in all regions of 
the eye, mtDNA damage increases as a consequence of ageing and age-related 
disease. One consequence of the inhibition of the ATP-binding transporter is the 
accumulation of lipofuscin. The accumulation of mtDNA mutations leads to cellular 
dysfunction and induce apoptosis and contribute to the pathogenesis of numerous 
sporadic and chronic disorders in the eye (281, 282). 
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Harman (1972) (283) proposed that mitochondria have a critical role in the 
process of ageing. His theory was that reactive oxygen species (ROS) generated by 
the mitochondrial metabolism and inflammatory responses increase in an age-
dependent manner with rising oxidative stress and that the ROS-mediated damage 
to proteins, lipids and mtDNA has a causative role in the morbidity of ageing and 
age-related disease. ROS mediated damage to mitochondrial proteins and DNA 
probably exacerbates leakage and oxidative damage to the cell (284). Because 
mitochondrial leakage cannot be resolved, the inflammation becomes chronic, and 
in itself exacerbates oxidative stress (275). 
 
Evidence from a number of studies now strongly supports the mitochondrial 
dysfunction initiated by mtDNA damage is a feature that underlies the 
development of retinal ageing and AMD. Increased mtDNA deletions have been 
documented in aged human and rodent retinas (285-287) and increased mtDNA 
damage and decreased repair are associated with ageing and AMD (287, 288). 
Furthermore, the repair of the RPE mitochondrial genome appears to be slow and 
relatively inefficient (289).  
 
The current pathophysiologic concept on AMD assigns a primary role to the age-
related, cumulative oxidative damage to the RPE due to an imbalance between 
generation and elimination of ROS (31, 290). Specifically, lipofuscin has been 
hypothesised to be the primary source of ROS responsible for both cellular and 
extracellular matrix alterations in AMD (291, 292) and thus lipofuscin is thought to 
be responsible for oxidative damage to RPE resulting in impaired metabolism and 
apoptosis characteristics for late AMD (293). A recent report shows that the aged 
RPE and choroid of rodents suffer extensive mtDNA damage and that this is likely 
to be due to decreased DNA repair capability (287). New therapeutic strategies 
targeting mitochondria and manipulate mtDNA replication, repair and levels of 
nucleotide precursors to maintain mtDNA integrity will be the challenge for the 
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future with the ultimate aim of blocking or delaying the effects of mitochondrial 
disease. 
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